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CHAPTER 1
INTRODUCTION TO THIS THESIS
Arco Verhoeven
comb/nafon therapy /n //»eu/nafo/d art/irifa's: chapter
Rheumatoid arthritis
RHEUMATOID ARTHRITIS (RA) is a disease of unknown aetiology, characterised by
inflammation of multiple joints and systemic manifestations [1]. The inflammation is primarily
located in the synovia and tendon sheaths of peripheral joints of hands, wrists and feet, and is
usually symmetrical. RA is a common disease with prevalence between 1 and 1.5% in people
above 40 years of age [2]. The peak incidence is in the fifth decade and women are affected
approximately twice as often as men are. Where in a minority of RA patients the disease has a
relatively mild course with non-erosive disease, the majority has an exacerbating and remitting
arthritis [3]. In these patients, RA usually leads to progressive disability due to destruction of joints
and surrounding structures [4-9]. Structural and irreversible damage to the joints is radiographically
demonstrated early in the course of the disease [10,11]. Progression of joint damage is associated
with disease activity and most prominent during the first years after onset [11,12]. The disease and
its therapy can cause organ dysfunction. There is an excess mortality among patients with RA;
estimated life expectancies are 3 to 10 years less than persons without RA [11-15]. To date, the
therapy is palliative and directed at decreasing symptoms, slowing joint destruction and optimising
physical function [16].
The treatment of RA
Traditionally the treatment comprised rest, life style rules, and non-steroidal and-inflammatory
drugs (NSAIDs, such as ibuprofen). NSAIDs relieve symptoms such as pain and stiffness, but do
not retard long-term joint damage and physical disability [17].
Patients who show none or insufficient response to the initial therapy receive - after some
time that is needed for evaluation of the treatment response - another pharmaceutical drug; a so-
called disease-modifying anti-rheumatic drug (DMARD). Unlike NSAIDs, these types of drugs do
have the potential to retard long-term joint damage and associated physical disability. Examples of
DMARDS are anti-malarials, gold salts, sulphasalazine, methotrexate, leflunomide, cyclosporin,
cyclophosphamide, and penicükmine. There is extensive documentation of their clinical effectivity
as well as their toxicity [18-25]. Moreover, evidence is accumulating that many of these (for
example, sulphasalazine and methotrexate) slow radiographic progression in RA [26,27]. Felson
and co-workers showed in two meta-analyses that of the individual second-line drugs methotrexate
and sulphasalazine had the best efficacy/toxicity profiles [28,29]. Not all of these data were
available at the time in which the GOBRA trial described in this thesis was designed; nevertheless
some indications already existed to favour sulphasalazine and methotrexate as effective agents with
relatively quick onset (compared with traditional "first choice" intramuscular gold salts) [30]. In
fact, it seems that in Europe a situation has developed in which sulphasalazine is DMARD of first
choice whereas in the New World this is methotrexate [31].
DMARDs are also called SAARDs [32]; slow-acting anti-rheumatic drugs as it may take
several months before the beneficial effects appear. Various adverse drug effects may occur and
give reason to switch to treatment with another DMARD [33]. A part of the patients that started
DMARD therapy will show insufficient response, and this also may give reason to switch to
another DMARD. Most properly this is a DMARD with a putatively more effective but also more
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toxic profile. Thus patient groups with insufficient treatment response or adverse drug events
climb the steps of the so-called 'therapeutic pyramid' [34]. As time passes without adequate control
of disease activity the consequences in terms of joint damage and disability accumulate.
During the last decades there was a call for earlier and more aggressive intervention directed
at suppression of the disease's activity, the inflammation of the synovia as well as the systemic
effects; some even speak of shift of paradigm [35-40]. A more aggressive approach may be
treatment with DMARDs earlier in the course of the disease, using combinations of DMARDs, or
treatment with corticosteroids early in the course of the disease [41,42].
Combination therapy
Combining anti-rheumatic drugs has theoretical appeal as it could result in more efficacy
when the mechanism of action of the drugs is different and possibly less toxic when the combined
drugs can be given at lower dose [43]. Interest in combination therapy was evident as early as 1951,
when means were sought to maintain the remission induced with corticosteroids at a lower dose of
these drugs [44]. Treatment with drug combinations appears quite common as revealed by several
surveys [45]. There are many ways to combine drugs; most frequently, a second drug is added
when the patient has insufficient response to the first. This can be seen as a variation of the
classical step by step approach in which a patient 'climbs the pyramid' of treatment with ever more
toxic and putatively more effective drugs. According to the call to 'remodel the pyramid', patients
with early RA can also be treated with multiple drugs to suppress activity before the irreversible
joint damage occurs. This means aggressive as well as early treatment. Alongside the COBRA
study described in this thesis [46], some empirical evidence has come available to support early
intervention with second-line anti-rheumatic drugs [47]. However, results from these and other
studies in terms of prevention of radiographic evident joint damage are modest.
Critical appraisal of previous studies that evaluated the advantage of anti-rheumatic drug
cwnfaraariwzs over single drug treatment concluded that such advantage remained to be proven as
many of the trials hampered by insufficient quality of design and reporting [48]. Notably, a rreta-
analysis of all kind of investigated combinations taken together failed to demonstrate efficacy of
combination therapy [49].
Corticosteroids
Corticosteroids are divided in glucocorticoids and mineralocorticoids. Both are hormones
produced by the adrenal cortex with broad anti-inflammatory and immunosuppressive effects of
which the underlying mechanisms are incompletely understood. Glucocorticoids are preferred to
mineralocorticoids for their smaller mineralocorticoid effect. Prednisone and prednisolone are
glucocorticoids that are widely employed for treatment of RA, but mostly in established disease
[34]. Despite dramatic short-term effects, physicians and patients became disillusioned soon after
the introduction of this medication during the fifties when the long-term side effects became
apparent [50-52]. Since then corticosteroids are widely regarded as agents of last resort, with nearly
unacceptable benefit-to-harm ratio [34,53]. Although the evidence to the contrary is building up
[54], the dogma holds that corticosteroids' action is merely symptomatic and not disease-
modifying [53]. Evidence from RA as well as other diseases treated with corticosteroids suggests
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that long-term treatment with 7.5 mg/day or less is associated with low toxicity [55-57]. Saag et <*/
concluded from a meta-analysis summarising data from sparsely available controlled studies, that
corticosteroids appear to be approximately as effective as the traditional second-line anti-
rheumatic drugs [58]. The therapeutic value of corticosteroids in addition or synergy with (other)
second-line drugs remains uncertain. There is great concern about adverse effects that
corticosteroids can bring. Obviously, the well-known and extensively reviewed adverse effects
associated with long-term and supraphysiological doses of corticosteroids should never be
neglected. They include suppression of the hypothalamic axis, increased susceptibility to infection,
gastrointestinal ulceration and perforation (due to combination with NSAIDs), osteopenia and
osteoporosis, aseptic necrosis of bone, skin changes, myopathia, psychosis, cataract, glaucoma,
fluid retention, hypertension, enhanced atherosclerosis, and insulin resistance. Controversy
remains around prevalence, magnitude, clinical relevance and minimum safe dose with almost
every glucocorticoid induced side effect. Attention is often focused at osteoporosis, as this is a
highly prevalent disorder in the general population of elderly. Furthermore, also RA itself is
associated with bone loss through functional impairment and active disease [59].
THIS THESIS contains three parts with chapters that all correspond to papers that are
published [46, 60-68]. THE FIRST PART - with chapters 2, 3, and 4 - respectively, describes a
systematic review on combination therapy, and two reports from the randomized controlled trial
named COBRA after the Dutch acronym "combinatietherapie bij vroege reumatoide artritis"
(combination therapy in early rheumatoid arthritis).
The systematic review in chapter 2 [60] fits in a sequence of systematic reviews; it is an
update of earlier publications [69/0]. The flow of new studies on combination therapy in RA gave
reason and opportunity to re-investigate the potential efficacy and synergy of various
combinations.
Chapter 3 [45] describes the randomised clinical trial performed to compare the clinical
outcomes of combined step-down prednisolone, methotrexate and sulphasalazine with
sulphasalazine alone in patients with early and active RA. The purpose of this large, and state-of-
the-art study was to clarify the till that point in time unproven value of intensive combination
therapy in early RA. The main outcomes were a pooled index (weighted change score of five
disease activity measures) [71] and Sharp/van der Heijde radiographic damage score in hands and
feet [7273]. Independent health-care professionals assessed the main outcomes without
knowledge of treatment allocations.
Monetary costs of RA are high due to increased use of medical services (such as medication
and hospitalisation), and work disability developing during the course of the disease [8,9/475].
Chapter 4 [61] evaluates the cost-effectiveness and cost-utility properties of the combination
therapy described in chapter 3. The study comprised full economic analysis of all direct costs, and
also assessed patient-derived utilities (quality of life) by rating scale and standard gamble
measurement techniques [76]. These have a theoretical advantage of allowing comparisons across
different diseases [7778].
/ntroduction
THE SECOND PART OF THIS THESIS - with chapters 5, 6, and 7 - focuses at deleterious
effects of corticosteroids in RA. Adverse effects of corticosteroids especially on bony tissues are
the topic of -justified- concern. In chapter 5 [62] corticosteroid induced bone loss is reviewed.
Initially, we sought for a quantification (dose-response relation) on the basis of data derived from
randomised controlled trials in this field. When it appeared that there were only two publications
of such studies (both with RA patients) [79,80], we broadened our scope to all prospective
research that was adequately performed and documented, i.e. all reports with reliable and serial
bone density measurements. Thus, we were able to shed some light on the relation between
changes in bone density, the disease treated, and the prescribed dose of corticosteroids.
In RA, there is inflammation at the site of joints, associated with typical juxtaarticular
osteoporosis. Apart from this, there is general bone loss associated with disease activity [59]. As a
result of pathologic destruction of collagen in bone and cartilage, crosslinks between mature
collagen fibers are resorbed more rapidly than normal. This causes a rise in circulating collagen
crosslink levels and their urinary excretion [81]. The concise report of the study described in
chapter 6 [63] was initiated to determine how well a urinary spot sample of patients with active
RA can predict 24-hours urinary excretion of collagen crosslinks (pyridinoline and
deoxypyridinoline).
Chapter 7 [64] is focused on changes in bone metabolism at different levels of disease
activity, both with and without oral corticosteroid therapy. The data were derived from the
COBRA study described in chapter 3; alongside with assessment of clinical measures, radiographic
outcomes and bone density, were samples of serum and urine stored for investigation.
THE LAST PART OF THIS THESIS - with chapters 8, 9, 10, and 11 - is on assessment of
outcomes in rheumatoid clinical trials. This is particularly difficult, as there are so many measures
of such wide variety to assess treatment efficacy in RA in and outside the context of a clinical trial
[82-84]. The OMERACT consensus on endpoint measures in RA facilitates comparison of results
from different trials in treatment evaluation [85,86]. Many have called for further validation of the
measures included in the core set adopted by the World Health Organization/ International
League of Associations for Rheumatology (WHO/ILAR) and American College of Rheumatology
(ACR) [87-90]. This WHO/lLAR core set to be used as a minimum in every RA clinical trial,
comprises an acute phase reactant, disability, pain, patient's and physician's global assessment,
swollen and tender joint counts, and radiographic studies of joints in any trial with a follow-up of 1
year or longer [87].
An important factor in the benefits that may be achieved with pharmaceutical treatment is the
duration of the disease. Seemingly, the odds for prevention of damage are better in the earlier
phases of the disease. On the other hand it remains fairly unknown why some patients with RA
respond better to treatment than others. It has been suggested that patients with more severe
disease may be less likely to show a response, and that patients who have previously been treated
with second-line drugs also may have more recalcitrant disease [16]. In addition, there are
indications that the biologic process of RA changes early in the disease, so that patients may be
less responsive to treatment over time [47,91,92]. It would also appear that patients with especially
active disease are more likely to respond to treatment, particularly in the context of a clinical trial
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Better response in these patients would then - partially - represent regression to the mean. Our
understanding of which types of patients with RA are most likely to respond to treatment has
implications for the aggressiveness of treatment of individual patients. In addition, there may be
implications for the design of clinical trials, in that the anticipated power of a trial may be a
function of the particular mix of patients that participate in the trial. To address these questions
patient data from 14 diverse clinical trials of second-line drugs and devices in RA conducted since
the early 1980s have been used. The COBRA trial described chapter 3 was one of these trials -
and the one with the earliest intervention [46]. The analysis is presented in chapter 8 [65].
Chapter 9 [66] fits in the process of the ongoing validation of the responsiveness of the core
set, of the ACR improvement and the European League Against Rheumatism (EULAR) response
criteria [93,94], and of other single measures and indices. Again, we used data from the COBRA
trial that allowed us to create one "gold" and one "silver" standard for relevant response against
which to validate performance of end point measures: we proposed the hypothesis a priori that
patients on combined treatment would on average show large and, certainly, relevant
improvements at week 16 of follow-up owing to the corticosteroid pulse (gold standard). Also, we
assumed on the basis of the well known effects of sulphasalazine on disease activity that patients
in the sulphasalazine-only group would also show relevant improvements, but to a lesser degree
(silver standard). Subsequently, we ranked all comprised end point measures and indices by their
relative responstsveness, and also by their ability to discriminate between treatment groups.
The measurement of relative changes in some of the core set outcome measures made us
aware of unforeseen pitfalls that urged us to formulate explicit recommendations as to the
calculation of relative changes in chapter 10 [67].
Physical function is an important outcome in RA and included in the WHO/lLAR core set for
assessment of this disease's outcomes [87]. Examples of widely used questionnaires to measure
physical function are the Stanford Health Assessment Questionnaire (HAQ) and Arthritis Impact
Measurement Scale (AIMS) [95,96]. However, these measures do not include patient priorities.
Including such priorities may lead to better face validity and responsiveness. An example of a
functional ability scale that takes account of patient priorities is the McMaster Toronto Arthritis
Patient Preference Disability Questionnaire (MACTAR) [97]. Its developers noted good
responsiveness in RA patients in a controlled trial that demonstrated clinically important change
[97]. In the MACTAR, the interviewer elicits which 5 impaired activities are most important to an
individual patient, and follows their changes over time. The MACTAR also includes questions on
social and emotional functioning and probes whether any problems are due to arthritis. Because of
this format, the MACTAR concept of function may be more comprehensive than that of traditional
fixed-item questionnaires such as the HAQ, and reveal issues that really matter to the patient.
Chapter 11 [68] presents a critical evaluation of the feasibility and validity of this instrument [98].
The data came from the same randomised trial of combined treatment in early RA patients,
described in detail in chapter 3 (COBRA study).
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CHAPTER 2
COMBINATION THERAPY
IN RHEUMATOID ARTHRITIS:
UPDATED SYSTEMATIC REVIEW
Arco Verhoeven, Maarten Boers, Peter Tugwell
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Combination Therapy in Rheumatoid Arthritis:
Updated Systematic Review
Abstract
In a second update of a systematic review, many new developments in the combined drug
treatment of rheumatoid arthritis (RA) are highlighted. In early RA patients, step-down bridge
dierapy that includes corticosteroids leads to much enhanced efficacy at acceptable or low toxicity.
The effects on joint damage may be persistent, but the symptomatic effects are probably
dependent on continued corticosteroid dosing. In late patients, cyclosporin improves a suboptimal
clinical response to methotrexate, and the triple combination of methotrexate, sulphasakzine, and
hydroxychloroquine appears to be clinically better than the components. Other combinations are
either untested, tested at low sample size, or show negative interaction. In view of the low volume
of evidence, most studies need confirmation by replication.
22
svstematfc reWew ofDMAKD comb/natton tfraraov
Introduction
There is a trend among rheumatologists to treat rheumatoid arthritis (RA) patients earlier and
more aggressively. New scientific evidence supports early intervention with disease-modifying anti-
rheumatic drug (DMARD) therapy [1]. Rapid and adequate control of disease activity is aimed at
prevention of structural joint damage and subsequent loss of function and quality of life. In this
setting, combining of so-called DMARDs might lead to additive effects. Alternatively, doses might
be reduced, and perhaps some of the toxicity avoided. Many rheumatologists already prescribe
combination dierapy, akhough until recently scientific evidence to support this policy was lacking.
Over the last years, an increasing number of high-quality trials has been published. We present a
second update of a systematic review of combination therapy in RA [2,3].
In combining DMARDs, three main strategies can be distinguished. In this review, the label
'step-up strategy" is reserved for trials in which patients with insufficient clinical benefit from one
second-line agent continued the use of this first drug and had another (or placebo) added to this.
The label 'parallel' was assigned to trials in which the patients started with a combination of new
drugs, and 'step-down' to trials with sequential withdrawal of simultaneously started drugs,
prescribed by protocol.
Methods
Study /denf/ficaf/on
The MEDLJNE database was searched from August 1992 (the closing date of the previous
review) to July 1997 using the MeSH headings: 'arthritis, rheumatoid'; and 'drug therapy,
combination'. The bibliographies of all retrieved articles were scrutinized for additional studies.
The first authors of studies published only in abstract were contacted. Such studies were eligible
for inclusion if a full manuscript was available. Titles and abstracts (when available) were screened
by one audior (MB up to August 1992, AV subsequently) and any article in English, French,
German, or Dutch that appeared potentially relevant was retrieved.
Sfudy se/ecf/on and va//drty assessment
First, the quality of die studies and, thus die strength of evidence was scored on a diree-point scale
on the basis of two primary criteria: randomisation and blinding. Accordingly, strong evidence
came from randomised, double-blind studies; moderately strong evidence from studies diat were
randomised, but open or partially blinded; and weak evidence from all odier studies. This score
specified die maximum strength we felt a study could yield. A second set of criteria, modified from
Sackett er a/ [4] was dien applied. These were: (a) adequate outcome assessment (blind and
comprising toxicity); (b) adequate description of study patients (report of at least age and sex,
some record on the previous disease severity and concurrent medication); (c) adequate description
of die dierapeutic maneuver (i.e. minimal potential of bias, with blinding, contamination, co-
intervention and compliance properly addressed); (d) complete accounting of study patients in die
results. To obtain die final quality score, points were subtracted for each of diese criteria not met.
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Date exfracf/on and ana/ys/s
The results of the trials yielding moderately strong or strong evidence in the previous reviews
(original and update) were added to the information from the new search. Data extracted from the
selected studies included baseline patient characteristics, study and concomitant treatment,
outcome measures, and details on toxicity, withdrawals and eligibility criteria for disease activity.
Clinical efficacy, i.e. improvement in clinical outcome measures, was compared between the
combined-treatment group and the single-treatment group. In the case of more than one control
group, comparisons were made between the combined-treatment group and each control group,
but eventually the comparison with the best performing control group was decisive. The WHO/
ILAR core set measures [5] assessed efficacy. These measures comprise tender and swollen joint
count (or a score), pain assessment, patient and physician (or observer) global assessment, physical
function index [here, in every case Health Assessment Questionnaire (HAQ) or a modification
thereof], and acute-phase reaction [Le. erythrocyte sedimentation rate (ESR) or Creactive protein
(CRP)]. When less than four of these measures had been assessed, first grip strength and second
morning stiffness were selected as well. Four levels of efficacy were distinguished based on
differences in improvement in the selected measures:
• combined treatment 'substantially more effective' ('++' in the summary table): significantly
greater improvement in the combined-treatment group in at least half of the selected measures
(minimum two out of four), plus improvement at least 150% that of the control group;
• combined-treatment 'more effective' ('+): significantly greater improvement in at least half of
the selected measures;
• 'positive trend' ('+?): significantly greater improvement in at least 25% of the measures, or
significantly greater improvement only in a predefined summary index of measures;
• 'no difference'('-): the remainder.
When the total number of core set measures (plus grip strength and morning stiffness) was
less than four, only trends were scored. Toxicity was rated as increased ('+*) when significantly
more patients from the combined treatment group were withdrawn from the study medication
because of adverse events. Likewise, it was rated as decreased ('-) when significantly less patients
from the combined treatment group were withdrawn from the study medication because of
adverse events. A significant difference (or trend) in numbers of adverse events not leading to
withdrawal was rated as 'trend of more toxkity* ('+?*) or "trend of less toxichy* ('-?). Where
possible, results of statistical tests comparing the effect or toxicity of the different treatments were
calculated or recalculated using the reported data.
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Results
Previous work had yielded eight relevant studies [2,3]. Six of these eight provided 'strong' or
'moderate strong evidence' and are included in the final selection [6,12,14,19,20,24]. The current
search, covering the interval between August 92 and July 97, yielded 231 new citations. Together
with previous reviews, this brings the total to 611 titles scanned, 100 were retrieved and 18
selected for review. Of the screened abstracts and titles, 38 were linked to a possibly relevant
article. Three articles in Japanese [26-28] were not rated. Not selected articles were case reports,
editorials, observational or non-randomised studies. Three studies that described adjuvant
treatment with oral corticosteroids, androgens and oestrogens, respectively, were not included
because they failed to meet the criterion of a one-type single DMARD control group [29-31]. Two
studies described an extended follow-up or radiological assessments of an already selected article
[32,33]; the data from these publications were added to those of the original study [19,20]. Two
articles were found in the reference list of selected articles [9,10]. Four possibly relevant reports in
abstract form were found in abstract book supplements. The corresponding manuscripts of two
recently published articles were obtained [21,22].
The total of 20 (six old, 14 new) included trials are listed in Table 2.1. The total number of
patients included in these trials is 1952. All trials used a more or less strict criterion to verify the
presence of active disease. The studies are ranked according to treatment strategy as well as the
DMARDs of choice. Six studies describe a step-up strategy, two of these used cyclosporin, three
used i m gold as anchor drug, and two methotrexate. Ten studies describe a parallel strategy, of
these, six used methotrexate (all but one as anchor drug), six studies used antimalarials (one as
anchor drug), three used sulphasalazine, one i.m. gold, dapsone or D-penicillamine (as anchor
drugs); also used were auranofin and azathioprine (as additional drug; total more than 10, due to
combinations). The studies with a step-down strategy (four in total) all used steroids (Lm.
methylprednisone pulses or predniso(lo)ne orally). Steroids were added to Lm. gold (in two
studies) or sulphasalazine (also in two studies; in one study prednisolone was added together with
methotrexate).
Sfud/es vw'f/7 sfep-up sfrafegy
Smyth et a/ [6] added 75 mg/d cyclophosphamide or placebo to a stable and continued pre-
trial dose of prednisone varying between 3 and 15 mg/day in 29 patients with established disease.
After 6 months, outcomes in the combined-treatment group were significantly more improved in
grip strength and an inflammatory index comprising swelling, redness, pain on motion, heat and
tenderness, but not in ESR. Only one case of alopecia was reported in the combined-treatment
group with no withdrawal due to toxicity in either group. Given the paucity of outcomes, this
suggests a trend of increased efficacy with no increase of toxicity, but the disease activity at
baseline was less in the placebo group.
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Table 2.1: Reviewed trials clustered by drug combination and combination strategy.
compared strength disease
first publ. » » drugs or therapy of duration
author ref. year pts groups combinations strategy evidence (yrs)
assess
ment 'O' effi toxi
(mo) score cacy city
Smyth [6] 75 29 2 (PredCyP) step-up moderate >2
« Pred
Moreland [7] '95 64 4 (MTX aCD4) step-up strong 9
«MTX
Tugwell [8] '95 148 2 (MTX CyA) step-up strong 10
«MTX
Bendix [9] '96 40 2 (AU CyA) step-up strong 11
p/AU
Yasuda [10] '94 24 2 (AU Buc) step-up strong 8
wAU
Porter [11] '93 142 2 (AU Hcq) step-up moderate 6
wAU
Scott [12] '88 101 2 (AUHcq) parallel strong 2
« A U
Faarvang [13] '93 91 3 (SSZ Hcq) parallel strong 7
w SSZ « Hcq
Gibson [14] '87 72 3 (Dpen Cq) parallel moderate 2
w Dpen « Cq
Haar [15] '93 80 3 (Daps Hcq) parallel strong 2
« Daps « Hcq
Trnavsky [16] '93 40 2 (Hcq MTX) parallel strong >2
« Hcq
Ferraz [17] '94 82 2 (MTX Cq) parallel strong 8
«MTX
OTDell [18] '96 102 3 (MTX SSZ* Hcq) parallel strong 9
« (SSZ* Hcq) « MTX
Williams [19] '92 335 3 (MTXAUR) parallel strong 5
« MTX « AUR
Willkens [20] '92 209 3 (MTXAZA) parallel strong 8
« MTX « AZA
Haagsma [21] '97 105 3 (MTX SSZ) parallel strong <1
« MTX « SSZ
Boers [22] '97 155 2 (SSZ MTX Predl) step-down strong <1
«SSZ
van Gestel [23] '95 40 2 (AU Pred) step-down strong 2
« A U
Corkill [24] '90 59 2 (AU MP) step-down strong 6
« A U
Ciconelli [25] '96 38 2 (SSZ MP*) step-down moderate 6
«SSZ
6 2/3 + =
3 0/6 = =
6 6/7 ++ =
6 1/7* = + ?
3 3/4 + +?
6 0/4 = =
12 1/4* +? +?
6 0;2/5 = =
12 0;l /5 = =
6 1;1 /4 = =
6 2/5 +? +?
6 2/4 + +?
9 2;2/5 +? =
12 0;0/5 = +?
12 0^/6 = +?
6 0;0/7 = =
6 6/7 + + -
3 3/6 ++ =
3 3/4 ++ +?
6 0/4 = =
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'O' score is the number of clinical WHO/ILAR core set outcome measures (see Methods) significantly
bener in the combined-treatment group in comparison with control group(s). Results from comparisons
with two control groups are separated by a semicolon (;). Behind the slash (/) is the total number of
assessed core set measures. NB. The efficacy rating is derived from the O score, and in some cases also
from improvement in 2 non-core set measures (grip strength and morning stiffness) or from improvement
in a predefined primary outcome index.
AU, i.m gold salts; AUR, auranofin; AZA, azathioprine; Buc, bucillamine; aCD4, monoclonal anti-CD4
antibodies (three doses); Cq, chloroquine; CyA, cyclosporin; CyP, cyclophosphamide; Daps, dapsone;
Dpen, D-penicillamine; Hcq, hydroxychloroquine; MP, methylprednisone pulses intravenously, MTX,
methotrexate; Pred, prednisone; Predl, prednisolone; SSZ, sulphasalazine.
*; Non-core set measures patient's and (non-blind) clinician's assessment of overall efficacy did show
significandy more improvement in the combined-treatment group.
t; The combined-treatment group showed significandy better scores for a validated disease activity index
based on five variables in a flow chart.
£ Low sulphasalazine doses in the combined-treatment groups; 1 g/d.
§; Low methylprednisone doses: 5 mg/Kg/pulse.
Moreland et Ä/ [7] performed a dose-finding study of monoclonal anti-CD4 antibody cM-
T412 in three different doses or placebo added to stable treatment with methotrexate ( < 15
mg/week) in 64 patients with refractory RA Assessments after 3 months treatment and 4 i.V.
pukes anti-CD4 did not show any relevant between-group difference in clinical efficacy or toxicity.
Tugwell et a/ [8] added cyclosporin or placebo to methotrexate in 148 patients with
established disease and insufficient response to methotrexate alone. After 6 months, all outcomes
widi exception of ESR were substantially and significantly better in the combined-treatment group
(HAQ and global assessments P < 0.001). Expressed in percentages, improvement as compared
with placebo varied between 19 and 26%. The frequency of adverse effects was similar to prior
trials of methotrexate and cyclosporin used alone. A threshold of 30% increase in serum creatinine
for dose reduction resulted in a relatively low mean cyclosporin dose (3 mg/kg). Eighty per cent of
die included patients had stable co-medication widi low-dose corticosteroids (< lOmg).
Bendix and Bjelle [10] added cyclosporin or placebo to i.ra gold treatment in 40 patients.
After 6 months, the combined treatment showed increased efficacy only in patient's global
assessments of overall health and clinical efficacy, and non-blind assessments by a treating
physician (/> < 0.01 and < 0.05); other core set measures, including blinded observer's global
assessment, showed no difference. No serious adverse effects were noted. Higher blood pressure
and signs of renal function impairment were found more often in the cyclosporin-treated group,
also dose reduction was required significandy more often in the cyclosporin group. Adverse events
requiring symptomatic treatment occurred only in eight patients; four in each treatment group. Six
mondis after die end of combination therapy, all differences had disappeared.
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Yasuda er a/ [10] added bucillamine, a drug developed in Japan, or placebo to Lm. gold
treatment in 24 patients. After 3 months, the combined-treatment group had significantly better
outcomes in swollen joint count, physician's global assessment and CRP (/> < 0.05), and similar
outcomes (trend) in tender joint count and ESR. Withdrawal for lack of efficacy only occurred in
the control group (five patients), and withdrawal due to toxicity occurred more often in the
combined-treatment group (5 w 3).
Porter et a/ [11] added hydroxychloroquine or placebo to i.m. gold treatment in 142 patients.
After 6 months, no differences were evident between the groups. Withdrawal (for all reasons) was
comparable in both trial groups (approximately 28%). Owing to the lack of description of previous
medication and patient compliance, the strength of evidence was rated as moderate.
Sfud/es vv/f/j para//e/ sfrategy
Scott et a/ [12] also tested the combination hydroxychloroquine and Lm. gold, but in a parallel
strategy against i.m. gold alone in 101 patients. After 12 months of treatment the combination
showed a positive trend in all of the outcomes, but only CRP (/> = 0.01) and the <* /won defined
composed summary index of disease activity were significantly better (P < 0.05). There was less
progression of joint damage on radiographs in the combined-treatment group, although this did
not reach significance. The total withdrawal rate was high: 42%. The authors report that toxicity
might be enhanced as 18 patients in the combined-treatment group T« 10 in the control group
were withdrawn for adverse effects.
Faarvang et <*/ [13] compared the combination of sulphasalazine and hydroxychloroquine with
each of these agents alone in 91 patients. Analysis of study completers after 6 months treatment
showed no difference between combined treatment and single sulphasalazine treatment. However,
combined treatment did show better outcomes in swollen joint count and patient's global
compared to hydroxychloroquine alone (/> < 0.05). In our view, this only confirms that
sulphasalazine is a more effective drug than hydroxychloroquine. Both groups showed similar
progression of joint damage on radiographs. Withdrawal, for adverse effects as well as other
reasons, in this trial was frequent in all treatment groups (32%).
Gibson et a/ [14] compared the combination of D-penicillamine and chloroquine in
comparison with each of these alone in 72 patients. After 12 months, the decreases in ESR in the
combined-treatment group were significantly larger compared to chloroquine, but not compared
to D-penicillamine. Improvements in morning stiffness, joint tenderness and swollen joint score
and grip strength did not show significant contrasts between treatment groups. There were
significantly more adverse effects in the combined-treatment and the D-penicillamine groups
compared with chloroquine.
Haar er <*/ [15] compared the combination of hydroxychloroquine and dapsone with each of
these drugs alone in 80 patients. After 6 months of treatment, the combination showed a positive
trend with a significant difference only in one measure: ESR, but the baseline values for ESR were
also better in diis treatment group. Patients treated with combined dapsone and hydroxy-
chloroquine showed less progression of joint damage, but this result was weakened by serious
disbalance between groups in baseline values. Withdrawals for toxicity were more numerous in the
combined-treatment group but this difference was not significant (8 Z5 3 and 4; P - 0.11).
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Trnavsky e£ <*/ [16] compared the combination of hydroxychloroquine and mediotrexate with
hydroxychloroquine and placebo in 40 patients. After 6 months, the combined treatment showed a
positive trend with significantly better outcomes in two of five core set measures; patient's global
and ESR (P <0.05). The combined-treatment group contained more patients without progression
of joint damage, but the report allows no conclusion on wether this difference was significant.
Withdrawal for adverse effects was rare (one case).
Ferraz et Ä/ [17] compared the combination of methotrexate and chloroquine to methotrexate
alone in 82 patients. After 6 months, the combination was more effective in tender joint count (P
= 0.04) and HAQ (P = 0.04). The authors state that combined treatment was slightly more toxic
(and effective), although only three patients were withdrawn due to adverse effects (two of whom
had combined treatment). The percentage loss to follow-up (partially related to non-compliance)
was quite high (9%) in this study.
ODeli et <*/ [18] compared the combination of methotrexate, sulphasalazine and hydroxy-
chloroquine to the combination of sulphasalazine and hydroxychloroquine, and to methotrexate
alone, in 102 patients. The dose of sulphasalazine (1 g/day) was low. Every 3 months, dose
adjustments of methotrexate were allowed, guided by assessments of the effect of therapy. The
main assessment of efficacy was after 9 months when no further opportunity was offered to adjust
the methotrexate dose in case of insufficient therapy response (by definition: < 50% improvement
in modified Paulus criteria). At this time, 27/31, 23/35 and 28/36 patients were considered
responders (x* test: triple therapy is sulphasalazine-hydroxychloroquine P - 0.04; is methotrexate
P - 0.32; overall P - 0.12). Based on survival analyses, die authors report significantly more
patients with a response to triple dierapy after 9 months and conclude that triple therapy results in
enhanced efficacy with no increase of toxicity. Non-responders were considered therapy failures
and further report on follow-up was restricted to responders. At 9 months of follow-up and
according to the rules of this review, triple therapy only showed a positive trend: significandy
better swollen and tender joint counts compared to mediotrexate, and significantly better swollen
joint count and ESR compared to hydroxychloroquine-sulphasalazine. At 2 yr follow-up (with
38% patients still in follow-up), the between-treatment group contrasts were larger (and highly
significant), but this concerns only the patients who had a sufficient response according to the
modified Paulus criteria at month 9. Withdrawal for toxicity was rare at year 2, but data on
wididrawals due to adverse events at month 9 were not available; however, overall withdrawal at
month 9 was about equal.
Williams et Ä/ [19] compared the combination of methotrexate and oral gold (n - 106) against
treatment with each of these agents alone in 335 patients. After 48 weeks, none of the five
assessed core set measures showed more benefit in die combined-treatment group. Withdrawals
for toxicity occurred somewhat more frequently in die combined-treatment group (21% w 15%
and 14%; trend, not significant). Subsequendy, Lopez-Mendez et d/ [32] reported no differences
between die groups in progression of radiographic scores at week 48.
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Willkens et <*/ [20] compared the combination of methotrexate and azathioprine with each of
these drugs alone in 209 patients. Data data on ESR and HAQ were subsequently added in a letter
[33], and data on 48 weeks of follow-up and radiologic progression were published later [34]. The
combination was not better in die between-group comparisons (withdrawals considered as
treatment failures), except for ESR when combined treatment was compared to single azathioprine
(P - 0.03). The authors also report a trend of less radiographic progression in the metiiotrexate
group. Adverse effects occurred primarily in the combined-treatment and azathioprine group
(trend). Numbers on withdrawn patients per treatment group due to toxicity are not available, but
therapeutic interventions related to advene events were reported more often in the combined
treatment group (48% is 25% and 21%).
Haags ma et a/ [21] compared the combination of methotrexate and sulphasalazine with each
of diese drugs alone in 105 patients. After 52 weeks, die combination was not more effective in
any of the four core set or odier measures. Response to treatment was exceptionally good in all
groups: 74% met the preliminary ACR criteria for improvement [35]. Fewer patients were
withdrawn for toxicity reasons in the single methotrexate treatment group compared to the
combined-treatment group (P - 0.025). In contrast with most other trials, the patients included in
this study had early disease. These results agree with those of a trial only published in abstract
form [36], but contrast with the results of an open trial (not included in this review) in which
patients with insufficient reaction to sulphasalazine first stopped this drug and afterwards were
randomised to combined methotrexate-sulphasalazine, or methotrexate alone. Here, the
combined-treatment group showed significantly better outcomes [37].
Sfud/es vwf/j step-down strategy
Boers et a/ [22] compared the combination of sulphasalazine (2 g/day), methotrexate (7.5
mg/week), and prednisolone (initially 60 mg/day, tapered in 6 weekly steps to 7.5 mg/day) with
sulphasalazine alone in 155 patients. The last assessment of therapy effect of combined treatment
was at week 28 of follow-up, as prednisolone and methotrexate were tapered and stopped after 28
and 40 •weeks, respectively. At week 28, significant better outcomes in the combined-treatment
group were seen in all composite measures and all but one of the core set measures (P <0.002). In
these measures, the improvement in die combined-treatment group was twofold or almost
twofold diat of the single sulphasalazine group. Seventy-two per cent of the patients in the
combined-treatment group is 49% in the sulphasalazine group had improved according to the
ACE. criteria (P - 0.006). The clinical difference between the groups decreased and was no longer
significant after prednisolone was stopped, and there were no further changes after methotrexate
was stopped. Withdrawal for toxicity during the first 28 weeks was significandy less in the
combined-treatment group ( l w 7; P - 0.04). The frequency of adverse events not resulting in
withdrawal was similar in both groups. In addition to the clinical results, progression of joint
damage in the combined-treatment group was one-third that in the sulphasalazine group. This
effect persisted until week 80, i.e. 1 yr after the withdrawal of prednisolone which started at week
28 of follow-up.
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Van Gestel et a/ [23] compared the combination of i.m. gold (50 mg/week) and prednisone
(initially 10 mg/day for 12 weeks, then tapered to zero in 2-weekly steps) with i.m. gold alone in 40
patients. The main assessment was at week 12, just before prednisone was gradually withdrawn. At
this time, all five assessed core set measures showed significantly greater improvement in the
combined-treatment group; the magnitude of this improvement is not reported. The improvement
in a composite index , the disease activity score (DAS) [38], in the combined-treatment group was
more then twofold that with single gold treatment. Progression of joint damage was similar in both
groups. Withdrawal due to toxicity was the same in both groups after 20 weeks (four patients in
each group). The authors report troublesome rebound effects in the combined-treatment group
after withdrawal of prednisone. This appears to be based on a single significant between-group
comparison in an array of 13: in week 20 of follow-up, the DAS in the combined-treatment group
was worse than in the control group. However, at this moment (and up to week 44), patients in
both groups were still better than at baseline. After 44 weeks (32 weeks after the beginning of
tapering prednisone), no between-group difference remained.
Corkill et a/ [24] compared the addition of three pulses of 120 mg Lm. methylprednisone (at
week 0, 4 and 8) to i.m. gold in 59 patients. After 12 weeks, the combined treatment was
significantly better in three of four core set measures; improvement in pain and physical function
was more than twice as high, and joint count almost twice as high. After 24 weeks, the between-
group difference had almost disappeared. Progression of joint damage was similar in bodi groups.
Withdrawal due to toxicity during 24 weeks was more frequent in the combined-treatment group,
but not significandy so.
Finally, Gconelli et <*/ [25] compared the addition of three low-dose Lv. methylprednisone
pulses (5 mg/kg), at baseline, month 1 and 2, with sulphasalazine alone in 38 patients. Eighty per
cent of the patients in both groups had a prescription of oral corticosteroids. In die 6 mondi study
period, no differences between treatment groups in efficacy or toxicity were found. The relatively
low dose of mediylprednisone in a population already treated with corticosteroids may have
decreased the possible contrast. This important co-intervention widi oral corticosteroids was die
reason to rate die strength of evidence from this trial as moderate.
Figure 2.1 summarizes heterogeneity of the findings of diis systematical review graphically.
Except for corticosteroids, there appears to be no trend for an overall beneficial effect of a
particular drug in a combination. The figure also shows the lack of data: low sample size in most
trials, and many untested combinations.
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Figure 2.1: Three-dimensional summary of efficacy of combination therapy.
From the perspective of the five most used drugs, the matrix describes the combinations of all
single drugs reviewed, and one two-drug combination. Each bar describes a specific combination
trial; its length reflects the sample size of the combined-treatment group, its shade reflects the
evidence that combined treatment is better than the single drug(s). £><*?& gnry, strong evidence that
combination is better or much better, /igfo grey, moderate evidence that combination is better (any
evidence or trend); xc/nte, no evidence that combination is better. Because the five primary drugs
are repeated on the long axis, a dark area in the matrix indicates overlap.
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Discussion
In its second update since 1991, this review highlights exciting new developments in the
combined drug treatment of RA. In early disease, step-down bridge therapy with corticosteroids
appears safe and, in the right dose and duration, truly disease modifying; however, the effect on
disease activity (not damage) appears dependent on continuation of low-dose corticosteroids. This
strengthens Kirwan ef <*/"s [29] finding of the damage control resulting from corticosteroid
adjuvant dierapy, a study not included in diis review because anti- rheumatic therapy was not
uniformly applied in the control group. In late disease, patients with a suboptimal response to
mediotrexate clinically improve with cyclosporin, and some patients on triple dierapy with
methotrexate, sulphasalazine and hydroxychloroquine appear clinically better off than patients on a
two-drug combination or mediotrexate alone. This lifts die gloom from die odier studies compiled
so far, where negative interaction (i.e. results of die combination are die same or only slighdy
better dian the single drugs) prevails, often at die cost of somewhat increased toxicity.
Interestingly enough, rheumatologists have not waited for these first positive results or heeded die
many negative trials; according to two recent surveys published in abstract [39,40] diey almost
universally embrace combination dierapy.
Felson et <?/ [41] recendy published a meta-analysis on combination dierapy in which he
pooled die available data. He found a negative answer to die question: 'Does combination dierapy
on average make a difference compared to average single dierapy?' In our view, die heterogeneity
in combinations, strategies and patient material makes diis a less interesting research question. As
shown in Figure 2.1, each combination needs careful study of its potential in several trials, which
can subsequendy be pooled.
Despite die results of Tugwell et <J/"S study, we feel a step-down or parallel strategy in general
shows more potential dian a step-up strategy. The reason is diat step-up trials select patients diat
have demonstrated less responsiveness to dierapy, dius a priori decreasing die chance of future
response. Also, if non-compliance is die basis for lack of efficacy, non-compliant patients are more
prone to being selected in a trial widi non-responders, and die subsequent dierapy will again be
more prone to fail.
Aldiough mediodology has improved significandy in recent years, we still found a number of
problems. Most selected studies had small patient numbers, and notably in die studies widi
negative results, post hoc sample size calculations were often lacking. In dieory, type II errors can
be minimized by sufficiendy large sample sizes. In practice, it is often hard to find eligible patients.
Reliable and responsive measurements can also help to record an actual contrast between groups.
For example, with joint score assessments, reliability can be improved by frequent training of die
assessors.
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Co-intervention and contamination are important issues in clinical trials and, obviously, any
type of co-intervention should be reported in a transparent way. Co-intervention with low-dose
corticosteroids was very common in many of the trials selected for diis review. Steroids quickly
reduce disease activity. With less room for improvement induced by the investigated treatment,
demonstration of contrast between treatment groups becomes harder. Corticosteroids are
generally known as symptom-relieving drugs. The data summarized here, make it clear that
systemic corticosteroids should be considered as disease-controlling anti-rheumatic therapy
(DCART) [42]. Accordingly, uncontrolled co-intervention with corticosteroids in RA clinical trials
needs reconsideration.
In conclusion, in early RA patients, step-down bridge therapy that includes corticosteroids
leads to much enhanced efficacy at acceptable or low toxicity. The effects on joint damage may be
persistent, but the symptomatic effects are probably dependent on continued corticosteroid
dosing. In late patients, cyclosporin improves a suboptimal clinical response to mediotrexate, and
die triple combination of methotrexate, sulphasalazine, and hydroxychloroquine appears clinically
better dian the components. Other combinations are eidier untested, tested at low sample size, or
show negative interaction. In view of the low volume of evidence, most studies need confirmation
by replication.
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Reply to comments on our systematic review on
combination therapy in rheumatoid arthritis.
Rheumafo/ogy 7999; 38; 789-90.
SIR, We thank Drs OTJell, Moore and Klassen for their reaction to our systematic review on
combined treatment with second-line anti-rheumatic drugs in rheumatoid arthritis [1]. This allows
us to discuss their study [2] in more detail than was possible in our original review [3]. Any review
contains arbitrary elements. Therefore, it is essential that all choices in the process of data
aggregation be explicit. In this way, the final evaluation is up to the readers. With Dr OTDell c.s.
we recognize the importance of long-term follow-up. Considering the small number of studies
with extended follow-up, we chose to compare data on outcomes from the selected high-quality
studies after the most extended period of treatment, with (1) patients in the intervention group(s)
still on their intended regimen and (2) before any selection of patients with regard to therapy
efficacy or other criteria had taken place (intention-to-treat principle).
We agonized over the best interpretation of the results of OT)ell # a/'s study, but finally
decided that we did not agree with their own assessment. The key difference in interpretation lies
at the 9 month point. OTDell er <*/ made a legitimate but arbitrary choice to regard any patient not
meeting the 50% Paulus criteria for improvement at 9 months as a therapy failure. Unfortunately,
these patients were not followed up further and no data is available on them. Notably, until 9
months, a suboptimal response could be handled by increases in methotrexate dose, so that most
drop-outs during this period would be for other causes, e.g. toxicity. In contrast, the majority of
drop-outs at or after 9 months would be for lack of efficacy.
In essence, the procedure results in 2 studies, reported as one: (1) a 9 month randomised
controlled trial with the 50% criterion as endpoint (overall results according to intention-to-treat, P
- 0.12, reported in our review as trend); (2) a further follow-up study of the responders. This has
the potential to magnify the (trend) differences at 9 months, e.g. when the mean level of Paulus
response in other groups would be slightly below 50%. In addition, after selection of responders at
the 9-month time point, the distribution of prognostic factors in the three groups (other than
treatment) cannot be assumed to be comparable in the way they were at baseline, immediately after
randomisation. In our view, any comparison of the three groups in such a follow-up study should
be viewed with caution, and certainly not be pooled with the primary results under (1).
To support ODell ef d^s conclusion that triple therapy is more effective than the other
modalities tested, we would need 2-yr data of all randomised patients.
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For instance, we would have liked to see 'sensitivity analyses' of the full dataset (i.e. all
randomised patients) using different cut-off points for response. This is pertinent in view of the
proven greater discriminative capacity of the ACR20 criterion [4]. It would also be nice to know
which patients actually started alternative therapy after they were judged to be treatment failures
according to the trial definition. Also, survival analyses are more suited for 'one-off events such as
recurrence of cancer, and less for disease activity, which is essentially a continuous variable. Thus,
an analysis of the area under the curve of response (or another index) of all randomised patients
might have added valuable information.
"With ODell, we do believe that their results indicate that responders on triple therapy are
more likely to maintain response on follow-up than patients in the other groups.
In conclusion, the final interpretation depends on whether one accepts the 50% Paulus
criterion as sole judge of efficacy and, in addition, whether one is willing to assume that the
selection of patients for follow-up after 9 months based on response did not influence the
distribution of prognostic factors in the treatment groups (other than treatment) present at
baseline.
We thank Dr Hurst for his reaction [5]. Pharmacokinetic explanations of differences in
efficacy of various drug combinations are outside the scope of our review. Nevertheless, we agree
with Dr Hurst that investigators should try to understand benefits that are due to altered
pharmacoiönetics. On the other hand, we do not think that complete understanding is a 'corac&'fio
siwe <7«a wow' for testing combinations, let alone a review on combination therapy. A recent study
shows there is no interaction between methotrexate and sulphasalazine with usual doses for
treatment of rheumatoid arthritis [6]. With regard to an interaction between methotrexate and
cyclosporin, data presented at the FDA Arthritis Advisory Panel Hearing show that although some
metabolites of methotrexate are slightly increased, these are not likely to have any anti-
inflammatory activity.
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Randomised Comparison of Combined Step-Down
Prednisolone, Methotrexate and Sulphasalazine
with Sulphasalazine alone in Early Rheumatoid Arthritis
Abstract
Background: The value of intensive combination therapy in early rheumatoid arthritis is
unproven. In a multicentre, double-blind, randomised trial (COBRA), we compared the
combination of sulphasalazine (2 g/day), methotrexate (7.5 mg/week), and prednisolone (initially
60 mg/day, tapered in 6 weekly steps to 7.5 mg/day) widi sulphasalazine alone.
Mefnods: 155 patients with early rheumatoid arthritis (median duration 4 months) were randomly
assigned combined treatment (76) or sulphasalazine alone (79). Prednisolone and methotrexate
were tapered and stopped after 28 and 40 weeks, respectively. The main outcomes were the
pooled index (a weighted change score of five disease activity measures) and the Sharp/van der
Heijde radiographic damage score in hands and feet. Independent health-care professionals
assessed the main outcomes without knowledge of treatment allocation.
F/nd/'ngs: At week 28, the mean pooled index was 1.4 (95% Q 1.2-1.6) in the combined-
treatment group and 0.8 (0.6-1.0) in the sulphasalazine group (P <0.0001). At this time, 55 (72%)
and 39 (49%) patients, respectively, were improved according to the American College of
Rheumatology criteria. The clinical difference between the groups decreased and was no longer
significant after prednisolone was stopped, and there were no further changes after methotrexate
was stopped. At 28 weeks, the radiographic damage score had increase by a median of 1 (range 0-
28) in the combined-treatment group and 4 (0-44) in the sulphasalazine group (P < 0.0001). The
increases at week 56 (2 [0-43] TO 6 [0-54], P = 0.004), and at week 80 (4 [0-80] TO 12 [0-72], P -
0.01) were also significant. Further analysis suggests that combined therapy immediately
suppressed damage progression, whereas sulphasalazine did less effectively and with a lag of 6 to
12 months. There were fewer withdrawals in the combined therapy than the sulphasalazine group
(6 [8%] TO 23 [29%J, and they occurred later.
/nferprefaf/on: This combined-therapy regimen offers additional disease control over and above
that of sulphasalazine alone and persists for up to a year after corticosteroids are stopped.
Although confirmatory studies and long-term follow-up are needed, this approach may prove
useful in the treatment of early rheumatoid arthritis.
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Introduction
The treatment of rheumatoid arthritis (RA) is traditionally characterised by escalation. The
first step is non-steroidal anti-inflammatory drugs (NSAIDs), and then if necessary a sequence of
progressively toxic second-line drugs (disease-modifying antirheumatic drugs) is introduced [1].
There is evidence that some of these disease-modifying drugs provide a degree of disease control
[2] - i.e. decrease disease activity but also maintain or improve physical function and retard
radiographic joint damage [3]. However, both patients and physicians are dissatisfied with the
long-term results of traditional therapy. A 1996 study suggested that early introduction of disease-
modifying drugs may be more beneficial than delayed introduction for patients with recently
diagnosed RA [4], Research is focused towards finding new, more effective drugs, reassessment
and earlier use of existing drugs (such as corticosteroids [5J, and treatment with drug
combinations [6].
The COBRA trial (COmbinatietherapie Bij Reumatoide Artritis) is an adaptation of die latter
two options - step-down bridge therapy with corticosteroids in early RA [1]. Our intention was to
rapidly bring die disease under control in a very early stage, with agents that have overlapping
windows of efficacy onset; and then, after 6 months to taper and stop die more toxic components
while retaining disease control. We devised a regimen comprising a short period of high-dose oral
prednisolone, rapidly tapered to a low maintenance dose. As the other components we chose
mediotrexate, commonly used as disease-modifying drugs of first choice in the USA, and
sulphasalazine as the anchor drug to remain after die other two drugs were withdrawn. In Europe,
sulphasalazine is commonly used as disease-modifying drugs of first choice.
We carried out a 56-week multicenter, randomised controlled trial among patients with early,
active RA to study the degree of disease control afforded by a combination of sulphasalazine,
mediotrexate and high/low oral prednisolone given in the first 28 weeks, compared widi diat
achieved with sulphasalazine alone; and to find out whether control could be maintained on
sulphasalazine alone, after sequentially tapering and wididrawal of prednisolone and methotrexate
in the second 28 weeks.
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Patients and Methods
Paf/enfs
We recruited patients between May, 1993, and May, 1995, in ten centres (nine in the
Netherlands, one in Belgium). To optimise the benefit/risk ratio in line with the study purpose, we
applied strict eligibility criteria to include patients with early RA who had very active disease and
were most likely to benefit from this intensive treatment, in whom effects could be easily
measured, and in whom we believed adverse effects would be least likely. The inclusion criteria
were: a diagnosis of RA (American College of Rheumatology (ACR) criteria [7j with onset of
disease at or after 16 years of age; active disease of the joints and inadequate control of arthritis
(due to lack of efficacy or toxicity of treatment); and treatment with NSAIDs in adequate doses
for at least 3 months. Such treatment could already have been initiated at the start of symptoms,
not necessarily at the time of diagnosis. We defined disease activity as die presence of six or more
actively inflamed joints, located at diree or more different sites (a site is defined as either one large
joint or a group of small joints: the joints of the wrist, die metacarpophalangeals, the proximal
hand interphalangeals, die distal hand interphalangeals, ankles, die tarsometatarsals, die
metatarsophalangeals, and die proximal and distal foot interphalangeals) and presence of at least
two of die following: nine or more tender joints (irrespective of site), morning stiffness of 45
minutes or longer, and a Westergren's erydirocyte sedimentation rate (ESR) of 28 mm or more in
die first hour.
We excluded patients who had had RA for longer dian 2 years, diose previously or currendy
treated widi any disease-modifying anti-rheumatic drug except anti-malarials (e.g., gold, D-
penicillamine, azadiioprine, or cyclophosphamide) or corticosteroids (for arthritis or anodier
disease), serious comorbidity or recent (widiin die 3 mondis before enrolment) major surgery, or
inability to comply widi die protocol. Adequate contraception was required. Further exclusion
criteria were age below 18 or over 70; hypersensitivity to study medication, sulpha-containing
compounds or aspirin; hypersensitivity to diree or more drugs; active infectious disease; a history
of tuberculosis, recurrent infections, recent (< 3 mondis) gastritis or gastrointestinal ulceration;
any history of gastrointestinal bleeding or neoplasia; diabetes mellitus; hypertension treated with
more dian one antihypertensive drug; significant cardiovascular disease; liver disease; cataract;
glaucoma; haematological disorders; partial or total colectomy, reduced renal function (creatinine
clearance <50 mL/h); proteinuria (>0.5 g/day); hypoalbuminemia; chronic dermatitis; treatment
widi phenytoin, phenylbutazone, salicylates, barbiturates, cholestyramine, probenecid, oral
anticoagulants (dicoumarol derivatives); and a history of alcohol or substance abuse (i.e. inability to
limit alcohol intake to a maximum of 70 g weekly) or use of any experimental drug less dian 2
mondis before inclusion.
The study protocol was approved by research and medical ediics committees in all
participating hospitals. The patients were fully informed about die potential side-effects of all die
drugs. To maintain allocation concealment, diey were told diat response to treatment was variable
in onset and efficacy widi all diree drugs. All patients gave written informed consent.
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/ntervenf/on
Both groups received sulphasalazine (Salazopyrine enteric-coated tablets of 500 mg,
Pharmacia & Upjohn, Uppsala, Sweden) 500 mg/day, increased to 2000 mg/day over a period of 3
weeks. In addition, the combination therapy group received prednisolone and methotrexate; the
control group received matching placebo tablets and capsules identical in appearance and taste.
The daily prednisolone dose was 60 mg in week 1, 40 mg in week 2, 25 mg in week 3, 20 mg in
week 4,15 mg in week 5, 10 mg in week 6, and 7.5 mg thereafter (week 1-6 - one gelatine capsule
containing the daily dose, capsule compound by Bufa, Uitgeest, Netherlands; week 7 and later - 5
mg tablets by CentraFarm Nederland bv, Etten-Leur, Netherlands; some of these tablets were
broken by the pharmacy so that 7.5 mg could be taken daily). The cumulative dose over the first 6
weeks was 1190 mg; over the first 28 weeks it was 2345 mg, corresponding to a mean of 12 mg
daily. The methotrexate prescription was 7.5 mg in a single weekly dose (PharmaChemie bv,
Haarlem, Netherlands). If an adverse event occurred, the drugs were temporarily withdrawn, and
reintroduced at lower doses according to a fixed protocol where possible.
Prednisolone and methotrexate were stopped after 28 and 40 weeks, respectively. Both drugs
were gradually withdrawn to decrease the chance of a disease flare. Thus, from week 29 to 35, a
day of zero prednisolone dose was introduced each week: first week, no prednisolone on
Wednesday, second week, no prednisolone on Tuesday and Saturday, third week, no prednisolone
on Monday, Wednesday, and Friday, until after 6 weeks, the prednisolone had been stopped. After
40 weeks of treatment, methotrexate was tapered: the drug was given at 5 mg per week for 3
weeks, then at 2.5 mg per week for 3 weeks, then stopped. If there was a flare in disease activity,
the last medication stopped was reintroduced. A flare was defined per protocol as an increase of
five in active joint count or an increase from zero to three compared to the situation at week 28
(an active joint is swollen or tender on pressure; counting of joint groups in one hand or foot as
above). If the research medication had to be stopped for any reason and a consecutive disease-
modyfing antirheumatic drug was started, the protocol recommended that a drug not in the
combination should be given, preferably intramuscular gold salts. After 56 weeks, the protocol
ended, and the treating physician was at liberty to change second-line therapy, or to attempt a
second tapering of methotrexate or prednisolone in those patients still on combination therapy.
Where possible, blinded protocol treatment was continued. To maintain allocation concealment
for other patients still in the protocol, the treatment code was revealed only for those patients still
on combination therapy after 80 weeks.
Concurrenf fherapy
NSAIDs and simple analgesics were allowed; discontinuation was actively pursued. A
maximum of two intra-articular steroid injections was allowed in two periods after week 28 of the
protocol, but not in the 6-week period preceding independent assessment. Any other intervention
with parenteral or oral corticosteroids was not permitted. All patients received folic acid (1
mg/day) during methotrexate or placebo prescription and elemental calcium (1 g/day, carbonate
composite) during prednisolone or placebo prescription. Vitamin D deficiency apparent at the
laboratory screening before inclusion was corrected.
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Treafrnenf a//ocaf/on
Patients who met the eligibility criteria were entered into the study and assigned a unique
study identification number by telephone. This number implied random allocation to one of the
two treatments with stratification by centre. For each centre, a separate randomisation list was
generated by an adaptive biased urn algorithm. In contrast to fixed blocks, this algorithm ensured
that the rheumatologists would have no clue to the allocation of each subsequent patient in a
setting where unblinding was possible; yet it also guaranteed an approximately equal distribution
over the groups even in the centres with smaller numbers of patients [8]. The assignment was only
known by the employees of the Maastricht Hospital pharmacy who prepackaged the medication; it
was disclosed to the treating physician only in case of an emergency. Primary analysis was done
with coded group allocation after entry of all study data. The full randomisation codes remained
concealed until completion of the primary analysis.
Organ/saf/on
Each centre was staffed by a rheumatologist, a research nurse and an independent assessor.
The rheumatologist was responsible for the identification and inclusion of the patients, and for all
medical policy decisions. The research nurse monitored patient safety through regular follow-up
schedules (first weekly, then every 4 weeks) and also measured disease activity. Independent
assessors (mostly physiotherapists) applied the outcome measures at baseline and at week 16, 28,
40, and 56; in almost every instance a patient was seen by the same assessor. These health
professionals were not involved in care of patients; they were also asked not to discuss disease
activity or the treatment with the patients. Independent assessment ensured optimum concealment
of primary outcome assessments, especially important in the first 6 weeks of the protocol, when
potential effects and side-effects of high-dosed prednisolone would be most apparent. These
assessments included all primary and core-set outcome measures except pain score, grip strength,
and ESR. The follow-up schedule is continuing; all outcomes of the first 56 weeks are reported
here. In response to criticism about the follow-up period for the radiographs, we read and
analysed the 80-week radiographs at a later stage.
Before the study and then once a year, all study personnel trained together to maintain
assessment quality and agreement between observers. A specially designed manual of procedures
and assessment techniques was available in each study centre. The trial was coordinated and data
managed in the University Hospital Maastricht. Safety and toxicity were monitored by a safety
committee of two independent rheumatologists, the Maastricht University pharmacist, and a
statistician (HS). The pharmacy centre of the University Hospital Maastricht was responsible for
drug production, packaging, and distribution.
of endpo/nfs
The primary endpoint of the therapeutic intervention was a pooled index summarising the
change in five measures after 28 weeks of treatment. Pooling is a validated method to increase
sensitivity of separate measures [9]. To obtain the pooled index of one of the groups at week 28,
we calculated a standardised change score of that group by dividing the mean change in one
measure by its pooled standard deviation of change at week 28. This procedure was repeated for
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each of the five measures; the pooled index is the mean of the standardised scores. To obtain
pooled index values for another time point, change scores at that point were standardised through
division by the same pooled standard deviation at week 28. Finally, a constant was added to all
index values so that the value at baseline was zero. We selected five measures for maximum
sensitivity to change [10]: Tender joint count (68 joints [ l l j ; overall assessment by the
independent assessor (on a 100 mm visual analogue scale, worst and best imaginable health status
at the left and right anchor, respectively); grip strength (by vigorimetry, Martin, Tottiingen,
Germany, range 0-150 kPa, mean of medians of three measurements in both hands [12]); ESR
(Westergren method); and McMaster Toronto arthritis questionnaire [13], which follows
improvement in five impaired activities elicited and priority-ranked by the patient during a baseline
interview, together with change scores for quality of life, psychological, social and emotional
wellbeing. The scores of this questionnaire reflect change, increase as disability improves, and vary
from 10 (maximum deterioration) to 40 (maximum improvement). In its original format, the
baseline questionnaire score differs from the follow-up scores because the change items are not
available. To make these scores directly comparable, we added mock change items at baseline and
scored them as "unchanged". Grip strength and ESR were assessed by the research nurses every
week at the start of the protocol, later at least every 4 weeks.
We assessed all remaining disease activity measures of the World Health Organisation/
International League of Associations for Rheumatology core set as secondary endpoints [14]. As
well was tender joint count, assessor's overall assessment, and acute phase reactant (ESR) included
in the pooled index, these measures are swollen joint count (48 joints: modified from American
College of Rheumatology 66-joint count [11]; small foot joints as one joint site and no midfoot
joints), pain (assessed by patient on a 100 mm visual analogue scale; worst imaginable pain at the
right anchor), and patient's global assessment (on a 100 mm visual analogue scale, worst and best
imaginable health status at the left and right anchor, respectively). To facilitate comparison with
other studies, the highly patient-specific MacMaster Toronto arthritis questionnaire was
complemented with the more generic health assessment questionnaire (HAQ; Dutch validated
version; scores 0-3, 3 indicating a poor functional state) [15].
We expressed improvement in individual patients by the American College of Rheumatology
preliminary criteria for remission [16] (occurrence and duration; because no inquiry on fatigue was
made we used the concept of a 'probable remission' for instances in which a patient would be in
remission when absence of fatigue was assumed). Furthermore, we used the American College of
Rheumatology preliminary criteria for improvement in RA [17] (i.e. minimum 20% improvement
in tender and swollen joint counts plus a similar improvement in at least three of five remaining
core-set measures). Before calculating improvement percentages, we ensured (by recoding if
necessary) that all scales decreased on improvement. We also report improvement with application
of a 50% threshold instead of 20% in the American College of Rheumatology criteria.
To facilitate comparison with other European studies, we report the disease activity score
(DAS) [18], a composite outcome measure containing the Ritchie tender joint index (RI), swollen
joint count (SJC), ESR and patient's overall assessment (POA);
DAS -0.54-VW + 0.065SJC + 0.33-lnESR + 0.007POA.
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The term disease-controlling has been suggested for antirheumatic treatment regimens that
improve disease activity, retain or improve physical function, and decrease progression of
radiographic damage [3]. A priori, we expected our study to be too small to detect small
differences in radiographic progression between the two groups, since both were treated with the
disease-controlling drug sulphasalazine. Nevertheless, two trained observers (AB & AV) assessed
radiographic damage, unaware of the identity of the patients. They separately scored radiographs
of hands and feet according to van der Heijde's modification of Sharp's method [2]. This method
reflects erosions and joint-space narrowing in 44 joints in the hands and feet. The principal
measure, the total score, is the sum of erosion and narrowing scores, and ranges from 0 to 448.
The method requires radiographs to be presented in ordered fashion (baseline, and weeks 28, 56
and 80). Scores can either be stable or increase; decrease (indicating improvement) is not possible.
We report the mean of the two observers' erosion, narrowing, and total scores.
As an exploratory analysis, we also report the cumulative number of joints free of erosions at
baseline in which at least one erosion developed during follow-up. For this purpose, joints were
grouped into four areas on each side: wrist (six joints), metacarpophalangeal (five joints); proximal
interphalangeal (four joints); and foot joints (six joints). The first erosion in each area was counted.
Furthermore, we explored the rate of radiographic change in each of the measurement periods by
calculating not only the change scores from baseline, but also the change scores between week 28
and 56 and between week 56 and 80.
Tox/crty and mon/toring
Laboratory monitoring at every control visit comprised complete blood count, measurement
of serum total bilirubin, aminotransferases, alkaline phosphatase, creatinine, blood urea nitrogen,
and electrolytes, and urinalysis for glucose and albumin. Toxicity was assessed by counting each
advene event reported and possible subsequent changes to treatment (e.g. withdrawal). Each
patient underwent pulmonary function tests (expiratory volume and carbon monoxide diffusion
capacity) at baseline and twice yearly thereafter. Bone densitometry was done by an operator
unaware of treatment assignment, in all centres where a dual-energy X-ray absorptiometer was
available (Lunar, Hologic or Norland, in eight centres). We report changes in bone density for
lumbar spine and femoral neck (mean of right and left hip).
We assessed IgM rheumatoid factor serostatus in a time-resolved fluoroimmunoassay (rabbit
IgG antigen; Nordic, Tilburg, Netherlands); values over 20 kU/L classified patients as positive for
rheumatoid factor [19]. Class II human leukocyte antigen (HLA) genotype was identified by
serological typing (Tissue Typing Laboratory, Maastricht University Hospital).
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Comp/Zance
We assessed compliance by tablet counts at every control visit, by questioning (including a
quantification of the number of tablets missed), and by measurement of sulphapyridine (a
sulphasalazine metabolite) in urine samples taken at weeks 16, 28, and 40. We classified as non-
compliant all patients on protocol treatment who were negative for sulphapyridine once or who
failed to return tablet boxes at control visits more than once. In the first 28 weeks, we made
judgements at every control visit, and classified as 'probably non-compliant' patients who in the
first 28 weeks on average missed more than one daily dose a week of sulphasalazine or
prednisolonej or more than one weekly dose of methotrexate over a period of 6 weeks.
The target sample size was 168 patients. This number yields a power of at least 90% to detect
a difference of 0.33 or greater in the pooled index (SD 0.45) between the treatment groups at two-
sided a - 0.05, given a maximum dropout rate of 50%. Enrolment stopped at 156 patients for
practical reasons, because the actual drop-out rate was 20%. All analyses were based on intention
to treat as initially assigned. All available data were used. Data missing due to loss to follow-up
were handled by a last observation carried forward approach. For other missing data, values were
interpolated if actual assessments were available at least every 28 weeks. No interim analyses were
done.
Measures wkh a Gaussian distribution are expressed at baseline as mean and SD, and as mean
change with 95% confidence intervals. The main endpoint was initially analysed by two-way
ANOVA with treatment, centre and their interaction as factors. The latter two factors were not
significant (centre /> - 0.07 ; interaction P = 0.79). In view of the large effect of treatment, further
analyses ignored centre as a factor, with exception of the multivariable analysis. Measures with a
non-Gaussian distribution are expressed as median and median change (minimum-maximum) and
analysed with Mann-Whitney tests; measures with a discrete distribution are expressed as counts
(%) and analysed by continuity-corrected x^  tests or Fisher's exact tests where appropriate. The
level of significance was set at /> <0.05, two-sided. No adjustment was made for multiple testing.
For the main clinical and radiological outcome, multivariable analyses tested whether
imbalance in important prognostic factors between the two groups remaining despite
randomisation affected the study results. The dependent variables were the pooled index and the
progression in total radiological damage score at 28 weeks. The latter was log-transformed (new
variable = log [total change score +1]) because of a skewed distribution. Full and parsimonious
models were constructed: the full models contained the predictive variables: treatment group,
centre, sex, age, disease duration, rheumatoid factor status, presence of HLA genotype DR4 or
DR2, number of years education, marital status, and baseline scores for DAS, HAQ, and
radiological damage. The parsimonious models contained only those variables selected in forward
stepwise regression analysis (F to enter >4.0). Plots of residuals versus fitted and versus predictor
values were inspected for departure of regression analysis assumptions. Because there was still
substantial skewness after log transformation on the total radiological damage score, the results of
the regression analysis on this variable must be interpreted with caution.
49
co/nfc/natfon tfjeraov w? rheumato/cf arthritfs: chaoter 3
random/sec/
a/focafed
COBRA Sulphasalazine
clinical outcomes 0,16, 28, 40, 56 weeks
radiological outcomes 0, 28, 56, 80 weeks
safety visits every 1 -4 weeks
rece/Ved freafmenf
<$ /nc/uded /n ana/ys/s
0
16 -
28 -
weeks
40 -
56 J
comp/eted fr/a/
1: ineligible
at start
1: 1 AE
2: 1 AE
1 LE
3: 3LE
8: 4AE*
2LE
2 AE+LE
9: 1 AE
7LE*
1 other'
3: 1 AE
2LE*
3: 1 LE
2 other'
Treafmenf protoco/
Figure 3.1: Trial profile.
* One patient lost to follow-up.
AE, adverse event; LE, loss of efficacy, 'other' includes protocol violations.
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Results
The trial included 156 patients (Figure 3.1). In one patient the protocol medication was
stopped within 1 week because his disease was in spontaneous remission at baseline. Data of this
patient are not reported. 76 patients received combination treatment, 79 sulphasalazine only. Five
patients (3%, all in the sulphasalazine group) were lost to follow-up before week 56. In six patients
(all withdrawn) the treatment assignment had to be revealed before week 56 for medical reasons.
The two treatment groups were similar in terms of baseline disease activity, radiographic
damage, demographic and odier prognostic variables (Table 3.1). Except for one Asian patient in
each group, all patients were white. Our eligibility criteria resulted in a study group with very early,
active, and severe RA; in 77% the trial medication comprised the first disease-modifying anti-
rheumatic drug. High rates of rheumatoid-factor positivity, HLA-DR4 genotype, and presence of
radiographic damage all indicate a poor a-priori prognosis (Table 3.1). In 21% of all patients (i.e.
32% of those with baseline erosive disease) erosions were initially found only in the feet.
Table 3.1: Baseline characteristics of study patients.
Demography
Age in years, mean (SD)
Female
Educational years, mean (SD)
Clinical characteristics
Combined treatment
(n-76)
49.5 ±11.9
50 (66%)
10.0 ± 3.0
Disease duration in months, median (min-max) 4 (1- 24)
Previous treatment with anümalarials
Hospitalized for RA at baseline
Positive IgM rheumatoid factor
HLA-DR4 positive *
HLA-DR2 positive *
Erosions on hand or foot radiographs *
16 (21%)
9 (12%)
59 (78%)
44 (60%)
16 (22%)
55 (74%)
Sulphasalazine
( » •
49.4
41
9.6
4
19
11
57
39
12
59
•79)
± 12.3
(52%)
± 3.3
(1-23)
(24%)
(14%)
(72%)
(56%)
(16%)
(79%)
* Human leukocyte antigen; homozygotic or heterozygotic DR type, assessed in 143 patients (92%).
t Patients with available baseline radiographs; combined-treatment rz -74, sulphasalazine group n -75.
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Changes in ESR in first 16 weeks are shown in graph in upper right corner (note different time scale).
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C//n/ca/ oufcome
Within a few weeks, combined therapy greatly improved disease activity in most patients
(Figure 3.2, Table 3.2). Sulphasalazine also improved disease activity substantially, although less
than combined treatment. There was an almost immediate response to combined treatment in all
other frequently assessed measures (e.g. grip strength, pain, ESR, the latter shown in Figure 3.2).
Despite a daily prednisolone dose of only 7.5 mg from week 7 onwards, further improvement
continued up to week 28. At this time, the clinical efficacy of combined treatment was almost
double that of sulphasalazine (Figure 3.2, Table 3.2). 55 (72%) of the combined-treatment group
compared with 39 (49%) of the sulphasalazine group had improved according to "20% ACR"
criteria (/> = 0.006), and 37 (49%) compared with 21 (27%) had improved under the "50%" criteria
(P = 0.007).
In the combined-treatment group 16 patients had probable remissions and five definite
remissions during the first 28 weeks (total 28%). In the sulphasalazine group, the corresponding
numbers were nine and four (total 16%; /> = 0.14). In the combined-treatment group only,
remissions clustered near the beginning and end of the first 28-week period. Almost all of these
ended when prednisolone was stopped, and in the second 28 weeks, only a few additional patients
had remissions. For the total study period, there were 18 probable and six definite remissions
(32%) in the combined-treatment group, compared with 14 and five in the sulphasalazine group
(24%; P = 0.38). Of these, only one patient in the combined-treatment group and three in the
sulphasalazine group had persisting remission at 56 weeks.
The difference in clinical efficacy between the treatment groups decreased and was no longer
significant after withdrawal of prednisolone, and there were no further changes when
methotrexate was withdrawn (Figure 3.2). However, differences in two of three measures of
physical function (HAQ, grip strength) remained near significance (Table 3.2). Prednisolone was
restarted (for disease flares) in six patients in the combined-treatment group. Methotrexate was
restarted in 13 patients in the combined-treatment group, and methotrexate placebo in three
patients in the sulphasalazine group.
Adjustment for prognostic variables did not change the difference in efficacy between
treatments (crude coefficient for the additional effect of combined treatment is sulphasalazine on
the pooled index at week 28: 0.63 [SE 0.12], /> < 0.0001; adjusted coefficient 0.59 [0.11], P <
0.0001). In stepwise regression analysis, baseline physical disability score and disease duration, as
well as centre, significantly affected the pooled index at week 28; patients with high initial disability
and shorter disease duration were more likely to improve. The effect of treatment was not changed
in the model incorporating these factors.
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Table 3.2: Main clinical outcomes of treatment after 28 and 56 weeks of combined (w = 76) and suiphasalazine (« = 73) treatment
Clinical outcomes at baseline 28 weeks 56 weeks
Mean (SD)
Combined SSZ
Mean (SD) change Mean (95%CI)
difference
Combined SSZ in change *
Mean (SD) change Mean (95%CI)
difference
Combined SSZ in change * />
Pooled index
Overall value f
Tender joint count
Grip strength (kPa) f
ESR (mm/hr)
Assessor's global
assessment (VAS)
MACTAR
questionnaire f
0 0
25 (14) 24 (14)
24 (15) 29 (20)
57 (14) 53 (32)
53 (14) 51 (22)
24 (14) 24 (4)
1.4 (0.7) 0.8 (0.7) 0.6 (.4, .8) <.0001 1.1 (0.8) 0.9 (0.8) 0.2 (-.1,.4) .20
-16 (14) -8 (14) 8 (4,13) .0004 -10 (14) - 9 (19) 1 (-4,7) .62
25 (17) 11 (15) 14 (9,19) <0001 18 (18) 13 (17) 5 (-1,10) .09
-40 (28) -27 (26) 13 (5,22) .002 -31 (28) -24 (27) 7 (-2,15) .13
-33 (26) -17 (25) 16 (8,24) .0001 -27 (28) -20 (27) 7 (-15,20) .13
10 (5) 7 (6) 3 (1,5) .0007 7 (7) 8 (6) -0.5 (-3,2) .62
Other core-set measures
Pain score (VAS)
Patient's global
assessment (VAS)
Swollen joint count
Health assessment
questionnaire
55 (21) 54 (22) -34 (25) -20 (30) 14 (5,23) .002 -23 (29) -25 (28) - 2 (-11,7) .66
47 (20) 52 (19)
16 (9) 24 (8)
-24 (25) -19 (29)
-10 (8) -5 (8)
5 (-4,14) .25
5 (2,7) .001
-14 (30) -21 (31) -8 (-17,2) .12
- 7 (7) - 5 (9) 2 (-1,4) .27
1.5 (0.7) 24 (0.7) -1.1 (0.8)-0.6 (0.6) 0.5 (.3, .7) <0001 -0.8 (0.8)-0.6 (0.7) 0.2 (-.0, .5) .06
Disease activity score 4.6 (1.0) 24 (1.0) -2.1 (1.2)-1.3 (1.2) 0.8 (.5,1.2) <.0001 -1.4 (1.2)-1.3 (1.4) 0.1 (-.4, .5) .78
SSZ = suiphasalazine alone; VAS = visual analogue scale; MACTAR = McMaster Toronto arthritis questionnaire.
* Combined minus suiphasalazine; positive values indicate better average outcome in combined treatment group.
t Positive values for change indicate improvement.
_step-ctown predn/sofone. M7X and SSZ vs SSZ
Jo/nf desfrucf/on on rad/ograpns
Radiographs of 147 patients (73 combined treatment, 74 sulphasalazine) were available for
assessment (baseline and at least one follow-up). The between-observer reliability of the assigned
total scores was satisfactory (within-class correlation coefficient of absolute scores 0.91, and of
change scores, 0.88. Because of skewness in the data we also calculated Spearman rank correlations
(absolute scores 0.90, change scores 0.89).
The groups were well balanced in terms of damage at baseline (Figure 3.3, Table 3.3). 26% w
22% of patients had no erosions; 23% w 19% had a total score of 0. The total score had increased
significantly more in the sulphasalazine group than in the combined-treatment group at 28 weeks
(P <0.0001), 56 weeks (P - 0.004); and 80 weeks (P - 0.01; Table 3.3, Figure 3.3). The differences
between the groups were greatest for increases in the erosion score (Table 3.3). At 28 weeks, 31%
of the combined-treatment group x* 13% of the sulphasalazine group had stable scores (P -
0.009); at 56 weeks, 19% ts 10% (P - 0.23); at 80 weeks, 10% w 7% (P - 0.75). In both groups,
patients without erosions at baseline showed little progression over 80 weeks: median increase 2
(0-25).
The findings on new erosive damage appearing in one of eight areas previously free of
erosions s were similar. After 28 weeks such damage had appeared in median zero areas (0-5) in
the combined-treatment group, compared with one (0-6) in the sulphasalazine group (P <0.0001).
The corresponding numbers at 56 weeks were zero (0-6) and one (0-7, P < 0.0001), and at 80
weeks one (0-7) and two (0-8, P - 0.0004).
28 56 80
Figure 3.3: Effect of treatment on total radiographic damage score
Box-whisker plots of absolute radiographic damage scores (Sharp/van der Heijde method; summed total
scores for erosions and joint-space narrowing in the hands and feet). Horizontal line in box is the median;
limits of box are 25th and 75th percentiles; whiskers indicate 10th and 90th percentiles; values below and
above these are plotted seperately.
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The damage rates calculated per study period showed slow progression of damage in the
combined-treatment group in the first period (baseline to 28 weeks), whereas progression in the
sulphasalazine group was more rapid (median increase in total score 0-28 weeks 1 [0-28] in the
combined-treatment group is 4 [0-44] in the sulphasalazine group; P < 0.0001). In the second
period, in which prednisolone and methotrexate were stopped (28-56 weeks), the rate of
progression was again lower in the combined-treatment group than in the sulphasalazine group
(median increase 1 [0-36] w 2.5 [0-27], P - 0.04), but during weeks 56-80 the rate of progression
did not differ significandy (1.5 [0-36] w 2.5 [0-32], P = 0.37).
Adjustment for prognostic variables did not change the difference in efficacy between
treatments (crude coefficient for the additional effect of combined treatment is sulphasalazine on
the log-transformed total score at week 28 -0.302 [SE 0.075], P < 0.0001; adjusted coefficient -
0.297 [0.062], P <0.0001). In stepwise regression analysis, baseline values for radiological damage,
DAS, HLA-DR4 genotype, and rheumatoid factor as well as centre significandy affected the
progression of radiological damage at week 28. Patients who had higher baseline values for
radiological damage and DAS and who were positive for HLA-DR4 and rheumatoid factor, had
higher rates of progression. Again, die effect of treatment was not changed in die model
incorporating diese factors.
Table 3.3: Radiographic outcome of treatment; median scores (min-max) [2]
Baseline* («)
Erosion Score
Narrowing Score
Total Damage Score
28 Weeks
Erosion Score
Narrowing Score
Total Damage Score
56 Weeks
Erosion Score
Narrowing Score
Total Damage Score
80 Weeks
Erosion Score
Narrowing Score
Total Damage Score
Combined
(7:
2
1
3
(7/)
0
0
1
(70)
2
1
2
(65)
4
2
4
* Mann-Whitney rank-sum test.
treatment
?)
(0-36)
(0-26)
(0-58)
(0-24)
(0-11)
(0-28)
(0-32)
(0-28)
(0-43)
(0-46)
(0^35)
(0-80)
Sulphasalazine
(74)
3 (0-48)
1 (0-22)
5 (0-48)
(71)
4 (0-26)
1 (0-20)
4 (0-44)
(65)
5 (0-32)
1 (0-30)
6 (0-54)
(56)
7 (0-52)
2 (0-34)
12 (0-72)
t Patients with baseline and at least one follow-up radiographic assessment.
P *
< 0.0007
0.04
< 0.0007
0.007
0.5J
0.004
0.004
0.40
0.07
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Significantly fewer patients stopped combined treatment than stopped sulphasalazine (Table
3.4, /> = 0.0008), and combination therapy patients dropped out later. Differences were apparent
for both toxic effects and lack of efficacy. For instance, all four withdrawals from the combined-
treatment group because of lack of efficacy occurred after week 28, when prednisolone and
methotrexate were stopped; by contrast, most of the 19 withdrawals for lack of efficacy in the
sulphasalazine group occurred before week 28 (Figure 3.1). The adverse reactions that led to
withdrawal of two patients in the combined-treatment group were gastrointestinal-tract complaints
and dyspnoea (final diagnosis exacerbation of chronic bronchitis). In the sulphasalazine group the
adverse reactions leading to withdrawal were rashes in four patients, gastrointestinal-tract
complaints in two (one with concurrent proteinuria), granulopenia with a concurrent increase in
aminotransferases in one patient, and thrombocytopenia (diagnosis preleukemic disease) in one.
The study medication was discontinued and restarted at an adjusted dose according to
protocol in five patients. Three of these five patients (one in the combined-treatment group) had
low granulocyte counts, the other two patients (both combined-treatment group) had high
aminotransferases concentrations and gastrointestinal complaints, respectively. The remaining
adverse events were not followed by withdrawal of study medication. These included 18 cases (12
combined treatment) of infection, treated as outpatients, 17 patients (nine combined treatment)
with gastrointestinal complaints (no ulcer or bleeding); ten (six combined treatment) with
cardiovascular disorders; including one myocardial infarction; and eleven (five combined
treatment) with skin disorders. Various other complaints and transient laboratory abnormalities
were reported in 37 cases (20 combined treatment).
Table 3.4: Reasons for withdrawal of patients from study
Reason
Lack of efficacy
Adverse reaction
Both
Other*
Protocol violation t
Combined treatment
median time
(weeks) to
« withdrawal
4 42
2 16
(min-max)
(36-48)
( 3-29)
S .
12
6
2
2
1
»hasalazine
mpHian Tiny*
(weeks) to
withdrawal
17
5
95
28
50
(min-max)
(16-40)
( 2-31)
( 9-10)
(16-40)
Total* 6 38.5 ( 3-48) 23 16 ( 2-50)
* One patient emigrated in week 40 of follow-up, one became pregnant,
t Treated with parental corticosteroids for pulmonary disease,
t Difference in total number of withdrawals: /> = 0.0008.
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Expected adverse effects such as weight gain and hypertension were monitored at every
control visit (i.e., at least every 4 weeks); osteoporosis was assessed by twice-yearly bone
densitometry where possible (64 combined treatment, 62 sulphasalazine patients assessed).
Patients in both the combined-treatment and sulphasalazine groups gained weight (mean gain at
28 weeks 2.5 kg [95% d 1.8, 32] « 0.7 kg [-0.2 , 2.2], P - 0.002; at 56 weeks 17 kg [0.8, 2.6] w
1.2 kg [0.2, 2.2] respectively, P - 0.49). Blood pressure remained stable in both groups. Baseline
characteristics and prognostic factors for osteoporosis were balanced and mean initial bone density
was normal (1.134 [SD 0.19] g/cm* in lumbar spine and 0.920 [0.14] g/cm* in femoral neck). Eight
women in the combined-treatment group and one in the sulphasalazine group were using
hormone replacement therapy. During the first 28 weeks, the mean changes in lumbar bone
density in the combined-treatment and sulphasalazine group (w = 64, 62) were -1.2% (-2.0,-0.3)
and 0% (-0.9, 0.9) (/> - 0.06). At 56 weeks, the changes were -1.3% (-2.3, -0.4) and -0.3% (-1.4,
0.8) respectively^ - 0.15). In the femoral neck the corresponding bone density changes were -0.6
(-2.1, 0.9) « -0.7 (-2.1, 0.7) over 28 weeks, and -1.9 (-3.1,-0.7) ts -1.3 (-2.5,-0.1) over 56 weeks
(both /> >0.2). Eight is six patients lost more than 5% (mean 8%) of spinal bone; 14 ra nine lost
more than 5% (mean 8%) of femoral neck bone. These losses typically occurred in the first six
months, with stabilisation or improvement thereafter.
Lung function measurements showed no important changes during the first 56 weeks (data
not shown).
Comp//ance and protoco/ wo/af/ons
Of patients who completed the 56-week treatment protocol, nine (six combined treatment,
three sulphasalazine) were classified as non-compliant - eight were negative for sulphapyridine in
at least one of the urine samples taken at weeks 16, 28, and 40; and one did not return medication
for pill counts more than once. Fifteen other patients (six combined treatment, nine
sulphasalazine) were classified as probably non-compliant. Thus, compliance was deemed
satisfactory in 131 patients (85%). Eight patients received intra-articular injections with
corticosteroids outside the permitted periods (two of them had been withdrawn; three were in the
combined-treatment group, five in the sulphasalazine group). Eight patients in the sulphasalazine
group started treatment with oral corticosteroids after they were withdrawn from the trial. In
addition, one patient in the sulphasalazine group was withdrawn because she needed
corticosteroids to treat pulmonary disease.
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Discussion
The combination of an extended oral pulse of corticosteroids, methotrexate, and
sulphasalazine led to an immediate, substantial, and highly significant improvement of disease
activity and physical function in most patients with severe, early RA. On a low daily maintenance
dose of 7.5 mg prednisolone from week 7 onwards, this improvement continued at a slower pace
up to week 28, and was almost double that of conventional treatment with sulphasalazine alone in
all clinical measures. The study did not have sufficient power to show statistical significance for
differences in remission rates. Combined therapy also had beneficial effects on joint damage as
shown on hand and foot radiographs. This degree of clinical efficacy could not be maintained by
sulphasalazine alone - most of the clinical differences between the groups decreased and were no
longer significant after prednisolone was withdrawn, and there were no further changes after
methotrexate was stopped. However, from inspection of an area under the curve we suggest that
the patients who received combined treatment had major clinical benefit throughout the year. This
view is supported by the low withdrawal rate for any reason during the study period. The benefits
of combined therapy on radiography persisted up to week 80. We believe, therefore, that
combined therapy can be classified as a disease-controlling and-rheumatic therapy [3].
The differences between COBRA and sulphasalazine are all the more striking because
sulphasalazine alone also performed well as a disease-controlling anti-rheumatic drug - the onset
of action was rapid, the withdrawal rate low (observed 29%, expected 27-40%), and the
radiological progression rate was similar to that in another study in early RA [2]. The true clinical
relevance of the effects of the combined treatment must be proven by follow-up studies.
However, since demonstration of any effect on radiological progression in RA in difficult, we
believe that the decrease, to a third of that of sulphasalazine - and possibly a sixth that of
"symptom-modifying and-rheumatic" drugs such as hydroxychloroquine - will prove clinically
relevant.
Wididrawal rates for bodi toxicity and lack of efficacy were much lower with combined
therapy than widi sulphasalazine, and expected side-effects (especially of prednisolone such as
osteoporosis) were of minor importance. The low wididrawal rate may by itself contribute to the
differences in efficacy by preventing the loss of anti-rheumatic effect during the time when
treatment is switched from one agent to another. There was a slight increase in infecdons with
combined dierapy but none led to (even temporary) protocol interrupdons and all could be treated
widiout hospital admission. Such toxicity figures must be interpreted widi caudon; widi its small
sample size and short follow-up, a clinical trial is not suited to reliably detection of side-effects diat
may be important. Given die limited period and dose of die combination, we do not expect
relevant late morbidity. Nevertheless, die study cohort is being followed up to so diat long-term
benefits and risks of die dierapy can be assessed. Thus we were able to read, analyse and report die
80-week radiograph data ahead of time in response to criticism diat 56 weeks of follow-up was too
short.
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The randomisation procedure of our trial created prognostically similar treatment groups.
Protocol violations, contamination and co-interventions were minor and did not affect the
conclusions from intention-to-treat analysis. Compliance was satisfactory, in an admittedly crude
assessment. However, concealment of allocation might raise some concerns. The treating
rheumatologists responsible for recruitment (but not assessment) could potentially become aware
of treatment allocation. However, the randomisation procedure guaranteed that they had no clue
to the treatment allocation of subsequent patients. Outcome assessment was fully delegated to
independent assessors: they were unaware of the rapid effects of corricosteroids because they were
not involved in the care of these patients, and assessed them only at baseline and at weeks 16, 28,
40, and 56. They were asked not to discuss the disease or its treatment with the patients. Since they
were health professionals but not physicians, they had less experience with corticosteroid side-
effects. The patients were fully informed about the potential side-effects of all the drugs. To
protect against unblinding, they were told that response to treatment was variable in onset and
efficacy with all three drugs. Although some unblinding due to large differences in efficacy cannot
be ruled out, the effects of the subjective clinical measures were consistent, and reflected those in
the objective measures (e.g. ESR).
Another concern that might be raised is the method of reading radiographs. To improve
precision, these were read without knowledge of the patient's identity or group allocation, but they
were ordered in sequence. This approach might be criticised as leading to bias. In general, opinions
are divided on the value of having previous information available when a judgement is made. In
the case of radiographs in studies of RA, and especially in early disease, random-sequence reading
introduces a lot of noise, because small changes in positioning can temporarily hide erosions. In
any case, both Larsen's original method [20] and the van der Heijde modification of Sharp's
method [2] require sequential reading; these are the methods used in the majority of published
studies (although some - e.g. Kirwan [5] - did score randomly). In our trial, any bias would work
in the same direction in both groups, and would not alter the conclusions based on the differences
between the groups.
The eligibility criteria in our trial selected RA patients with poor a-priori outlooks. For
instance, a high proportion of patients had erosive disease at baseline (77%), partly because we
included of foot radiographs: on the basis of hand radiographs only the proportion of patients
with erosive disease would have been 47%. Nevertheless, some patients included may not have
needed such an intensive approach as our combined treatment, since predictive variables never
provide 100% accuracy [21]. On the other hand, such patients would probably show good clinical
response, and withdrawal of prednisolone and methotrexate would be possible; thus the risks
involved in their overtreatment are limited. We arbitrary excluded patients older than 70, and
further study is needed before this therapy can be advised to patients over 70, or for patients with
a longer duration of RA or concurrent disease. Thus, our results apply to otherwise healthy
patients with early and active RA treated in a specialist setting. The opportunity to intervene early
with second-line antirheumatic drugs relies heavily on the early diagnosis of RA and rapid referral
of patients; health-care systems should be specifically organised to facilitate this process.
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Combination therapy can be applied in many different ways. We chose a step-down strategy
with rapidly acting drugs. This approach optimised the chance of efficacy in a potentially limited
window of opportunity. Our results supports the view that corticosteroids are among die most
effective and rapidly working disease-controlling antirheumatic drugs. A meta-analysis has
confirmed that low-dose corticosteroids can be beneficial [22]. The toxic effects of corticosteroids
may be comparable to those of some odier disease-modifying anti-rheumatic drugs and even
NS AIDs; and tlteir use in established RA is widespread. However, doubts over the longevity of the
effects, and fears of cumulative morbidity have limited their use in early RA. The optimal dosing
schedule is also unclear.
In 1959 a trial of prednisolone at daily doses of 10-20 mg indicated anti-rheumatic properties
(bodi clinical and radiological), but with substantial side-effects [24]. Kirwan and colleagues [5]
showed an effect of 7.5 mg prednisone dairy on the development of radiological damage together
with only temporary effect on disease activity measures, and no side-effects. These investigators
have since reported that joint destruction recommences after corticosteroids are withdrawn [25].
By contrast, the effect of our combined treatment on the progression of joint destruction persisted
up to 1 year after corticosteroids were stopped. The initially more rapid progression in the
sulphasalazine group slowed and approached tiiat of die combined-treatment group with a lag of 1
year. These differences between our study and that of Kirwan might die result of more effective
treatment not only in our experimental group but also our control group.
Van Schaardenburg and colleagues [26] found only temporary clinical effects of a prednisone
regime starting widi 15 mg dairy. Other studies widi step-down strategies and oral or parental
steroid pulses showed limited benefit and troubling rebound effects [27-29]. The limited clinical
efficacy of corticosteroids in odier trials may be due to the use of doses inadequate to bring the
disease under control from die outset. Our results support die concept of step-down bridge
dierapy, and suggest that immediate and intensive suppression of high damage progression rates
by a rapidly acting regimen may be sustained by another regimen widi a slower mode of onset
(e.g., sulphasalazine).
60 mg of prednisolone is a high daily dose for RA However, die rapid tapering schedule
resulted in a mean daily dose of 12 mg overall, and 7.5 mg daily from week 7 onwards. Also, die
initial dose is not high compared widi standard (but not always proven) dierapy for most odier
severe autoimmune diseases (e.g., myositis, vasculitis, lupus nephritis) and is much lower than the
intravenous metiiylprednisolone pulses diat have been tried widi limited success for many
indications, including RA The tapering schedule after week 28 proved to be too rapid, resulting in
partial loss of benefit and some disease flares. This factor may have contributed to die relatively
low numbers of lasting remission. We look forward to further studies widi slower tapering
schedules.
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We chose methotrexate as second drug in the combination because the onset of effect is
rapid. However, in this and another trial, the response to sulphasalazine was as rapid as that to
methotrexate [30]. In die design phase, we set a fixed, low dose of mediotrexate because little was
known about die toxicity of our combination. We would, widi die data in available, now probably
try dose intensification of mediotrexate or sulphasalazine in case of suboptimum response (widi
die risk of additional toxic effects). The value of die combination of mediotrexate and
sulphasalazine is uncertain [30-32]. In our study, tapering of mediotrexate had little impact on die
mean results, aldiough some patients had disease flares, which might be attributable to die
wididrawal of prednisolone in die preceding period. The contribution of 7.5 mg mediotrexate
weekly to efficacy and toxicity was probably relatively small in die second 6 mondis of treatment.
However, whedier die efficacy of die full combination in die first 6 mondis can be equalled by
prednisolone/sulphasalazine or prednisolone/mediotrexate combinations remains to be seen. In
view of die high benefit-risk ratio of our combined treatment in die first 6 mondis, we believe
maintenance of diis ratio in die subsequent period is more desirable dian reduction of die already
low risk in die first 6 mondis.
To date, most drug combination trials have not shown addition or synergy, (i.e. benefits equal
or better dian die sum of benefits attributed to die single drugs). At best, investigators showed
some enhanced efficacy at die expense of some extra toxic effects. However, Tugwell and
colleagues [33] found diat patients widi long-standing RA who had only a partial response to
mediotrexate show clinically important improvement when cyclosporin was added to dieir
regimen. OTDell and colleagues achieved 50% improvement in composite symptoms of arthritis
with mediotrexate, sulphasalazine and hydroxychloroquine [34]. 80% and 50%, respectively, of die
patients in diese two studies were on low-dose corticosteroid maintenance dierapy. Bodi studies
show diat substantial improvement is possible in established disease, and diat more study on die
merits of combination dierapy is necessary.
Our study supports die view diat corticosteroids in die proper regimen are among die most
powerful disease-controlling anti-rheumatic drugs available. Early and intensive intervention in RA
widi diis combination step-down schedule offers additional disease control over and above diat of
sulphasalazine alone. Damage control persists up to 1 year after corticosteroids are stopped, but to
maintain optimum clinical efficacy after 28 weeks, anodier tapering schedule is probably necessary.
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Cost-Effectiveness and Cost-Utility of Combination Therapy
in Early Rheumatoid Arthritis: Randomised Comparison of
Combined Step-Down Prednisolone, Methotrexate and
Sulphasalazine with Sulphasalazine Alone
Abstract
Ob/ecf/Ve: Assessment of the cost-effectiveness and cost-utility of early intervention in
rheumatoid arthritis (RA) patients, with combined step-down prednisolone, methotrexate, and
sulphasalazine, compared to sulphasalazine alone.
/Wetfiocte: Multicentre 56 week randomized double-blind trial with full economic analysis of direct
costs and utility analysis with rating scale and standard gamble measurement techniques.
Resu/fs: The combined-treatment group included 76 and the sulphasalazine group 78 patients.
The mean total costs per patient in the first 56 weeks of follow-up were $5519 for combined
treatment and $6511 for treatment with sulphasalazine alone (P - 0.37). Out-patient care, in-
patient care and non-health care each contributed about one-third to the total costs. The
combined-treatment group appeared to generate savings in length of hospital stay for RA, non-
protocol drugs and costs of home help, but comparisons were not statistically significant. Protocol
drugs and monitoring were slightly more expensive in the combined-treatment group. Clinical,
radiographic and functional outcomes significantly favoured combined treatment at week 28
(radiography also at week 56). Utility scores also favoured combined treatment.
Conc/us/on: Combined treatment is cost-effective due to enhanced efficacy at lower or equal
direct costs.
Introduction
Rheumatoid arthritis (RA) is a systemic disease with symmetrical inflammation of joints in
upper and lower extremities as most important feature. Patients suffer from pain, stiffness,
impaired function in daily life and at work, increased dependence on family and friends, and
decreased participation in leisure activities. RA is associated with morbidity, worsening of quality
of life and mortality [1,2].
The monetary cost of RA is high due to increased use of out-patient medical services,
increased hospitalization rates and major work disability in the course of the disease [3].
Intervention studies that include an economic evaluation in RA are rare [4] and, to our knowledge,
nonexistent in early RA.
A combination therapy regimen of step-down prednisolone, methotrexate, and sulphasalazine,
tested against sulphasalazine alone in early RA patients, demonstrated excellent clinical response,
low toxicity and slowing of radiographic progression [5] (COBRA trial; COmbinatietherapie Bij
Reumatoi'de Artritis). The current full economical analysis addresses the question whether this
combined treatment is also cost-effective.
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Patients and methods
Sfudy des/gn
The methods of the OOBRA study have been reported extensively [5]. Briefly, in a 1-year
double-blind randomized clinical trial, 156 RA patients (ACR criteria [6j aged 18-70 yr, were
randomly assigned to two treatment groups. All patients had early, active disease. No prior
treatment with second-line and-rheumatic medication, apart from antimakrials, was allowed. One
group was treated with a combination of sulphasalazine, methotrexate and prednisolone; the other
group was treated with sulphasalazine and double placebo. Prednisolone and methotrexate (or the
placebos) were tapered and stopped after week 28 and week 40, respectively, while sulphasalazine
was continued. All patients had calcium supplementation (1 g/day) prescribed for as long as they
used prednisolone, and folic acid (1 mg/day) for as long as they used methotrexate. The primary
clinical outcome was a pooled index [7]; a composite measure that reflects each patient's clinical
improvement. This measure is suited for the comparison of clinical benefits between groups. In
this report, the benefits are also expressed in terms of improved physical function and utility. All
utility assessments were performed by trained independent assessors who contacted the patients
only at baseline and four times thereafter. This way, the assessors stayed blind for effects of high-
dose prednisolone during the first 6 weeks of the protocol. The study protocol was approved by
research and medical ethics committees in all participating hospitals (nine clinical centres in The
Netherlands and one in Belgium). All patients gave informed consent in writing before they
entered the study protocol between May 1993 and May 1995.
Cosfs
Costs were elicited from a societal perspective. To evaluate the economic consequences of
combined treatment, only direct costs were considered. Direct costs are costs that are directly
related to the intervention. These are detailed below in 5 parts: (1) costs of the intervention
(protocol drugs and monitoring), (2) costs of non-protocol drugs, (3) other costs of out-patient
care, (4) costs of in-patient care, (5) direct non-medical costs. The period of follow-up comprised
56 weeks in all patients.
Costs were primarily expressed in 1995 Dutch guilders and subsequently converted into US
dollars ($) at the 1994 Purchasing Power Parities rate of 2.143 : 1 [8]. Where possible, specific cost
prices were derived from cost research performed in the University Hospital Maastricht (Financial
Control Group internal report, February 1996). These cost prices were generalized to all
participating clinical centres. Data on health care utilization were obtained from patient diaries
specifically developed for this study. Patients were asked to complete forms for 56 weeks; these
weekly forms were collected at every control visit. Additional data was collected from hospital
records and biannual structured interviews. In case of doubt, the hospital record was decisive (e.g.
to determine the exact duration of hospitalization). Patients were asked to report every health care
utilization, regardless of whether it was related to their disease, because the symptoms and signs as
well as the side-effects of treatment in RA are very heterogeneous, and possibly unknown [9].
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Total intervention costs comprise costs of the therapeutic intervention itself and costs related
to the necessary monitoring of adverse effects. The costs of protocol medication -were calculated
per patient by multiplying prices (1995 Dutch pharmacy standards, handling costs included) by
volume of protocol medication in the first 56 weeks. The costs of calcium and folk acid
supplements were only attributed to the combined-treatment group, although patients in both
treatment groups had these prescribed. The costs of monitoring were based on a post hoc
consensus among the trial rheumatologists who were knowledgeable on the prevalence of toxicity
that had occurred during the trial. They set the frequency of out-patient rheumatology consultation
at seven in the first year for either treatment, the frequency of laboratory monitoring for
sulphasalazine treatment at seven and that for combined treatment at eight. With respect to the
extensiveness of laboratory monitoring, we referred to the program that was used during the trial
This is open to discussion, and will be dealt with in the sensitivity analysis. Annual radiography of
hands and feet to assess joint damage was considered to be part of normal clinical practice in
patients with early RA and the integral monitoring schedule of bodi treatment groups. These costs
were included. In addition, bone density measurement and thorax radiography were considered
mandatory in patients before starting combined treatment to assess preexisting osteopenk and to
exclude pulmonary tuberculosis; these costs were attributed to combined treatment only.
Remaining costs strictly related to the execution of the trial were not included; e.g. costs of
outcome assessments and extra visits.
Costs of non-protocol medication (prescription and 'over the counter' drugs) were assessed by
records from the diaries. Four different classes of medication were distinguished: Non-steroidal
anti-inflammatory drugs (NSAIDs) and analgetics, gastroprotective agents, disease-modifying anti-
rheumatic drags (DMARDs) (apart from protocol medication) and miscellaneous.
Apart from medication, health care utilization included visits to the general practitioner,
specialists, physiotherapists, and any diagnostic and all therapeutic procedures ordered as a
consequence of these visits. The costs of consultation of a general practitioner ($15) or
physiotherapist ($16) were based on charges. The costs of out-patient department specialist
consultations (ranging from $22 to 55 per consultation) were based on records of 26 (17%) trial
patients in the University Hospital Maastricht and generalized per treatment group to patients
from other participating clinical centres. Although registered, costs for any aids (protheses and
ortheses) and adjustments to the patients' homes are not reported here (the volume of different
aids and adjustments is relatively small, and the reimbursement systems both in The Netherlands
and Belgium vary substantially by municipality).
Costs of hospitalization were priced at $400/day in a university or non-university hospital
(based on cost-research) and $110/day in a rehabilitation center (charge derived from the literature
[10J.
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The direct non-medical costs comprise COSB for professional Of n6n=prüfessioöal help at
home, costs rekted to loss of leisure time of the patient and an accompaflyifjg person where
necessary, transportation costs, and out-of-pocket expenses for disease-rekted aedvkies and
purchases. Costs of paid and unpaid help were derived from the time estimates registered in the
•weekly patient diary. The price for qualified house keeping was set at $11. Unpaid help was yalucd
at 80% of the price for professional help. Loss of leisure lime due to visiting health care-providing
institutes was valued at $2.12/hour, a price derived fron» a literature survey [10], Travel costs were
calcukted from the number of visits (excluding those for trial purposes only) and costs per visit
Kilometre distances were gathered from a route-planning computer package that uses postal area
codes. The kilometre price was set at $0.27, an amount also in use for reimbursement purposes.
Out-of-pocket expenses include such costs as swimming in extra heated pools and costs of
alternative health care (calculated from patients' reports in the biannual interviews).
As the time frame of follow-up in this report is only little over 1 yr, no discounting of future
costs (or benefits) back to current value was carried through. Arthritis-related indirect costs, such
as sick leave or occupational disability, are not reported here, but will be elucidated in a separate
article with a follow-up period of > 1 yr.
Efficacy measures; c//n/ca/ effeefs
The primarily clinical outcome was a pooled index. This composite measure comprised each
patient's standardized improvement in erythrocyte sedimentation rate (ESR), grip strength, tender
joint count, observer's global assessment and improvement in functional ability (scored from the
MacMaster Toronto Arthritis patient preference interview [11]). A secondary endpoint was
radiographic damage of joints in hands and feet, expressed in a quantitative score for erosions and
joint-space narrowing [12]. Many clinicians feel that this type of radiological damage score
represents cumulative disease activity [13]. Radiographs were read by two trained independent
observers unaware of treatment allocation. Physical function was evaluated by a validated Dutch
version of the Health Assessment Questionnaire [14,15] filled out by the patients at baseline, and
at weeks 16, 28,40, and 56.
Interpolation of each patient's scores at five time points yielded a time-integrated score
reflecting average clinical benefit and disability during the 56 week follow-up period. Direct costs
in both treatment groups were rekted to the clinical benefits; between-group differences in time-
integrated units of the pooled index, progression of radiographic damage and time-integrated
functional disability scores maybe used in cost-effectiveness ratios.
Eff/cacy measures; uf/7/f/es
In addition to traditional measures of efficacy, utilities by standard gamble and rating scale
methods were measured at baseline, and weeks 28 and 56. A utility is a single comprehensive
outcome measure that reflects the value or preference that respondents assign to a particukr
health state. This value is expressed on a scale ranging from 1 (perfect health) to 0 (death), and
takes into account both the positive treatment effects and the negative side-effects. We elicited
utilities from patients participating in the trial by means of the Maastricht Utility Measurement
Questionnaire, a relkble and validated adaptation in Dutch of the MacMaster Utility Measurement
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Questionnaire [16,17]. It is administered as an interview. Utility measurement using this
questionnaire comprises the rating scale and the standard gamble methods. The rating scale
measures utilities directly by asking the patients to place health states on a thermometer scale (i.e.
vertical visual analogue scale). The standard gamble method derives utilities from the patients'
responses to decision situations under risk. A chance board with a probability wheel was used as a
visual aid to facilitate the standard gamble questions.
The quality adjusted life year (QALY) is a measure that expresses effects in terms of both
quality of life and survival. A calculation of the area under the curve of the baseline and biannual
assessments of utility yielded an approximation of QALY gained in each treatment group. We
restricted our time window to the first 56 weeks of the protocol in every patient, i.e. we did not
extrapolate by multiplying the result with a life expectancy approximation. Direct costs in both
treatment groups were related to the gained QALYs to yield cost-utility ratios.
Sens/f/V/fy ana/ys/s
Sensitivity analysis tested the robustness of the cost estimates obtained. Volumes, as well as
prices, especially those solely based on assumptions, were varied to evaluate the resulting change in
the costs. The focus was on the influence of set prices of hospital admissions and help at home, as
in this study other volumes were based on empirical data. Each of these two prices were varied by
adding and subtracting 25%. The relative price for help by non-professionals was also reduced
from the original 80% to 0% of professional charges. Monitoring costs were set at a fixed level in
the primary analysis. The monitoring schedule is the consensus of the trial rheumatologists
achieved in completion of the study. The economic consequences of different monitoring
schedules (i.e. a 25% increase) were considered, as not only the frequency, but also the
extensiveness of the monitoring schedule for combined treatment is open to discussion. The
monitoring costs for treatment with sulphasalazine alone were derived from a published ACR
recommendation [18]. Here, we did not change the frequency of laboratory checks as our protocol
agreed with this standard.
Sfaf/sf/ca/ ana/ys/s
To analyse the difference in costs between the combined-treatment and sulphasalazine group,
costs per patient-year (of 56 weeks) were calculated and expressed as means per patient per group.
As costs are cumulative, the mean is a useful statistic because of its direct relation to the sum.
Although the distribution of costs was skewed, the number of patients in our trial permitted
parametric (Student's f) testing for between-group differences in mean aggregate costs (central
limit theorem). In the secondary analyses on the differences in volumes, nonparametric Mann-
Whitney tests were preferred. All differences in volume were tested per semester because a priori
maximal contrast was expected in the first semester considering the withdrawal of combined
treatment after week 28. No adjustments were made for multiple testing. All analyses were
performed on an intention-to-treat basis.
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Results
In one patient (randomized to combined treatment), protocol medication was stopped within
one week because his disease was in remission at baseline. Another patient (randomized to
sulphasalazine treatment) dropped out in week 2 due to adverse effects (skin rash) and was lost to
follow-up for most cost parameters. Data from these two patients were excluded from the
analysis. Consequently, the combined-treatment group included 76 patients and the sulphasalazine
group 78 patients. Data on costs were complete for all these patients. Both groups were balanced
in most important demographic and prognostic variables (Table 4.1).
Table 4.1: Baseline characteristics of the study patients, according to treatment group*
Age(yr)
Female
Educational years
Married
Professional occupation >2 days/week
Disease duration (months)
Previous treatment with antimalarials
Hospitalized for RA at baseline
Positive IgM rheumatoid factor
Erosions on hand or foot radiographs^
Number of tender joints (0-68)
Grip strength (kPa)
Erythrocyte sedimentation rate (mm/h)
Global assessment observer (mm; 0-100)
MACTAR functional ability questionnaire
Health assessment questionnaire (0-3)
Combined
treatment
(«=76)
49 + 12
50 (66%)
10 ± 3
69 (91%)
25 (33%)
4(1-24)
16 (21%)
9 (12%)
59 (78%)
55 (74%)
25 ± 14
24 ± 15
57 ± 34
53 ± 24
24 ± 4
1.5 ± 0.7
* mean ± S.D., count (%) or median (minimum-maximum).
t patients with available baseline radiographs; combined treatment w
Sulpha-
salazine
(« = 78)
49 ± 12
40 (51%)
10 ± 3
71 (91%)
26 (33%)
4 (1- 23)
19 (24%)
11 (14%)
57 (72%)
59 (79%)
24 ± 14
29 ± 20
53 ± 32
51 ± 22
24 ± 4
1.4 ± 0.7
- 74, sulphasalazine group rj - 75.
The mean total costs per patient in the first 56 weeks of follow-up were $5519 for combined
treatment and $6511 for treatment with sulphasalazine alone (/> - 0.37; Table 4.2). Out-patient
care, in-patient care and non-health care each contributed about one-third to the total costs. In the
first semester, total costs were almost twice those in the second semester. By definition, combined
treatment (protocol drug cost) was more expensive than sulphasalazine: $326 t« $181 per patient.
Likewise, the monitoring schedules cost $839 per year in the combined-treatment group is $559 in
the sulphasalazine group (Table 4.3). The costs of drugs outside the protocol were significantly
lower in the combined-treatment group ($237 is $329; /> < 0.001). This was mainly due to lower
use of NSAIDs, analgetics and gastroprotective drugs in the combined-treatment group, especially
during the first semester.
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Table 4.2: Direct costs of treatment in 56 weeks of follow-up
Direct costs (US$)
Health care
Intervention:
Protocol drug(s)
Monitoring
Non-protocol drugs
Other
Out-patient care; total
In-patient care
Non-healdi care
1st semester (week 0-28)
Combined
treatment
mean (SEM)
190
652
130
364
1336 (39)
1002(478)
1018(205)
Sulpha-
salazine Difference
mean (SEM) -
88
409
186
444
1127 (34)
1868(390)
1223(178)
102
243
-56
-80
208
-866
-205
95% C.I. P
*
0.003
0.0«
113;303 <0.00?
-2076343
-739329
O./tf
0 . «
2nd semester (week 29-56)
Combined
treatment
mean (SEM)
137
187
108
378
810 (25)
532(304)
821 (182)
Sulpha-
salazine
mean (SEM)
93
150
143
414
800 (32)
582(286)
911(134)
Difference
-
44
37
-35
-36
10
-50
-90
95% C.I.
-70; 91
-874;772
-534356
P
*
#
0.0<f
0.03
0.7?
o.?o
0.(5?
1st year (week 0-56)
Combined Sulpha-
treatment salaz
mean
326
839
237
742
2,146
1,534
1,840
mean
181
559
329
858
1927
2451
2133
. Difference
-
146
280
-92
-116
219
-917
-293
95% C.I.
62; 375
-2573; 739
-1232; 645
P
*
*
<0.00/
0.3«
0.007
0.P7
0..5*
Total 3356(600) 4218(457) -863 -2343;617 0..Z5 2163(407) 2293(330) -130 -1161;902 0.«0 5,519 6511 -992 -3204;1220 0.37
Combined treatment: » = 76 ; Sulphasalazine: » = 78. Positive values indicate higher costs for the combined-treatment group. SEM; standard error of the mean.
*; Costs fixed per protocol.
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Apart from intervention under study and non-protocol drugs, the costs of ambulant care were
slightly lower in the combined-treatment group. Patients in the combined-treatment group
consulted their general practitioners more often, but paid less visits to physiotherapists and
ergotherapists (Table 4.4). Taken together, the effect of protocol treatment predominated to make
combined treatment $219 more expensive than sulphasalazine in out-patient costs (P - 0.007).
Table 4.3: Costs of possible monitoring schedules during first 56 weeks of treatment (US$)
For combined treatment (post hoc consensus rheumatologists, see Methods):
8 x laboratory tests: ESR, hemoglobin, hematocrit, white blood cell count (WBQ including
differentiation, platelet count and mean corpuscular volume, ALAT, AS AT, bilirubin,
alkaline phosphatase, glucose, creatinine, sodium, potassium, phosphate, calcium,
albumin and total protein, urinalysis (albumin and glucose) 292
1 x hands and feet radiographs 124
1 x diorax radiographs 36
1 x bone densitometry lumbar spine and one hip 207
7 x consultation rheumatologist 180
Total 839
For sulphasalazine treatment (post hoc consensus rheumatologists):
7 x times laboratory tests (see above) 256
1 x hands and feet radiographs 124
7 x consultation rheumatologist 180
Total 559
For sulphasalazine treatment according to ACR recommendations [18]:
7x laboratory tests: hemoglobin, WBC including differentiation and platelet count 53
1 x hands and feet radiographs 124
7 x consultation rheumatologist 180
Total 357
Costs of in-patient care were mean $917 lower for combined treatment compared to
sulphasalazine (P - 0.27). This was mainly due to a significantly lower number of in-hospital days
in admitted patients during the first semester 515 ra 190 days (P - 0.05). In the first semester, the
number of hospital admissions was 18 in the combined-treatment group ts 24 in the
sulphasalazine group, in the second semester, there were 7 admissions in both groups. Admissions
were shorter in the combined-treatment group; mean 11.6 ts 20.1 days.
Total direct non-medical costs were a mean $1840 for patients in the combined-treatment
group and $2133 in the sulphasalazine group (P = 0.54). Home help accounted for 94%. Not all of
these costs were really spent, as not only professional but also voluntary help by spouse, family or
friends was appraised. The demand decreased slightly in the second semester. Patients in the
combined-treatment group reported less help than patients in the sulphasalazine group, but this
difference was not significant.
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The clinical effects have been fully reported elsewhere [5]. Briefly, at week 28 the mean
improvement in terms of the pooled index was 1.4 for the combined-treatment group and 0.8 for
the sulphasalazine group (P < 0.0001). At week 56, these values were 1.1 w 0.9. Comparison of
time-integrated indices (with four follow-up measurements and baseline by definition equal to
zero) shows mean improvement of 1.1 i s 0.7 (P — 0.0001). Radiographic damage scores of both
group were comparable at baseline. At this time, 23% of the patients in the combined-treatment
group and 19% in the sulphasalazine group showed no damage. After 56 weeks, the median
progression in the radiographic damage score was two points in the combined-treatment group w
six in the sulphasalazine group (P - 0.004). Baseline and follow-up data on disability of 154
patients were available (76 combined-treatment and 78 sulphasalazine). Baseline scores of both
group were comparable. At week 28, the improvement in the disability score was 1.1 for the
combined-treatment group t s 0.6 for the sulphasalazine group (P < 0.0001). At week 56,
improvement compared to baseline was 0.8 w 0.6 (P = 0.06). Comparison of 56 weeks time-
integrated scores showed mean improvement scores of 0.83 w 0.50 (P = 0.0003).
Table 4.4: Volumes of out-patient care. Number of visits to health care professionals
General practitioners
Physiotherapists
Ergolherapists
1st semester (wk 0-28)
combined
treatment
104
428
31
sulpha-
salazine
76
706
85
2nd semester (wk 29-56)
combined
treatment
108
318
11
sulpha-
salazine
97
407
48
1st year (wk 0-56)
combined
treatment
212
746
42
sulpha-
salazine
173
1113
133
Utility assessments including baseline and two follow-up assessments were available for 67
patients in the combined-treatment group and 75 in the sulphasalazine group. Baseline utility
assessment resulted in similar scores for both treatment groups; scores with the rating scale
method were 0.55 (S.D. 0.18) and 0.55 (0.20) for the combined-treatment and sulphasalazine
group, respectively, scores with standard gamble were 0.78 (S.D. 0.16) and 0.76 (0.19). At week 28,
rating scale utility scores increased by 0.24 (S.E.M. 0.02) in the combined-treatment and 0.15 (0.02)
in the sulphasalazine group (P - 0.006). Standard gamble utility scores increased by 0.10 (0.02) in
the combined-treatment and 0.06 (0.02) in the sulphasalazine group (P - 0.05). At week 56, most
of the between-group contrast seen after the first semester was lost: mean improvement with
rating scale 0.18 (0.03) in the combined-treatment w 0.16 (0.02) in the sulphasalazine group, and
with standard gamble 0.07 (0.02) w 0.07 (0.02). The area-under-die-curve calculation of the utility
scores demonstrated a significantly better gain of 0.06 QALY in the combined-treatment group
assessed by rating scale (P - 0.01; 9 5 % Q : 0.02- 0.10). Assessed by standard gamble, the difference
was 0.02 gained QALY (P - 0.33; 9 5 % d : -0.02- 0.06).
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Ine efficacy C4 the combined treatment in clinkäl outcomes is superior to sulphasak?ine
alone. The total costs are slightly lower, although net signifkandy so in the combined group.
Acconiingh/, rektive cost-efficacy favours combined treatment; it will be cost-effective when
implemented in patients comparable to those included in this OORRA trial, likewise,, significantly
better utility scores and equal costs result in better cost-utility ratios in the combined-treaünent
group.
No extra toxieity due to die extra medication in die combbed-asatment group occurred Cfe
the contrary, significantly fewer patients in the combined-treatment group stopped protocol
medication due to adverse events or lack of dierapy effect; 6 w 23 in the sulphasalazine group (P
= 0.0OQ8). The drop-outs in the combined-treatment group also occurred later. Loss of bone
mineral density in spine and hips was modest, and not significantly different in bodi groups; in the
combined-treatment group, bone density in the lumbar spine decreased by a mean 13% in %
weeks.
In die sensitivity analysis, when the price of hospkalization was reduced by 25%, the mean
total cost remained $849 lower in die combined-treatment group. Tlie same adjustment in the
charge for help at home resulted in a smaller between-group contrast of $900. When the price for
help at home by non-professionals was set at zero, mean total costs of combined treatment
remained $443 lower dian costs of treatment widi sulphasalazine. Finally, the consequences of
adjustments to die monitoring schedule were tested (Table 4.3). The adjusted monitoring costs
were $1049 (+25%) and $357 (-36%) for combined treatment and sulphasalazine, respectively,
this still resulted in $580 lower total costs for combined treatment.
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Discussion
In the setting of a randomized trial, this full economic analysis revealed combined treatment
with step-down prednisolone, methotrexate and sulphasalazine to be more effective than
sulphasalazine alone at equal or lower costs. The combined-treatment group had lower expenses
for non-protocol medication and in-patient care, and lower costs outside the health care system
that offset the higher costs for protocol medication and monitoring.
The efficacy of the combined treatment in clinical as well as radiological outcomes is superior
to sulphasalazine alone. As the total direct costs in the combined-treatment group were equal or
lower, relative cost-efficacy favours combined treatment. Utility scores, as a generic measure of
therapy benefits, also favoured combined treatment. Concordant with other reported studies, the
scores derived with the standard gamble method were at an absolute higher level and least
responsive to change. This has been attributed to risk-aversive attitude of patients with a putatively
non-fatal or chronic disease like RA [19].
The time frame of this study is long compared to most other studies, but still relatively short
for a chronic disease like RA, and definitely too short to evaluate the incidence of late effects.
Continuing follow-up of the included patients will provide important answers on costs and
outcomes in the long run. Prednisolone might have induced modest (non-significant, mean < 1%)
and partially reversible bone loss, but this did not result in symptomatic fractures or complaints in
any of the patients.
Like most clinical trials, this trial was primarily designed to study clinical benefits and thus
probably underpowered to prove cost benefits. A post hoc power calculation reveals minimum
group sizes of 374 necessary for the between-group difference found to reach the level of
significance (/> < 0.05, two-sided). The only significant difference in cost found favoured the
sulphasalazine group; i.e. $219 lower costs for out-patient care. However, this can be largely
attributed to the per protocol (fixed) difference in intervention costs.
Sensitivity analysis showed the robustness of the conclusions in the economic analysis. The
direct costs of combined treatment are not significantly lower (and must thus be presumed to be
similar to the costs of treatment with sulphasalazine alone). On the other hand, calculations with
considerable alternations in the assumptions of charges and extensiveness of monitoring schedules
consistently showed lower costs for combined treatment. As the primary analysis of the trial
showed significantly less drop-out due to therapy failure and adverse events in the combined
treatment group, a less frequent and extensive monitoring schedule than that performed during
the trial might be appropriate in normal clinical practice. Abo, the necessity of initial bone
densitometry - in this analysis still regarded as mandatory for combined treatment - is
questionable with regard to the observed modest effects on bone.
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The generalizability of our findings is principally restricted to the health care systems in The
Netherlands and Belgium. The health care system in these countries is characterized by universal
access and equal facilities for all inhabitants, and small distances between patients' homes and
clinical centers. From a North American perspective, patients were frequently hospitalized [20].
Notably, at baseline all included patients had active disease, and restrictions to the number or
duration of hospitalizations would most likely have worsened the outcomes in the more frequently
hospitalized sulphasalazine group [21]. Moreover, the costs of health care found in this study do
not seem to be 'out of range' in comparison with figures from an American health care setting
[9,20].
In comparison with sulphasalazine, combined treatment is the dominant therapeutic option,
due to equal or lower costs and enhanced efficacy. This full economic analysis confirms that
combined treatment with step-down prednisolone, methotrexate and sulphasalazine may be a
rational choice in early and active RA.
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Limited Bone Loss Due to Corticosteroids; a Systematic Review
of Prospective Studies in Rheumatoid Arthritis and Other
Diseases
Abstract
Ooy'ecf/Ve: To clarify the relation between changes in bone density, the treated disease and dose
of corticosteroids prescribed.
A/fef/?ods: MEDLINE database (1966-95) and bibliographic searches selected cohorts of RA
patients and non-RA patients, studied by reliable serial bone density measurements.
/?esu/fs: Two randomised controlled trials in early RA found greater lumbar bone loss after
cordcosteroid treatment (pooled effect size at 6 months 3.9%; 95% Q: 1.9; 6.0%). The other
studies included 66 RA patients on mean 7 mg prednisone/day, 371 'untreated' RA patients; and
216 non-RA patients on mean 20 mg prednisone/day. Lumbar bone mass changed (weighted
mean) 0.0% (-0.6; 0.7%) per year in steroid-treated RA, -0.6% (-0.9; -0.2%) in 'untreated' RA and
-4.7% (-5.2; -4.3%) in non-RA. Femoral neck changed -3.0% (-4.2; -1.8%), -0.7% (-1.0; -0.3%)
and -1.5% (-2.5; -0.4%), respectively. In RA, most bone was lost in the first half year, and in early
or uncontrolled disease.
Conc/us/on: In RA patients bone loss is limited, influenced by the interaction of disease
characteristics and low-dose corticosteroid therapy. In contrast, non-RA patients on higher doses
of corticosteroids may lose clinically relevant amounts of bone (i.e. >5%) within 1 year.
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Introduction
Osteoporosis is a common finding in patients with rheumatoid arthritis (RA), especially in
women over 50. It is unclear how much of this loss is attributable to treatment, specifically
corticosteroids, and how much to the disease itself.
RA is a systemic disease characterized by polyarthritis that impairs mobility and physical
function, and a catabolic state. The polyarthritis, most frequently situated in the smaller joints of
hands and feet, causes juxta-articular bone loss of die affected joints. In addition, there is often
considerable generalized loss of bone mass that predisposes to fractures of vertebrae, hips, wrists
and ribs. Beside the effects of corticosteroids and possibly other drugs, the disease itself can cause
generalized bone loss, evidenced in untreated RA patients. Potential disease-related causes for diis
bone loss include systemic actions of inflammatory products associated with disease activity, and
changes in circulating hormones, in calcium metabolism, and in load bearing of the skeleton. The
interplay of all factors is complex: for example, bone loss correlates independendy both with
markers of disease activity and widi disability. On die odier hand, corticosteroid treatment may
reduce disease activity and increase mobility, which might offset the negative direct drug effect on
bone.
Corticosteroids decrease bone mass by impairing intestinal calcium uptake, thus possibly
causing secondary hyperparadiyroidism; in addition, corticosteroids depress osteoblast activity and
may also direcdy stimulate osteoclast activity. Chronic corticosteroid dierapy can result in
significant loss of bone mass, especially in skeletal sites widi high proportions of trabecular bone,
where bone turnover is highest. For example, vertebral wedge and crush fractures are a frequent
complication of long-term steroid-treatment in asthmatic patients; anodier important site at risk is
die proximal femur. The fracture risk correlates widi die duration and dosage of corticosteroid
therapy and is related to low bone density.
Bodi in RA and in odier diseases it remains unclear how large die effects of corticosteroids
on bone really are. The extensive literature on diis subject comprises mosdy cross-sectional and
case-control studies, prone to bias by design. Recendy die number of prospective studies has
increased. In addition, precise and reliable measurement techniques such as dual energy
quantitative computer tomography (DQCT), dual photon absorptiometry (DPA) and dual energy
X-ray absorptiometry (DXA) have replaced less reliable techniques such as single photon
absorptiometry (SPA) and single energy quantitative computer tomography (SQCT).
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Methods
/denf/Y/caf/on of sfud/es
To locate the primary studies of interest, i.e. those with repeated bone density measurements,
we performed computer searches in the MEDLINE database (1966 to 31 December 1995). We
defined 3 search clusters, termed osteoporosis, CDmasteroKi and iM.
The cluster osteoporosis comprises all citations containing any of the text or thesaurus words
'osteoporosis', 'osteopenia', 'bone density", 'bone mass', 'densitometry', 'absorptiometry' and
'fractures' (all trees and exploded, all subheadings). Similarly the cluster cwticosteroiflls comprises all
citations containing any of die text words 'predniso*', 'corticoster*', 'glucocort*' (* indicates a wild
card) or thesaurus words 'anti-inflammatory-agents-steroidal' or 'glucocorticoids-synthetic'. Finally
the cluster /L4 comprises the combined text words 'rheumatoid arthritis' and the thesaurus word
'arthritis, rheumatoid' (not exploded). To obtain all studies on comcosteroid induced osteoporosis
(RA and non-RA) we intersected the csteqporasw and o>mc<KtenM<is cluster. To obtain all studies on
osteoporosis in RA we intersected die osteoporosis and RA cluster.
Se/ecf/on of sfuc/y cohorts
First screen; appropriate studies
We excluded animal studies, editorials, letters and reviews, retrospective results and cross-
sectional studies, studies employing single measurements, studies employing bone mineral
density/content measurements odier dian DQCT, DPA or DXA, and studies without data on
either lumbar spine or femoral neck. We also excluded studies on diseases, treatments, or
situations diat affect bone mass, other dian RA and corticosteroids. This includes Gushing's
disease, hypogonadism, hyper(para)diyroidism, chronic liver disease, insulin dependent diabetes
mellitus, renal insufficiency, anorexia, cancer, Addison's disease and malabsorption syndromes
including inflammatory bowel diseases, kidney or liver transplantation, and patients under 18
years.
Second screen; appropriate cohorts
Our study analyzes changes in bone mass over time in 3 types of cohorts: RA patients on
systemic comcosteroid treatment, RA patients not on comcosteroid treatment, and non-RA
patients on comcosteroid treatment. We excluded any cohort that received treatment other than
calcium for osteoporosis, e.g. a treatment arm in a controlled trial. On die odier hand we would
include die control group receiving placebo treatment in such a trial. We excluded studies diat did
not provide a clear description of amount, kind and duration of comcosteroid treatment and
studies diat did not explicidy distinguish between patient groups that did or did not have
comcosteroid dierapy, or between RA and non-RA patients. To be included, studied RA patients
had to meet die American College of Rheumatology classification criteria for RA We screened
tides and abstracts from die search and any study diat appeared potentially relevant to at least one
of us was retrieved. There were no restrictions towards die language of die articles. The same
criteria as noted above were used to screen retrieved articles.
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H a bMopspfaies of As selected articles ia tfais selection and six key review aroeles on
eojikssteroM isdaeed osteoporosis weis scnaisiaed for addkJooal studies.
of slüdy
No fomial ssaadairfbed assessmsst of si» quality of the eligible cohorts was dose apart from
the sefcetJos cÄeria of p«jspeeswe daa acquirement ami cfear description of the group treatment.
Data derived from plicetso-eooöoled dodble feliad randomised trials (RCTs) oa the bone effects
of eoröeesseroäd tbesapy is RA paönäs were "fudged best (class a), and considered separately.
Mas, data 6om a control grosp is a randomised conaolled trial ^as peiceiwed to be of higher
qia&f fdass b) Aaa cfafa feas aay odser prospecävely folkswed cohort |ckss c).
Date
Oteee slse aitkles -^ESC colecsed and chases oa the basis of the selection criteria, the data
essacsioa «ss dosse bf botfa aattois sepaiately. Any cfiscispaacies were resolved by matual
agsenKBt. Wfaeae a ccdjos •gas lEposed laore ^ a once, the ruost extensive report %as used.
Atalysis aarf sla0s#cal fecAwgöes
Prinary osacoEae is the mean fas of boae densäy expressed as peicentage of the initial
. io the tables, cohoits are oafaed aceoidüng to ihe asderlyiiag disease {diat is RA or
J, accorsfcg tö tseaaiKSt widi cortkosförokls (yes or IKJ) aad prk>r treatment with
Eoa&^ $o validity class ^J ore) aial accoidmg to daily corticosteroki dose.
We setitemsdf data oa a OIK jear foüow-ap period from test, tables and figtass» la 3 studies
used a fiaeady äseipoiastos fasss 2-^ar fcAsw^np data so obtaia a oae-year esoiiste. In one
itaaily esaapolased fooss half jear dam, GsafitieBee i^rrals m r^e cafculatied from
die sesseved siaadard errors of the rasas. Most studies reported data oa boae deasky %rans per
surface unit), some only on grams per volume of a circumscribed area (content).
When no mean percentage of bone loss was reported, we approximated this value by dividing
the absolute change in bone mass in a group by its baseline value. When only percent difference in
Z-scores was reported (i.e. the percentage of percentage difference in standard deviation units
from the distribution of bone density in age- and sex-matched normal subjects), we used these as
approximate.
Reported corticosteroid doses represent prednisone equivalents; we weighted the mean
corticosteroid dose in each of the cohorts by its sample size to obtain the mean dose of the 2
treated cohort groups (RA and non-RA).
We calculated a pooled effect size of the RCTs on the effects of corticosteroids in RA.
Similarly, for each of the 3 main groups of cohorts, we calculated mean weighted changes in
lumbar spine and femoral neck. To obtain this mean, we weighted each individual change score
(Xj) through multiplication with the inverse of its variance; (W; - 1/var x,), and then summed the
results. The weighted mean is this sum divided by the sum of weights Z[w,xJ/ Ew ,^ with variance
Zw=.
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Table 5.1: Bone loss in the lumbar spine and femoral neck in two randomized controlled trials on the effect of corticosteroids in RA.
study cohort corticosteroids bone mass change*
first author [ref] n* wo- post- mean disease FI DMARD tech- preci- Ca- prior peak daily 6 months 1 year 1 year
men menop.' age duration ' ' nique' sion" suppl." use dose dose lumbar spine lumbar spine femoral neck
(%) (%) (yrs) (mo) (type) (%) (mg/d") (mg/d") (A%)95%c.i. (A%)95%c.i. (A%)95%c.i.
Laan
corficoste rowfy
|22] 20 70 45 53 22 0.7 AU DQCT/C 6.1
van Schaardenburg (23) 27 71 71 69 11 1.7 — DXA /C 1.9 +
10 7.5
15 8.0
-8.2 -12.7.-3.7
-33-4.8,-1.8 -3.8-5.8,-1.8 -4.1 -5.7,-2.6
ÄA /jaf/entt nor on i
Laan (22J 19 70 30 56 30 0.6 AU DQCT/C 6.1
van Schaardenburg [23] 20 43 43 70 10 1.6 CQ DXA /C 1.9 +
extra / O M in /M p a r i e n » on i
Laan
van Schaardenburg
pooled effect size
0 0 +1J -3.1,5.7
0 0 -0.1 -1.8, 1.6
9.5 3.4,15.6
3.2 1.0,5.4
3.9 1.9.6.0
-2.0 -4.5,0.5 -2.6 -4.8.-0.4
1.8 -1.3,4.9 1.5 -1.1.4.1
* ; percentage change in absolute (Laan) or Z-score (van Schaardenburg) compared to baseline, negative numben indicate bone loss. I
t ; n: number of patients at the end of follow-up.
t ; post-menop.: percentage of post-menopausal women in the total cohort
II ; FI: functional index, Dutch Health Assessment Questionnaire (range 0-3,3 signifies severe disability).
$ ; DMARD; concomitant disease modifying anti-rheumatic drug; AU: intramuscular gold salts, CQ: chloroquine.
1 ; DQCT: dual energy quantitative computer tomography in a trabecular region of interest; DXA: dual energy x-ray absorptiometry,
/C: bone mineral content (van Schaardenburg measured bone mineral density in the femoral neck).
•* ; precision is defined as the coefficient of variation for repeated measurements,
t t ; Ca-suppl.: +: standard supplement of 500 mg calcium per day. -: no calcium supplement
t$ ; in mg/day prednisone equivalent.
: not available.
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Results
The search yielded 2057 citations. A total of 110 studies were retrieved of which 23 were
included. The bibliographic search of 6 key reviews and citations in the selected studies and
inquiry among colleagues added one relevant study. One potentially relevant abstract in English
pointed to a study in Japanese. This study was not included. The final selection comprises 24
studies, 23 in English and one in German [22-45]. Two studies provided two cohorts. Two others
provided three: Gough et a/ distinguished high-dose steroid users, intermediate dose users and
non-users, Hall et <«/ followed an extra cohort in addition to 2 cohorts in a trial on hormone
replacement therapy.
We present the extracted data in 4 parts; first the data from cohorts in randomised trials that
studied the effect of corricosteroid therapy on bone mass in RA patients (Table 5.1); subsequently
cohorts with RA patients on corticosteroid therapy (Table 5.2, upper part), cohorts with RA
patients not on corticosteroid therapy (Table 5.2, lower part) and finally cohorts with 'non-RA
patients' on corticosteroid therapy (Table 5.3).
RCTs on cort/costero/'d-/'nduced osteoporos/s /n R/A
Two randomised trials studied the effect of corticosteroid therapy on bone mass in RA.
These trials report on 39 and 47 RA patients, studied for one and 2 years respectively (Table 5.1).
Laan ef #/ compared the bone content of early RA patients on low-dose corticosteroids or placebo
by DQCT. The authors assessed areas of trabecukr and cortical bone in the lumbar spine
separately, in trabecular bone they found a difference between the groups after 6 months of 9.5%
(95% confidence interval [95%d] 3.4; 15.6%; P = 0.003): -8.2% (loss) in the corticosteroid
group, compared to 1.3% (gain) in the placebo group. Of note was that this loss was largely
reversible after tapering the corticosteroids in the second half year (5.3% gain; P - 0.03 in the
corticosteroid group versus 1.5% loss; P = n.s. in the placebo group).
Van Schaardenburg er d/ studied spine and femoral bone mass in elderly, mostly early RA
patients by DXA. In the lumbar spine they found a difference between corticosteroid and
'placebo' group of 3.2% (95%Q: 1.0; 5.4%, P < 0.006) after 6 months: -3.3% (loss) in the
corticosteroid group, compared to -0.1% in the 'placebo' group (this group received chloroquine
as an antirheumatic drug) (Table 5.1). At one year the difference between the groups in this study
had decreased to 1.8% (P = n.s.): -3.8% in the corricoid group and -2.0% in the placebo group.
In the second year of follow-up, neither group lost bone (data not shown).
The pooled effect size of these 2 studies is 3.9% (95%Q: 1.9; 6.0%), corresponding to the
extra bone loss in the lumbar spine of RA patients due to treatment witii corticosteroids for 6
mondis. This figure should be interpreted with caution due to heterogeneity in study populations
and the differences between the outcome measures (method and unit of measurement). Van
Schaardenburg et a/ also studied the femoral neck. At this site both treatment groups lost bone
mass, especially the corticosteroid group; the difference of 1.5% between the groups was not
significant (Table 5.1). In contrast to the lumbar spine, femoral bone loss continued at the same
rate in both groups in year 2.
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Table 5.2: One-year bone loss in the lumbar spine and femoral neck in 17 cohorts of RA patients,
treated with corticosteroids (upper part) or not treated with corticosteroids (lower part).
study cohort corticosteroids bone density change'
study wo- post- mean disease tech- preci- Ca- prior peak daily
first author [rcf] type' n* men menop* age duration nique' sion' suppl" use dose" dose" lumbar spine femoral neck
(%) (%) (yrs) (yrs) (type) (%) (mg/d) (mg/d) (A%) 95%c.i. (A%) 95%ci
/M pa/ienf5 on
Messina
Gough
Gough
Hall
Sambrook '92
Sambrook '89
aggregate
Mac Donald
van den Brink
Eggelmeijer
Sileghem
Hall
Hall
Sambrook '85
Gough
Sambrook '92
Sambrook '89
Shenstone
aggregate
(24]
[23]
[25]
[261
(27)
[28]
no,
[29]
[30]
[31]
[32]
(26)
[26]
133)
(23)
[27]
[28]
(34)
corticojfcroWj
b
c
c
b
c
c
8
7
10
16
10
15
66
f O/J cor
b
b
b
b
b
c
c
c
c
c
c
13
18
44
10
67
18
17
85
17
15
67
371
100
67»
67»
100
100
100
ft'coste
100
100
71
100
100
100
100
67«
100
100
60
0
47
47
100
100
n.a
roiYfa
100
100
25
50
100
100
71
47
100
n.a
36
37
n.a.
n.a.
56
59
55
55
63
49
54
56
n.a
55
n.a
59
55
60
2
1«
1«
14
17
15
17
9
4
10
12
12
1
1«
11
11
2
DXA/C
DXA/D
DXA/D
DXA/D
DPA/D
DPA/D
DPA/D
DXA/D
DXA/D
DPA/D
DXA/D
DXA/D
DPA/C
DXA/D
DPA/D
DPA/D
DXA/D
1.5
0.8
0.8
0.9 +
1.8 n.a.
2.6
2.0 -
1.0 -
1.4 -
1.8
1.6 +
1.6 -
1.8
0.8
1.8 n.a.
2.6 -
n.a.
10
5
>5
+ n.a.
+ 10
+ 10
0
0
0
0
0
0
0
<1
0
0
0
10
1-5
>5
6
6
7
7
0
[+2.2]
-2.4
-0.6
-0.1
-0.5
+0.2
0.0
-0.5
-2.0
+0.1
-2.0
+0.2
-0.9
-1.0
-1.1
+0.2
+0.1
-1.4
-0.6
n.a.
-6.0, 1.2
-3.4, 2.4
-4.5,4.3
-2.6, 1.6
-0.7, 1.1
-0.6,0.7
n.a.
-8.3,4.3
-1.8,2.0
-3.5,-0.5
-1.0,0.6
-2.0, 0.2
-2.2, 0.0
-1.9,-0.3
-1.5,1.9
-0.9, 1.1
-2.9,0.1
-0.9,-0.2
[-7.0]
-3.6
-4.8
-0.3
-2J>
-2.0
-3.0
n.a.
-1.6
-2.9
n.a.
- 0 3
-0.8
n.a.
-1.4
-1.1
-1.9
-0.2
-0.7
n.a.
-8.5,1.3
-8.5,-1.1
-1.2,0.6
-6.2,1.2
-3.8,-0.2
-4.2,-1.8
-11.4,8.2
-4.5,-1.3
-1.9,1.1
-2.3,0.6
-2.5,-0.3
-2.6,0.4
-3.3,-0.5
-1.3,0.9
-1.0,-0.3
tt
; change in absolute or Z-score (MacDonald) compared to baseline. Negative numbers indicate bone loss,
change scores approximated from group means between brackets.
; see methods, ref: reference number, n.a.: not available.
; number of patients at the end of follow-up (with repeated measurement of lumbar spine at one year follow-up).
; p-m.w.; percentage of post-menopausal women in the total cohort.
; DPA: dual photon absorptiometry, DXA: dual energy x-ray absorptiometry, /D: bone mineral density, /C: — content.
; precision is defined as the coefficient of variation for repeated measurements.
; +: standard supplement of 500 or 1000 mg calcium per day, -: no calcium supplement.
; mgprednisone equivalent per day.
; data refer to the initial group that had baseline assessments (n=l 54), 2 women on hormone replacement therapy.
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Table 5.3: One-year bone loss in the lumbar spine and femoral neck in 11 cohorts of non-RA
patients treated with corticosteroids*
study cohort corticosteroids bone density change'
study wo- post- mean tech- preci- Ca- prior peak daily
first author [ref] type n men menop age nique sion suppl use dose dose lumbar spine femoral neck
diagnosis (%) (%) (yrs) (type) (%) (mg/d)(mg/d) (A%) 95%c.i. (A%) 95%c.i.
Mulder [35] b 10 100 100 72 DXA/D n.a. 60 11 -5.0 -6.3,-3.8 n.a.
temporal arteritis
Olgaard [36] b 11 27 0 39 DPA/D 4.5 - - 80 25* -115 -13.6,-11.4 n.a.
nephrotic syndrome
Nordborg 137] c 44" 82 82 71 DPA/D 3.0 - - 40 10 -3.6 -5.2,-2.0 n.a.
giant cell arteritis
Sambrook '94 [381 c 25 16 n.a 48 DXA/D < 1 - - 1250« 50 -7.8 -9.6,-6.0 n.a.
heart transplantation
Luengo [39] b 20 60 n.a 60 DPA/D 1.4 + + 30 11 - 2 J -4.1,-1.0 n.a.
asthma
Nelson [40] b 27 70 33 44 DPA/D n.a. + + 50 13 1-2.8] n.a. n.a.
asthma
Bijlsma [41] b 10 70 40 50 DPA/D 2.0 + + n.a. 15 +1.8 -0.4,4.0 - 0 3 -2.1,1.6
5 SLE, 4 myositis
1 myasthenia gravis
Böhning [42] b 17 18 18 56 DPA/C n.a. - + 50 2« -5.0 -9.9,-0.1 -4.3 -8.4,-0.2
asthma
Worth [43] b 19 53 42 58 DPA/D - 2 + + n.a. 28 -8.61 -11.1,-6.1 n.a.
asthma
Rizzoli («I c 21 56 39 52 DPA/D 2.1 + + 23 12 +2.4 -0.1,4.9 +0.6 -2.9,4.1
8 asthma, 8 SLE or collagen disease,
4 transplantation", 3 sarcoidosis
Sambrook 90 [45] c 12 100 33 38 DPA/D 1.8 - + n.a. 17 +0.6 -0.5.1.7 -2.4 -4.0.-0.8
7 SLE, 2 asthma,
1 connective tissue disease,
1 Sjögren's disease,
1 Waldenström's macroglobulinemia
aggregate 216 20 -4 .7 -5.2,-4.3 -1 .5 -2.5.-0.4
* ; for explanation of table format and abbreviations: See Table 2.
t ; change in absolute or Z-score (Rizzoli and Nelson) compared to baseline.
t ; approximation calculated from the reported cumulative dose in the first year.
II ; morning administration in 24 patients, alternate day treatment in 20 patients.
§ ; 1000 mg methylprednisolone pulses perioperatively; maximum dose thereafter 0.5 mg prednisolone per kg per day.
1 ; extrapolation from half a year change of 4.3%.
** ; transplantation of heart or liver, maximum 4 liver transplant patients in this cohort
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Cohorts w/fh RA paf/enfs on cort/'cosfero/d fherapy
The RA cohorts on corticosteroid dierapy comprise a total of 66 patients (in 6 cohorts),
mosdypost-menopausal women (Table 5.2, upper part). Patients widi bodi an early and advanced
stage of RA were treated with low-dose corticosteroids: mean 7.0, range 1-10 mg prednisone
equivalent per day. Changes in bone mass in die lumbar spine ranged between -2.4 (loss) and
2.2% (gain); weighted mean 0.0% (95%Q: -0.6; 0.7). Bone loss in the femoral neck ranged
between -7.0 and -0.3%; weighted mean -3.0% (95%Q: -4.2;-1.8). Gough et a/ reported that
loss of bone occurred preferentially in RA patients with a daily prednisone dose between 1 and 5
mg, as opposed to patients widi a dose higher than 5 mg per day.
Cohorts w/fh R>!\ paf/enfs nor on cort/costero/d fherapy
The RA cohorts not on corticosteroid dierapy comprise a total of 371 men and women (in 11
cohorts; Table 5.2, lower part). Again, bodi early and late RA patients were studied. Changes in
die lumbar spine ranged between -2.0 and 0.2%; weighted mean -0.6% (95%Q: -0.9;-0.2).
Changes in die femoral neck ranged between -2.9 and -0.2%; weighted mean -0.7% (95%Q: -
1.0;-0.3). Comparison of die weighted means of the 2 cohort groups shows no significant
difference in die lumbar spine, but 2.3% extra femoral bone loss in die steroid cohorts (P - 0.02).
Cohorts w/fh non-R^ pafVenfs on cort/costero/'d fherapy
The non-RA patient cohorts comprise a total of 216 men and women (in 11 cohorts), treated
widi corticosteroids for various diseases, including asdima, autoimmune diseases, and heart
transplantation (Table 5.3). Approximately half of die patients had previously had corticosteroids
or were on maintenance therapy. Peak (median: 50 mg/d) and daily dose (mean: 20 mg/d) were
markedly higher dian in die RA cohorts. One-year changes in bone mass in die lumbar spine
ranged between -12.5 and 2.4%; weighted mean -4.7% (95%Q: -5.2;-4.3). One year changes in
die femoral neck ranged between -4.3 and 0.6%; weighted mean -1.5% (95%Q: -2.5;-0.4).
Five studies in non-RA patients presented data on follow-up exceeding one year (data not
shown). In giant cell arteritis patients Nordborg et a/ noted partial reversibility of bone loss on
tapering die corticosteroids after one year. Rizzoli et d/ reported a further increase in lumbar spine
density up to +3.6% at one and a half year of follow-up in 21 patients. Nelson et <*/ rescanned 8
patients at 2 years of follow-up and reported continued loss of bone density in die lumbar spine.
Bijlsma et <«/ reported only 2 year follow-up assessments in 10 patients (interpolated to a one year
period in Table 5.3); diey found no significant change in lumbar and femoral bone mass.
Sambrook et <*/ presented data based on linear regression equations (6 measurements widiin 2
years in 12 women on chronic steroid dierapy); diey found stable lumbar bone densities
diroughout die 2 years in diis cohort. In die same study diey report on anodier cohort diat started
widi corticosteroid dierapy. This cohort was not included in our review because it did not
distinguish between die RA and non-RA patients. However, it is noteworthy that in diis cohort
widi higher baseline values, bone density loss was -1.7% per year over 2 years in die lumbar spine,
and -4.6% in die femoral neck. These losses are larger dian in dieir 'chronic' cohort (Table 5.3) (/>
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Discussion
Our review based on cohorts suggests that short-term (< 1 war), low-dose cortkosterokl
treatment {< 10 rag prednisone/day) in RA leads to bone loss that is Emked ia die femoral seek,
and negligible m the lurnhar spine. Higher dose corticosteroid treatment tn non-RA patients led £8
more marked bone loss in the lumbar spine, but comparable losses in the femoral neck (only 4
series available).
In view of the large body of literature on this subject, we are disappoinsed with die paucity of
prospective data. We •were amazed to see mat the RA group was twice as large as the non-RA
group. Our conclusions must remain tentative in view of the low number of patients in
heteiogenous settings regarding disease treated, disease activity, previous corticosteroid therapy,
corticosteroid dosage, other risk factors (e.g. age and menopausai state)» and measurement
technique. The relative low number of RA patients on coraeosteroid therapy as opposed K> RA
without steroids and non-RA, is reflected in a wider confidence interval for the estimates of bone
loss.
In RA patients Laan et a/ and van Schaardenburg ef a/ reported significant corticosteroid-
induced spinal loss of bone in die only 2 randomised, placebo-controlled trials on the effects of
steroid treatment on bone mass. In addition, van Schaardenburg reported significant losses in the
femoral neck. The interpretation of the pooled estimate of bone loss is not straightforward -
possibly even invalid - as the estimates from the 2 studies differ greatly, both in magnitude and in
precision. A likely explanation for diis discrepancy is method of measurement, another may be age
difference. Although both studies reported bone mineral content (instead of bone density), Laan
used DQCT and focused on the trabecular bone within die lumbar spine, whereas van
Schaardenburg used DXA DQCT is in itself a less precise method man DXA; in addition,
corticosteroid treatment increases marrow fat, spuriously indicating a fall in mineral content as
measured by DQCT. Thus die results of van Schaardenburg et al. more likely reflect true bone
mass changes.
Our review supports die observation that RA itself can cause discrete bone loss. On aggregate
the small losses in spine and femur in die RA patients not on corticosteroids are compatible widi
normal ageing. However, most cohorts or subgroups widi early disease, widi active disease, or
•with more disability showed more marked loss, especially in die femur. In addition, Gough et */
showed that patients widi early RA, treated widi 1-5 mg prednisone daily, lost more bone dian
patients daily doses above 5 mg. This suggests that in early disease, bone loss due to insufficiendy
controlled RA disease activity can be more important than bone loss due to corticosteroids.
Although bodi Laan # <*/ and van Schaardenburg ef <*/ reported only a short-term beneficial effect
of low-dose corticosteroid treatment on RA disease activity, this beneficial effect might still offset
the direct detrimental effects of corticosteroids on bone. Compared to die RA cohorts, die non-
RA cohorts showed larger spinal bone loss and similar femoral bone loss (4 series) at higher
corticosteroid doses.
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Important issues to discuss are the reversibility of treatment effects and the pertinence of
short-term prospective follow-up in a situation of longer term treatment. It is heartening that one
study in RA patients and two in non-RA noted complete or partial reversibility of bone mass loss
after stopping corticosteroids. Regarding long term follow-up, the non-RA patients on
corticosteroids showed further loss after intermediate dose corticosteroids, but the RA groups on
low-dose corticosteroids (< 10 mg/d) showed stabilization of bone mass in year 2 or 3. Further,
Reid who determined bone loss in RA and non-RA patients by measurement of total body
calcium has also concluded that bone loss occurs early in the course of corticosteroid dierapy and
stabilizes thereafter. Such findings do need confirmation in larger studies. We do not have enough
data to discern such a differential effect in our cohorts.
Individual patient factors such as age, sex, menopausal status, disease, disease duration,
current and previous corticosteroid dose probably contribute heavily to loss of bone. The design
of this review precludes meaningful analysis of risk factors. However, we hope to interest the
authors of these and other studies to cooperate with us: we could then pool individual patient data
and perform a 'mega-analysis'.
Structured reviews are of necessity out of date by the time they appear in print. For example,
Buckley et aL recently published a trial demonstrating that supplementation of calcium together
with vitamin D3 prevents spinal bone loss in rheumatoid arthritis patients who were treated widi
low-dose corticosteroids. One of their control arms would have increased our RA on
corticosteroids group by 50% (» = 35, mean daily prednisone dose: 5.6 mg, 77% women, 57%
menopausal women, mean age: 54 years, mean disease duration: 8 years). Annual bone losses were
-1.3% in the lumbar spine and only "tendis of percents" in the femoral neck Including these
finding« io our srmJy would .haw changed our estimates of bone Joss only slightly (data nor
shown).
Loss of bone density in relation to risk of fractures is probably better described by the
proportion of die population that suffers from a clinically relevant (that is potentially hazardous)
loss of bone density, than by die population's mean decrease. The relation between bone density
and fracture risk has only been studied in senile osteoporosis; in this setting bone mineral content
may or may not be a better predictor dian bone mineral density. In senile osteoporosis, keeping in
mind die accuracy of current measurement techniques, one might put the minimum clinically
relevant loss of bone density (not bone content) at die femoral neck at 5%, because at diis level
individuals may have a 50% increase of dieir fracture risk. A cohort mean change of 5% (i.e., half
of die individuals widiin die cohort subject to an additive risk of 50% or more) was only reached
in cohorts of non-RA patients who used more dian 10 mg prednisone per day. However, it must
be considered diat bone quality may be affected differendy by RA or corticosteroid treatment dian
by senile osteoporosis, leading to an increased fracture risk at die same density level. In addition,
some RA patients, especially early cases and diose with continuously active disease, may lose 5%
bone mass or more regardless of corticosteroid dierapy.
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one }«ar, BA paöeats nsay lose dseise MaeuRis of bone mass, especially in ear^' Of aesve dkeast»
Tlsis effecc s ass^nsnted is ite fena» by low-dose coiiieosterok! therapy» rfowevef, s*sessmg die
net effect öi csstkosleRÄfs OS bane ienains difikult in RA because ©f bsaeffckl sffeets on
disease sctröky. IE «3Ö-RA |ai»aB on higher doses of costeesteiolds significant losses occur,
especialf ia the spsse. la w w of the potential leveisibfllry of eordcosteioid effecö after tapering
and «ahffizaaon on contisiicd therapy» these findings are probably only clinkally releväfll in
paaens where h ^ i dose coiücos&toid tiier^y (> 10 rag/day) E continued for longer periods of
time.
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Reliability of Spot Samples for Assessment of Urinary Excretion
of Pyridinoline in Patients with Rheumatoid Arthritis
Abstract
Oiy'ecf/Ve: To determine how well a spot urine sample of patients with active rheumatoid arthritis
(RA) can predict 24-hour urinary pyridinoline and deoxypyridinoline excretion.
Methods: Urine samples of 11 hospitalized RA patients taken on 2 consecutive days at 8 a.m. and
4 p.m. were compared with samples from 24-hour collections (gold standard). High-performance
liquid chromatography was used to measure the collagen crosslink concentrations.
/?esu/fs: Sampling time was the only significant factor (repeated measurement ANOVA).
Significant differences were found between morning and 24-hour samples and between morning
and afternoon samples, but not between afternoon and 24-hour samples.
Conc/us/ons: Samples collected in the afternoon (4 p.m.) give the best approximation of 24-hour
urinary pyridinoline excretion in patients with active rheumatoid arthritis. In longitudinal studies
die sampling time should be fixed.
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Introduction
The pyridinium derivatives pyridinoline (PYD - hydroxyfysylpyridinoline) and deoxy-
pyridinoline (DPD - lysylpyridinoline) are collagen crosslinks in bone, cartilage and skin. When
bone is resorbed, these pyridinium crosslinks are released into the circulation and subsequently
excreted in the urine. DPD is present in type I collagen which is the main protein component of
bone and dentine. Most excreted DPD comes from bone as this tissue has quick remodelling.
Therefore, urinary excretion of DPD is a marker of bone resorption. PYD is more widely
distributed and is present in considerable amounts in cartilage-specific collagens: types II, IX and
XI. The excretion of PYD and DPD is not influenced by diet or physical exercise. However, a
circadian rhythmicity in bone remodelling has been shown for die excretion of pyridinium
crosslinks in healthy premenopausal females [1]. It is as yet unclear to what extent a circadian
rhythm is present at higher excretion levels of PYD and DPD [2].
Rheumatoid arthritis (RA) is a systemic disease widi destruction of joints in hands and feet as
a hallmark. This destruction of collagen in bone and cartilage in RA can be accompanied by an
increase in PYD and DPD excretion, reflecting disease activity [2]. To date, 24-hour collection to
assess excretion is die standard. For practical reasons, spot sampling (or collection of urine during
a part of the day) is desirable [3]. The aim of this study was to determine how well a sample of
urine of patients widi active RA can predict 24-hour pyridinium crosslink excretion.
Methods
Sfudy c/es/gn
Urinary samples were collected from 17 RA patients (ACR 1987 criteria [4j hospitalized in
the Department of Internal Medicine of die Maastricht University Hospital for exacerbation of
disease activity. There were no dietary restrictions. Concentrations of PYD, DPD and creatinine
(Cr) as well as 24-hour urinary volumes were measured.
Urine collection started at 8 a.m.; a first spot sample was taken at 4 p.m., and a second one t ie
next day at 8 a.m just before completion of 24-hour collection. Ten milliliter aliquots of each
sample were stored at - 2 0 t . A third aliquot was sampled from die 24-hour collection (after
stirring). This procedure was conducted in each patient on 2 consecutive days.
For each patient sex, birth date, RA disease duration (from date of diagnosis), weight, height,
erydirocyte sedimentation rate (ESR), medication and serum creatinine were noted. As criterion
for appropriate urine collection, we used die ratio of total creatinine excretion on day 1 and day 2;
diis ratio had to be between 0.8 and 1.25 (not more dian 20% discrepancy between die 2
collections) [4].
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Pyr/d/no//ne and deoxypyrid/no//ne c/jromafograp/7/c ana/ys/s
The total amount of excreted PYD and DPD was measured by high-performance liquid
chromatography (HPLQ [5]. Urine samples were hydrolysed in 6M HQ, dried and reconstituted
in 50% acetic acid and injected onto a HPLC system with on-line purification on OC31 cellulose
using a Prospekt solid-phase extractor (Separations, The Netherlands). The retained crosslinks
were eluted from the OGl material and chromatographed on-line on a cation exchange column
(Whatman Partisil SCX). Eluted crosslinks were detected by a Jasco fluorometer (Model FP-920,
Separations, The Netherlands). The PYD/DPD HPLC Calibrator (Metra, Palo Alto, CA) was used
as the standard. Intra- and interassay coefficients of variation were < 3% and < 5%, respectively,
for the PYD and DPD measurements. Urinary excretion rates are expressed as nmol/mmol
creatinine. Creatinine was measured by the Kodak Ektachem Clinical Chemistry Slide (CREA;
Eastman Kodak Company, Rochester, NY, USA).
Sfaf/'sf/ca/ ana/ys/s
The PYD/G" or DPD/Cr ratios in the sample taken from the 24-hour urinary collection ('day
sample") were taken as the gold standard. Results are expressed as means with standard deviations.
Agreement between each spot sample and the 24-hour collection was expressed as an intra-class
correlation (ICQ. PYD/Q and DPD/Cr were analyzed separately. A full repeated measurement
ANOVA model quantified variance associated with differences between individuals, between
sampling days (day 1 or 2; df = 1), between sampling time each day (8 a.m., 4 p.m. or 24-hour
collection; df - 2), as well as the interaction between day and sampling time (df = 2) with
correction according to Bonferroni-Dunn for repeated testing. Post-hoc contrasts between each
spot and 24-hour sample, and between the two samples were calculated.
Table 6.1: Patient characteristics and laboratory values (n - 11; 7 females and 4 males).
age
disease duration
body weight
serum creatinine
erythrocyte sedimentation rate
pyridinoline excretion
deoxypyridinoline excretion
creatinine excretion
pyridinoline/ creatinine excretion
desoxypyridinoline/ creatinine excretion
(yis)
(y«)
(kg)
(mmol/ 1)
(mm/ 1st h)
(nmol/24h)
(nmol/24h)
(mmol/24h)
(nmol/ mmol)
(nmol/ mmol)
median
64
4
67
67
65
321
74
7.7
50
9.5
(min-
( 42-
( 0 . 3 -
( 59-
( 57-
( 9 -
(140-
( 32-
( 5 . 3 -
( 23 -
( 3 . 9 -
max)
75)
34)
98)
152)
95)
1015)
191)
11.0)
126)
18.9)
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Results
Data from 3 patients was excluded because the urinary collection was not accurate (see
Patients and Methods). Data from 3 other patients was excluded because PYD/CT measurements
were not available at all 6 points of time. Therefore, data from 11 RA patients was analyzed; 7
women and 4 men. Their mean age was 61 years (range 42-75). They were of normal stature and
weight (mean body mass index 26 kg/m^), the mean disease duration was 8 years (median 4) and
the ESR was 54 mm/hr (median 65). Three patients were on oral corticosteroids (maximum 12.5
mg prednisone/day). Excretions of PYD and DPD were increased both in absolute terms and when
expressed as the ratio crosslinks to creatinine (Table 6.1). The PYD/DPD ratio was similar in the
spot and 24-hour samples (mean 5.9, median 5.4).
In the full ANOVA model, sampling time was a significant factor PYD/Cr (mean ± SD) was
71 nmol/mmol ± 45 in samples taken at 8 a.m., 55 ± 35 in samples taken at 4 p.m., and 57 ± 33 in
24-hour collections (/* = 0.01). There was no evidence for an effect of measurement day (day 1 or
day 2; /> - 0.93), or for an interaction between day and sampling time (/> - 0.72). The same applied
to DPD/Cn 14.6 ± 7.5 in samples taken at 8 a.m., 10.9 ± 5.9 in samples taken at 4 p.m., and 11.5
+ 5.6 in 24-hour collections (/> = 0.02). Here again there was no evidence for an effect of the
measurement day (/> = 0.93) or an interaction between the day and sampling time (/> - 0.26).
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Figure 6.1: Pyridinoline to creatinine ratios (left) and deoxypyridinoline to creatinine ratios (right)
in 24-hour urinary collections compared to ratios measured in spot samples taken at 8 a.m. and 4
p.m. All results represent the mean of 2 samples per patient taken on 2 consecutive days. The line
of identity is shown for reference.
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Post-hoc contrasts revealed significant differences between moming and 24-hour samples
(PYD/CT, P - 0.02, D P D / O , P - 0.03), and between morning and afternoon samples ( P Y D / O , P
- 0.007, DPD/Cr, P - 0.012), but not between afternoon and 24-hour samples (PYD/O, P - 0.69,
DPD/CT, P - 0.67). Agreement analysis confirmed these results: PYD/CT in samples taken at 4
p.m. agreed well with values from 24-hour collection samples; the mean difference widi the day
sample ratio 14%, with an intraclass correlation of 0.96. For DPD/& the mean difference was
16%, intraclass correlation 0.93. Samples taken at 8 a.m. agreed less well: for PYD/Cr, the mean
difference with the day sample ratio was 34% and the intraclass correlation was 0.81; for DPD/Cr
die mean difference was 37% and the intraclass correlation was 0.79. Figure 6.1 shows the 4 p.m.
samples close to die line of identity with the day samples (slight underestimation); this contrasts
with die overestimation in the 8 a.m. samples.
Discussion
In rheumatoid arthritis patients widi active disease, we observed a circadian rhydim in cross-
link excretion at an elevated level. Morning sample values reflect elevated excretion during the
night, as has already been observed before in individuals without RA. Therefore moming samples
may overestimated 24-hour excretion, whereas afternoon samples are more accurate. Day-to-day
variation is small.
Previous studies on circadian rhydims in crosslink excretion were performed in healdiy
volunteers using 24-hour collection or morning samples taken before breakfast as die gold
standard. Gonsistendy, none of these studies found P Y D / G and DPD/Cx higher dian 40 and 8
nmol/mmol, respectively [6,7], The hospitalized arthritis patients in diis study had modesdy raised
levels of PYD and DPD excretion level. The specific laboratory mediods used may have influenced
our results, but die similar PYD/DPD ratios in die spot samples and die 24-hour excretion samples
suggest the reliability of the measurement techniques used. Differences in urinary frequency and
subsequently the amount of urine in die bladder at moments of sampling may have increased die
variance. We applied correction for this by calculating the ratios creatinine excretion but in die
experimental settings the timed sampling of portions is preferred (widi fasting before moming
samples). This sampling schedule is hardly feasible in the routine follow-up of patients, and as our
findings were meant to be generalized to die follow-up of ambulant as well as hospitalized
patients, we chose a relatively simple sampling mediod. Despite die small number of patients
studied, significant differences were revealed.
In conclusion, the collection of spot samples for the assessment of pyridinoline excretion is
best performed in die afternoon (4 p.m.), when accurate approximation of average day excretions
is the goal. In longitudinal studies, at die very least die sampling time should be fixed.
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Bone Turnover, Joint Damage and Bone Mineral Density
in Early Rheumatoid Arthritis Treated with Combination
Therapy Including High-Dose Corticosteroids
Abstract
Ob/ect/Ves: Exploration of bone metabolism changes at different levels of disease activity, both
with and without oral corticosteroid therapy, and prediction of changes in joint damage and
changes in bone density from the observed changes in markers of bone turnover.
Me^ /)OC/S: Data analysis from a randomized clinical trial with 155 rheumatoid arthritis (RA)
patients; median age 50, early and active disease (diagnosis < 2 yr); one group treated with a
combination of sulphasalazine (SSZ; 2000 mg/day), methotrexate (MTX; 7.5 mg/week) and
prednisolone (initially 60 mg/day, tapered in six weekly steps to 7.5 mg/day), the other group with
SSZ alone. Prednisolone and MTX were tapered and stopped after week 28 and week 40,
respectively, while SSZ was continued. Urine and serum samples were collected at baseline and
weeks 16,28, 40 and 56. Measurements of urinary pyridinoline (PYD) and deoxypyridinoline (DPD)
and serum alkaline phosphatase (tAP) and osteocalcin (OQ were performed, as well as standard
clinimetry and bone densitometry.
Resu/fS: Over time and in both treatment groups, bone formation and bone resorption markers
showed a pattern similar to erythrocyte sedimentation index (ESR): A significant decrease
compared with baseline and a larger decrease with combined treatment at weeks 16 and 28. PYD
excretion, tAP, OQ and joint damage scores were significant lower in the combined-treatment
group. Changes in bone density (of spine and hips) did not significantly differ between treatment
groups. Mainly cumulative ESR explained progression of joint damage.
Conc/us/ons: Prednisolone and disease-modifying anti-rheumatic drug therapy in patients with
early and active RA are both independently associated with decreased levels of urinary excretion of
bone collagen resorption markers: PYD and DPD. Markers of bone formation aw^ resorption
closely followed changes in ESR in toA treatment groups. Reduced bone resorption together with
reduced bone formation - initially at a somewhat faster pace - resulted in less bone turnover and
explain the observed (non-significant and partially reversible) extra bone loss in the lumbar spine
associated with prednisolone (combined treatment).
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Introduction
Rheumatoid arthritis (RA) is a systemic disease with inflammation and destruction of joints in
hands and feet as a hallmark. As a result of pathological destruction of collagen in bone and
cartilage, crosslinks in mature collagen are resorbed more rapidly. This causes a rise in circulating
collagen crosslink levels and their urinary excretion. In RA, apart from the crosslink resorption at
the site of inflamed joints, there might be increased resorption due to general bone loss associated
with disease activity [1,2].
The most important collagen crosslinks of bone and cartilage are the pyridinium derivatives,
pyridinoline (PYD or hydroxylysvlpyridinoline) and deoxypyridinoline (DPD or lysylpyridinoline).
Most DPD is present in type I collagen which is the main protein component of bone and dentine.
Most excrete/ DPD comes from bone as this tissue undergoes relatively rapid remodelling.
Therefore, urinary excretion of DPD is considered a more or less specific estimate of resorption of
bone by osteoclasts. PYD is more widely distributed and present in considerable amounts in
cartilage specific collagen: types II, IX and XI; it may present a marker of destruction in cartilage
and other soft tissues [3]. Diet or physical exercise do not influence excretion of PYD and DPD.
Because of circadian rhythm in bone remodelling [4,5], excretion in 24-hours collection is widely
considered the standard, but samples collected during a fixed day time with concentrations
corrected for creatinine (Cr) reflect 24 h excretion levels as well [6].
Treatment in RA traditionally starts with non-steroidal anti-inflammatory drugs (NSAIDs),
and continues if necessary with a sequence of progressively toxic so called disease-modifying
antirheumatic drugs (DMARDs) [7]. Some DMARDs and corticosteroids provide a degree of
disease control, i.e. they decrease disease activity, maintain physical function and attenuate joint
damage visible on radiographs [8-11]. Recent studies suggest that early introduction of DMARDs
and corticosteroids may be beneficial for patients with recently diagnosed RA [12,13]. However,
the use of corticosteroids is controversial due to side-effects, including osteoporosis. The COBRA
study [13] (GOmbinatietherapie Bij Reumatoide Artritis) aimed at rapid disease control in early RA
patients by a step-down bridge combination therapy with agents that have overlapping windows of
efficacy onset; the regimen comprised a short period of high-dose oral prednisolone. The other
components of the combination were methotrexate (MTX) and sulphasalazine (SSZ) as an anchor
drug to remain when the other two drugs were tapered and stopped after 6 months to prevent
adverse effects while retaining disease control. The combination therapy regimen demonstrated
excellent clinical response, comparatively few adverse effects, and less progression in radiographic
joint damage.
This report has two main goals. First, to clarify the changes in bone metabolism at different
levels of improvement in disease activity over a 56-week follow-up period, both with and without
oral corticosteroid therapy. Second, to investigate the possibility to predict changes in joint damage
and bone mineral density (BMD) from the observed changes in markers of bone turnover.
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Patients and Methods
Paf/er/fs, c//n/ca/ efficacy measures and adverse effects
All measures were done in the setting of the COBRA study [13]. This concerned a 1-yr clinical
trial with 155 RA patients (1987 American College of Rheumatology (ACR) criteria [14]) aged 18-
70, who were randomly assigned to one of two treatment regimes. All patients had early, active
disease (diagnosis < 2 yr). No prior treatment with second-line anti-rheumatic medication apart
from anti-malarials was allowed. One group was treated with a combination of SSZ (2000
mg/day), MTX (7.5 mg/week) and prednisolone (initially 60 mg/day, tapered in six weekly step to
7.5 mg/day). The other group was treated with SSZ and double placebo. Prednisolone and MTX
(or the placebos) were tapered and stopped after weeks 28 and week 40, respectively, while SSZ
was continued. The total amount of prednisolone prescribed according to the study protocol was
2345 mg, the mean dose over the first 28 weeks of follow-up 12 mg/day. All patients had calcium
supplementation (1 g/day) prescribed for as long as they used prednisolone, and folk acid (1
mg/day) as long as they used MTX. Vitamin D supplements were given when vitamin D
deficiency was present at baseline.
Clinical improvement was expressed by the preliminary ACR criteria [15] that require a
minimum of 20% improvement in tender and swollen joint counts plus a similar improvement in
at least three of five remaining core set measures: patient and physician global assessment, pain,
acute phase response, and physical function. We also report the n«wafcer of core set measures with
20% improvement, and change in the Disease Activity Score (DAS) [16], a composite outcome
measure containing the Ritchie tender joint index (RAl) [17], swollen joint count (48 joints
assessed), Westergren's erythrocyte sedimentation rate (ESR), and patient's global assessment (10
cm visual analogue scale) - 0.54-VRAI + 0.065-swollen joint count + 0.33-ln(ESR) + 0.07-patient
global assessment. Improvement in physical function was reflected by a validated Dutch version of
the Health Assessment Questionnaire (HAQ) [18,19] completed by the patients.
Bone-related outcomes were joint damage and BMD. Progression in joint damage was
assessed by van der Heijde's [8] modification of Sharp's scoring method; a quantitative score for
erosions and joint space narrowing visible on radiographs of hands and feet. Radiographs taken at
baseline and weeks 28 and 56 were read in sequence by two trained observers, unaware of
treatment allocation. BMD in lumbar spine and femoral neck was measured at baseline and weeks
28 and 56 in centres where dual energy X-ray absorptiometry was available. Changes in BMD
(g/cm*) were reported by percentage compared with baseline; for the femoral neck, the mean of
both sides was calculated. For further analysis, every patient's propensity to lose bone was
categorized as male, pre-menopausal female, post-menopausal female, or post-menopausal female
with hormonal replacement therapy.
The study protocol was approved by research and medical ethics committees in all
participating hospitals (nine clinical centres in The Netherlands and one in Belgium). All patients
gave written informed consent before they entered the study protocol between May 1993 and May
1995.
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B/ocftem/sfry
Urinary spot and serum samples were collected at baseline and weeks 16, 28, 40 and 56, and
stored in 10 ml aliquots at -20<C The total amount of excreted PYD and DPD was measured by
high-performance liquid chromatography (HPLQ. Urine samples were hydrolysed in 6 M HQ,
dried and reconstituted in 50% acetic acid and injected onto a HPLC column with on-line
purification on CC31 cellulose using a Prospekt solid-phase extractor (Separations, The
Nedierlands). The retained crosslinks were eluded from the CC31 material and on-line
chromatographed on a cation exchange column (Whatman Partisil SCX). Eluded crosslinks were
detected by a Jasco fluorometer (Model FP-920, Separations). The PYD/DPD HPLC Calibrator
(Metra, Palo Alto, CA, USA) was used as standard. The intra- and interassay coefficients of
variation were <3 and <5% for PYD/Cr as well as DPD/Cr, respectively. Urinary excretion rates
are expressed as nmol/mmol Cr. Cr was measured in the same urine samples by the Kodak
Ektachem Clinical Chemistry Slide (CREA; Eastman Kodak Incorporate, Rochester, NY). Bone
formation was calculated using total serum alkaline phosphatase (tAP). These were routinely
assessed and registered by standard laboratory techniques in each clinical centre at every
monitoring visit. Thus, diey were available more frequently than every 16 or 12 weeks. Finally,
serum osteocalcin (OC) was measured in collected serum samples by a commercial kit (N-Mid-
Osteo; Osteometer, Copenhagen, Denmark) and expressed as ng/ml. Intra- and interassay
coefficients of variation of these measurements were <5 and <8%.
Sfaf/sf/ca/ ana/ys/s
Change in comparison to baseline values was calculated for all variables. In the case of a non-
Gaussian distribution, change scores were transformed (with natural logarithm). Paired and
unpaired Student r tests were used for comparisons of changes with baseline and between groups,
respectively. Post-hoc subgroup analysis was performed for hormonal status. The ratio of tAP and
natural log-transformed PYD excretion (i.e. tAP/ln[PYD/Cr|) is presented to reflect changes in the
balance between osteoblast and osteoclast activity.
To elucidate further the relationships between PYD excretion and disease activity, we
calculated Pearson's moment correlation between changes in PYD/Cr and DPD/Cr at week 28,
changes in all ACR core set measures, the number of ACR core set measures with at least 20%
improvement, and change in DAS. From the literature, as well as from primary analyses, acute
phase reactants such as ESR emerge as adequate measures to reflect disease activity [15,16]. Time-
integrated values of ESR were calculated, as diis representation of cumulative acute phase reaction
is known to correlate well with progression in joint damage [20]. Time-integrated PYD/Cr,
DPD/Cr, ESR and tAP were correlated with progression in joint damage score, and with changes
in BMD of spine and hips.
To determine if die changes in pyridinoline excretion can be explained solely by
glucocorticoid-induced changes in disease activity, a multiple regression analysis was carried out
with PYD excretion at week 28 as a dependent variable, and ESR change, treatment group
allocation and interaction between group and ESR as independent variables.
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The potential contribution of pyridinoline excretion as a predictor of outcome independent of
ESR was evaluated by stepwise multiple regression analyses in which natural log-transformed
change in joint damage and changes in bone density served as dependent variables. Their
respective baseline values, time-integrated ESR and PYD excretion, and treatment served as
predictors (independent variables); F to enter >4.0.
Table 7.1: Baseline characteristics median (minimum-maximum) or count (%) of study patients
according to treatment group
Characteristic Combined
Treatment
(n -76)
Sulpha-
salazine
(« -79)
Age(yrs)
Female
pre-menopausa]/ post- / HRT
Disease duration (months)
Previous treatment with antimalarials
Hospitalised for RA at baseline
Positive IgM rheumatoid factor
HLA-DR4 positive *
HLA-DR2 positive *
ESR(mm/lh)
PYD/Q (nmol/mmol)
DPD/Q (nmol/mmol)
Alkaline Phosphatase (IU/ L)
Osteocalcin (ng/ml)
Erosions on hand or foot radiographs '
Lumbar spine BMD (g/m*) *
Femoral neck BMD (g/nr) *
51
50
4
16
9
59
44
16
51
78
21
85
6.1
55
1.13
.93
23-70
66%
25/ 17/ 8
1-24
21%
12%
78%
60%
22%
2-136
6-261
1-61
49-343
1-25
74%
.74-1.46
.66-1.31
51
41
4
19
11
57
39
12
47
80
20
85
7.9
59
1.11
.92
24-70
52%
21/ 20/ 1
1-23
24%
14%
72%
56%
16%
2-118
9-441
1-86
44-394
1-44
79%
.66-1.54
.58-1.25
HRT; hormonal replacement therapy, ESR; erythrocyte sedimentation rate, PYD; pyridinoline,
DPD; deoxypyridinoline, Cr, creatinine.
*; Human leukocyte antigen; homozygotic or heterozygotic DR type, assessed in 143 patients,
t; Baseline radiographs available; combined-treatment group n = 74, suLphasalazine (SSZ) group rc
44 BMD; bone mineral density, combined-treatment group n - 64, SSZ group n - 62.
S; combined-treatment group « = 61, SSZ group » - 59.
75.
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Results
Clinical effects have been reported elsewhere [13]. Briefly, at week 16, a substantial and
significant improvement in almost all measures was observed in bodi treatment groups.
Improvement stabilized or increased towards week 28, with improvement in die combined-
treatment group being almost double that in die SSZ group. After 28 weeks of follow-up, die
mean decrease in ESR was 40 mm/h in die combined-treatment group x« 27 mm/h in die SSZ
group (P - 0.0022; Figure 7.1). Radiographic damage scores in bodi groups were similar at
baseline (Table 7.1). After 56 weeks, die median progression of die radiographic damage score was
two points in die combined-treatment group w six in die SSZ group (P - 0.004). During die first
28 weeks, BMD in the lumbar spine decreased mean 1.2% in die combined-treatment group (» -
63) is 0.0% (rc - 62) in die SSZ group (P - 0.06). In die femoral neck, die corresponding changes
were -0.3% w -0.7% (n = 59 and 57). Significandy fewer patients in die combined-treatment
group stopped protocol medication because of adverse events or lack of dierapy effect; six w 23
in die SSZ group; P = 0.0008. Wididrawal occurred later in die combined-treatment dian in die
SSZ group.
Changes in PYD/Cr and D P D / Q were calculated in 115 patients; 55 in die combined-
treatment group and 60 in die SSZ group. These changes showed a similar pattern to those
observed in die odier outcome measures such as ESR At weeks 16 and 28, PYD excretion
decreased significandy compared widi baseline values (all P < 0.0001). There was a rapid decrease
up to week 16 and a slower decrease up to week 28, widi a significant difference between
treatment groups at week 28; PYD/CT 45% w 18% reduction in die combined-treatment and SSZ
groups (P - 0.02); D P D / Q 33% w 15% reduction (P - 0.11; Figure 7.1). Also, the PYD/DPD
ratio showed a decrease in die combined-treatment group at weeks 16 and 28 (between-treatment
differences at weeks 16 and 28: P = 0.04 and 0.02).
Change in tAP agreed widi die general pattern of decreased disease activity in reaction to
treatment (Figure 7.1). At baseline, mean tAP was slighdy elevated in bodi groups. Change scores
on tAP were available for 74 patients in die combined-treatment group and 73 in die SSZ group.
Similar to ESR, tAP dropped rapidly in die combined-treatment group (widiin 4 weeks). At week
16, diere was a significant decrease in bodi groups (P < 0.001) and a significandy larger decrease in
the combined-treatment group (difference: 21 IU/ml, P < 0.001; 95% confidence interval (d) 11-
31; 31% w 11% reduction). In contrast widi die changes observed in PYD/Cr and D P D / Q , die
between-group difference in tAP did not increase between weeks 16 and 28 of follow-up. At
weeks 16 and 28, serum OC concentrations in die combined-treatment group (« - 56; SSZ group
w = 62) showed a significant decrease (all P < 0.0001). Maximum and significant between-group
contrast occurred at week 16 (P < 0.0001; Figure 7.1). This corresponds widi a maximum
between-group contrast in tAP/ln[PYD/Cr] ratio at diat time (P - 0.09).
Post-menopausal women (« = 39) tended to have larger reductions in PYD excretion, as well
as in tAP, especially in die combined-treatment group (not significant). This might be due to
initially higher values along widi greater disease activity in diese patients.
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Figure 7.1: Parameters of bone metabolism, acute phase reaction (ESR), joint destruction, and
BMD, per treatment group at baseline and follow-up at weeks 16, 28,40, and 56; week 40 is i
the tapering and withdrawal of predtiisolone in the combined-treatment group, week 56 is «/ter the
withdrawal of methotrexate. Open circles: SSZ treatment; dark diamonds: combined-treatment.
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Continued legend: Mean ± S.E.M. *: unpaired t test /> <0.05, **: /> <0.01
APYD/Cr changes compared with baseline in urinary excretion of pyridinoline/creatinine ratio
(nmol/mmol), ADPD/Cr changes in urinary excretion of deoxypyridinoline/crearinine ratio,
PYD/DPD: ratio, AESR: change compared with baseline in erydirocytes' sedimentation rate,
ln(A joint damage score + 1): natural logarithm transformed joint damage change score plus one
[Sharp/van der Heijde method; erosions and joint space narrowing in hands and feet],
tAP: total serum alkaline phosphatase (international units/ml), O C serum osteocalcin (ng/ml),
tAP/lnPyd: ratio, %ABMDspine: percents change compared to baseline in bone mineral density (g/citf)
measured by dual energy x-ray absorptiometry in the lumbar spine, %ABMDfemur - in die femoral neck
Table 7.2 shows correlations of changes in PYD excretion with ACR outcome measures and
DAS. Of all core set measures, ESR shows the highest correlation with PYD excretion. Qianges in
tAP also show significant correlation with changes in PYD excretion. Calculations per treatment
group show similar correlations (data not shown).
Table 7.2: Correlations between changes in PYD excretion and changes in other outcome
measures at 28 weeks of follow-up
A ESR
A global assessment observer
A global assessment patient
A pain
A tender joint count
A swollen joint count
AHAQ
# ACR20%
A Disease Activity Score
AtAP
A O C
APYD/Cr
(»-115)
.56***
.50***
.25*
.20
.22
.15
.46***
-.36***
.33**
.31*
.12
A DPD/Cr
(w -108)
.54***
.51***
25
2 5 *
.24
.11
.45***
-.35**
.31*
.33**
.25
A; change score i.e. difference compared to baseline, HAQ; health assessment questionnaire,
# AQR20%; number of core set measures wrdi _>20% improvement, OQ osteocalcin,
tAP; total serum alkaline phosphate,. ***; /> <0.0001, **; /> <0.001, *; P <0.01.
Change scores for joint damage showed significant correlation with time-integrated
pyridinoline excretion: 0.37 and 0.33 for PYD/Cr and DPD/Cr, respectively. Time-integrated ESR
and OC yielded larger correlation coefficients. Changes in BMD of the lumbar spine did not yield
a significant correlation with PYD excretion. Bone loss in the femoral neck, on the contrary did
show a weak and significant association with rime-integrated pyridinoline excretion (Table 7.3).
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In multiple regression analyses with change in PYD/Cr and DPD/Cr over 28 weeks as
dependent variables, the change in ESR was the only significant attributing variable (P = 0.002 and
0.011, respectively, 7^ - 31% and 29%). Treatment group and interaction between treatment and
change in ESR did not significandy increase die proportion of explained variance.
Table 7.3: Spearman's rank correlations of 'bony outcomes' with time-integrated PYD and DPD
excretion, ESR, tAP and OC at 28 weeks of follow-up
PYD/Cr AUC
DPD/Cr AUC
ESR AUC
tAP AUC
OCAUC
AX
(n-142)
37 ***
.33**
.49 ***
.11
.38 ***
ABMDLS
(» = 125)
- . 0 6
- . 0 6
- . 0 5
.01
-.11
A B M D P N
(w- 116)
- . 3 1 *
- . 3 3 *
- . 1 5
.10
-.17
A; difference compared to baseline, AUQ area under the curve (time-integrated),
X, van der Heijde's modification of Sharp's radiographic joint damage score;
BMDLS; bone mineral density lumbar spine, BMD^; bone mineral density femoral neck.
***/> <0.0001, **/> <0.001, •/> <0.01.
In a stepwise regression analysis with (log-transformed) progression in joint damage at week
28 as the dependent variable, time-integrated ESR, log-transformed baseline joint damage score,
and treatment group entered die model. The proportion of variance explained (Ä*) was 53%.
Time-integrated PYD excretion did not enter this model. At week 28 of follow-up, changes in
BMD of the lumbar spine and femoral neck proved to be less easy to predict with /?* =5% and
10%, respectively. For die prediction of spinal bone loss die only variable which was selected was
treatment group; for die prediction of changes in femoral bone density, only log-transformed
time-integrated PYD/Cr was selected.
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Discussion
Over time and in both treatment groups, PYD excretion showed a pattern similar to the other
variables assessed in the COBRA study. Combined treatment with step-down prednisolone, MTX
and SSZ caused significantly larger reductions in initially elevated urinary PYD excretion than
treatment with SSZ alone. The decreased levels of bone resorption together with decreased bone
formation point to a state with less bone turnover. Treatment with SSZ alone also led to a
decrease of bone turnover, but this effect was smaller. Markers of bone formation and bone
resorption reflect overall disease activity, but the measurable response of osteoblasts (i.e. bone
formation) was quicker than that of osteoclasts. A rapid decrease in osteoblast activity- compared
to a slower decrease in osteoclast activity - can explain the 'early phase' of bone loss observed in
RA patients who start treatment with corticosteroids [21].
Alkaline phosphatase is produced in other cells than osteoblasts and a direct effect of trial
medication on this marker cannot be excluded. However, as simultaneously measured
transaminase and bilirubin levels, as well as afterwards measured y-glutamyl transpeptidase levels,
did not show significant changes during prednisolone therapy, we can be rather confident that the
changes measured in tAP reflect mainly AP's bone fraction. We prefer tAP instead of OC as a
marker of bone formation, as OC is more properly a marker of bone f«r77Oier rather than a
specific marker of bone/bmMfz'on [22]. Over time, serum OC levels in both treatment groups also
mimicked tAP/ln(PYD/Cr) ratios that served as proxy for bone turnover rates - even with storage
conditions that were not optimal for O C
The level of disease control during the first 28 weeks of follow-up achieved with combined
treatment was substantial. Markers of bone resorption (PYD and DPD urinary excretion) reflect
this, as well as 'proxy* bone formation marker tAP, and clinical outcome measures. In the
correlation analysis, changes in bone resorption markers were strongly related with acute phase
reaction and functional ability (i.e. HAQ) and to a lesser extent to markers of bone formation. The
observed changes in pyridinoline excretion may be mediated by reduced disease activity alone. An
effect of prednisolone on bone turnover at doses as prescribed, separate from altered disease
activity, was not demonstrable; treatment group allocation did not significantly improve prediction
of changes in PYD excretion once changes in ESR were taken into the regression model.
In the prediction of progression in joint damage in this patient group with early disease, the
contribution of observed changes in bone resorption turned out to be modest, especially when
markers of acute phase reaction, such as ESR, were available. The relatively high correlation
coefficients between cumulative ESR and joint damage score in the SSZ group might be explained
by larger variation in therapy effects with less adequate suppression of disease activity through
single SSZ therapy. The modified Sharp score comprises joint erosions as well as joint-space
narrowing. Bone-specific DPD levels were expected to correlate less with narrowing scores dran
PYD, because narrowing reflects loss of (joint's) cartilage. This however, could not be
demonstrated.
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Decreasing PYD/DPD ratios reflect relatively large resorption of bone as compared with other
collagenous tissues. Decreasing levels of PYD, DPD, and PYD/DPD together, as seen in the
combined-treatment group, suggest a beneficial effect on predominantly non-bone collagenous
tissue; presumably cartilage. In contrast, Sharif # a/ [23] could not show changes in putativery
markers of cartilage loss such as 5D4 keratan sulfate epitope in a RA patient group treated with
prednisolone, although there were clear signs of reduced synovitis and bone turnover.
We observed a small extra decrease in spinal BMD in the combined-treatment group (/> -
0.06). This was most probably a prednisolone effect. After prednisolone was tapered and stopped,
the cumulative bone loss stabilized [13]. At this site there was no significant correlation between
BMD and cumulative PYD excretion (or disease activity). In contrast, in the femoral neck no
difference in BMD loss between the groups emerged, but there was a significant correlation
between time-integrated PYD excretion and BMD change. Gough et a/ earlier described an
association between urinary PYD excretion and bone loss at the femoral neck [1]. These BMD
changes appear not to be directly mediated by cumulative disease activity, as the correlation with
time-integrated ESR is low, and furthermore time-integrated P Y D / G proved to be the only
significant predictor for bone loss in the hip. It may be that specifically at the site of the femoral
neck corticosteroid-induced bone loss has been balanced by the bone-saving effect of
prednisolone through reduction of disease activity [24].
Many pathways of bone metabolism, such as inhibition of matrix metalloproteinases, remain
to be clarified. PYD and DPD are valuable markers to show actual bone resorption, especially
mechanisms that are not mediated by cytokines or take action at a different level. As an example,
those and future bone-specific markers may be necessary to further elucidate the complex
relationships between bone metabolism at different sites, RA disease activity and its suppression
e.g. bycorticosteroids.
In conclusion, the changes in bone metabolism in reaction to treatment with and without
corticosteroids, are predominantly mediated by therapy-induced reduction of disease activity. In
early RA, the contribution of urinary PYD excretion in the prediction of disease outcome may be
modest, especially when markers of acute phase reaction are readily available. Nonetheless, PYD
may give us insight into bone metabolism and help us to understand better the actual changes in
bone and cartilage caused by RA and its treatment.
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Factors Predicting Response to Treatment in Rheumatoid
Arthritis: the Importance of Disease Duration
Abstract
Ob/ecf/Ve. To use individual patient data from rheumatoid arthritis (RA) clinical trials to identify
factors that affect the response to treatment as defined by the American College of Rheumatology
(ACR) criteria for improvement (the "ACR response").
Mef/iods. Primary trial data from 14 diverse, randomized, controlled trials of second-line drugs or
devices in RA were analyzed. The trials included 11 methotrexate (MTX) trials (5 placebo
controlled and 6 comparative, of which 2 were unpublished), 1 combination trial of cyclosporin
plus MTX, 1 induction trial of a combination treatment in early RA (the COBRA trial), and 1
placebo-controlled trial of a new device (Prosorba). Both patient factors and disease activity
measures (primarily, items from the ACR core criteria set) were available.
Resu/fs. A total of 1,435 patients (549 in placebo-controlled trials, 886 in comparative trials) were
studied. In both active treatment and placebo groups, disease duration had a strong effect on the
likelihood of patient response (e.g., with any active treatment, the response rate was 53% for
patients with _< 1 year of disease, 43% for 1-2 years' disease duration, 44% for 2-5 years, 38% for
5-10 years, and 35% for > 10 years; P = 0.001). Decreasing response with greater disease duration
was seen during treatment witii most of the individual active drugs, as well as with placebo. Other
factors decreasing the rate of response to treatment included any prior use of a disease-modifying
anti-rheumatic drug (DMARD), higher disease functional class (according to the Steinbrocker
criteria), low disease activity (according to patient's global assessment), and female sex. Each ACR
core set variable exhibited a diminished response to treatment in patients with long-standing
disease. The difference between active treatment and placebo response rates was not affected by
disease duration nor by other factors associated with the ACR response.
Conc/us/on. RA patients with longer disease duration do not respond as well to treatment
compared with patients with early disease, and female sex, prior DMARD use, disease functional
class, and disease activity also have effects on the likelihood of patient response to treatment. This
has implications for trial interpretation and for the clinical expectations of RA patients.
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Introduction
It is unknown why some patients with rheumatoid arthritis (RA) respond to treatment better
than others. It has been suggested that patients with more severe disease may be less likely to show
a response, and that patients who have previously been treated unsuccessfully with second-line
drugs also may have more recalcitrant disease [1]. In addition, diere are indications that the
biologic process of RA changes early in tiie disease, so that patients may be less responsive to
treatment over time [2-5]. The interval in early disease during which response may more readily
occur is not clearly defined, so that the relationship between disease duration and response to
treatment is of considerable interest. It would also appear that patients with especially active
disease are more likely to respond to treatment, particularly in a clinical trial context. Better
response in these patients would represent regression to die mean.
An understanding of which types of patients widi RA are most likely to respond to treatment
has implications for the aggressiveness of treatment of individual patients. In addition, diere may
be implications for die design of clinical trials, in diat die anticipated power of a trial may be a
function of die particular mix of patients who participate in die trial. To address diese questions,
we have made use of patient data from a variety of clinical trials of second-line drugs and devices
in RA diat have been conducted since die early 1980s. We selected only trials in which patient
response, as defined by die American College of Rheumatology (ACR) criteria for improvement
[6] (referred to herein as die "ACR response"), could be determined, and in which individual
patient and disease factors were available.
Patients and methods
We analyzed primary trial data from randomized, controlled trials of second-line drugs or
devices in RA. Criteria for selection of die trials included treatment wrdi second-line drugs and die
availability of individual patient data on baseline and outcome variables, so diat die response rate
(according to die ACR 20% improvement criteria) [6] could be calculated. The ACR improvement
criteria require diat a patient improve by at least 20% in each of his or her tender joint count and
swollen joint count during a clinical trial, and also improve by at least 20% in at least 3 of die odier
5 core set measures (patient's assessments of pain and physical function, patient's and physician's
global assessments, and an acute-phase reactant measure).
We evaluated whether each subject met die ACR criteria for improvement at die end of die
trial by an intent-to-treat approach using the last observation carried forward. We did not
odierwise make use of any intermediate assessments in assessing whedier a patient satisfied die
ACR response criteria. In the 3 most recent trials, die Health Assessment Questionnaire (HAQ)
[7] disability score was die physical function measure used in die calculation of improvement,
while in die earlier trials, grip strengdi was available as die physical function measure for diis
calculation. We have previously shown a moderate correlation between change in grip strengdi and
change in self-reported functional status [6].
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We used logistic regression to analyze the factors affecting the likelihood of patient response,
with initial tests performed on each of the candidate factors separately. These factors fell into 2
groups: patient factors (age, sex, disease duration, Steinbrocker functional class [8], any prior use
of second-line drugs, and any prednisone use during the trial) and disease activity factors (each of
the ACR core set items evaluated at baseline). In all logistic regression analyses, we controlled for
treatment, with an indicator variable for each non-placebo treatment. We did not include the trial,
or "study," as an effect in these analyses because some active treatments were studied in only 1
trial. It was therefore not possible to control for both study and treatment. We retained, for
subsequent multivariate analyses, any patient or disease activity factor with a P value less than 0.15
in its statistical association with the ACR response.
Because of missing data on several items in some trials, we constructed 2 data sets for the
multivariate analyses. These were an "all variable" data set, consisting of the trials in which all
retained candidate variables were available, and an "all trial" data set, from which some of the
retained variables were missing and therefore not analyzable. In the multivariate analyses, we
assessed the simultaneous associations of candidate factors with response. Data on the strength of
the association identified in the multivariate logistic regressions are expressed as an adjusted odds
ratio (ORjjj) that represents the odds ratio per unit increase in a variable when other variables are
also in the model.
For factors found to have an association with response to treatment, we looked for possible
effects on the statistical power of trials. We used logistic regression to test the interaction of active
treatment versus placebo with the factor to determine whether the difference in response between
active treatment and placebo varied with factor leveL In further logistic regressions, we also
examined the association between the response (> 20% improvement) in individual ACR core set
items and these same factors.
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Results
We analyzed data from 14 RA trials. These included 11 methotrexate (MTX) trials (5 placebo
controlled and 6 comparative, of which 2 were unpublished) that were conducted in the 1980s and
assembled into an archive [9-18] and unpublished observations (from Schmid FR and from Wilke
WS). Three additional trials from the 1990s were also studied: 1 combination trial of cyclosporine
plus MTX [19], 1 induction trial of a combination treatment in early RA [20] (referred to as the
COBRA trial), and 1 placebo-controlled trial of a new device (Prosorba) [21]. Table 8.1 lists the 14
trials with their publication dates and treatments, as well as the sizes and ACR response rates for
each treatment group. The treatments included MTX, auranofin (AUR), the combination of MTX
and AUR, sodium aurothiomalate (injectable gold), azathioprine (AZA), cyclosporin, sulpha-
salazine (SSZ), the combination of MTX, SSZ, and prednisolone, and Prosorba.
We studied 1,435 patients (549 participating in die placebo-controlled trials, 886 in die
comparative trials). Overall response rates were higher in die comparative trials (ranging from 38%
to 53%) than in die placebo-controlled trials (5% to 37%).
Table 8.2 shows the mean values and range of means for die patient factors and disease
activity measures in the 14 trials. In some respects, the trials were similar, in diat each had a
majority of female patients and the average age of die patients ranged from 50 years to 60 years.
The trials varied considerably, however, in average disease duration, which ranged from 0.5 years
in die COBRA trial [20] to 15.5 years in die Prosorba trial [21] to 17.7 years in 1 of die small trials
of MTX versus placebo (Schmidt FRJ unpublished observations). The trials also varied in the
distribution of patients according to Steinbrocker functional class (12-47% of patients in class III
per trial), die extent of prior use of disease-modifying antirheumatic drugs (DMARDs) (10-100%
of patients per trial), and die baseline disease activity (for example, die average number of swollen
joints ranged from 15 to 30 across the 14 trials).
The "all variable" data set did not include 4 comparative trials because 1 or more of die
variables of prior DMARD use, physician's global assessment, or Steinbrocker functional class was
eidier not assessed or not recorded in diese 4 trials. The largest of diese trials was die COBRA
trial, in which only die Steinbrocker functional class was not available for our analyses.
As shown in Table 8.3, die univariate analyses identified 4 patient factors associated widi a
reduced likelihood of treatment response: female sex, longer disease duration, higher Steinbrocker
functional class, and prior DMARD use. The univariate effects persisted in die multivariate
analyses. In multivariate analyses using the "all variable" data set, die odds of response to
treatment for women were 0.72 times diose for men. Similarly, die odds of response were only
0.60 for patients in Steinbrocker functional class III versus diose in functional class II, and prior
DMARD use was associated widi a similar reduction in die odds of response, to 0.62. The disease
duration effect on odds of response was 0.74 when expressed per 15-year increase in disease
duration (0.98 per extra year of disease duration). Despite die possibility of strong correlations
between diese patient factors, particularly between prior DMARD use and disease duration, each
maintained an independent effect in die multivariate analysis.
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Table 8.1: Trials included in study of factors affecting response to second-line drug treatment in rheumatoid arthritis*
Trial Reference Number of % of subjects Treatments
first author, No. subjects in meeting ACR20 in the
(year of publication) the trial response trials
Per treatment group
number of subjects
(% meeting ACR20 response)
I
D
0)
a
I
OO
Placebo Controlled Trials
Weinblatt (1985)
Fürst (1989)
10
11
Schmidt unpublished
Williams (1985) 12
Wilke unpublished
Tugwell (1995) f
Prosorba (1998)
Total no. of subjects
Comparative Trials
Weinblatt (1990)
Williams (1992)
Suarez (1988)
Morassut 1989)
Hamdy (1987)
Bell (1988)
Boers (1997)
Total no. of subiects
19
21
13
14
15
16
17
18
20
35
59
11
191
19
143
91
549
274
318
38
33
40
28
155
886
34%
37%
18%
20%
5%
27%
22%
46%
43%
40%
42%
38%
43%
53%
MTX vs Placebo
MTX vs Placebo
MTX vs Placebo
MTX vs Placebo
MTX vs Placebo
MTX + Cyclo vs MTX
Prosorba vs Placebo
MTXvsAUR
MTX/AURvsMTX
vsAUR
MTX vs Gold
MTX vs Gold
MTXvsAZA
MTXvsAZA
MTX/SSZ/PredvsSSZ
MTX 17 (65); placebo 18 (6)
MTX 42 (40); placebo 17 (29)
MTX 5 (20); placebo 6 (17)
MTX 94 (34); placebo 97 (6)
MTX 11 (9); placebo 8(0)
MTX + Cyclo 70 (41); MTX 73 (12)
Prosorba 48 (33); placebo 43 (9)
MTX 135 (65); AUR139 (28)
MTX 110 (43); AUR 108 (34);
MTX + AUR 100 (51)
MTX 20 (35); Gold 18 (44)
MTX 18 (50); Gold 15 (33)
MTX 21 (38); AZA 19 (37)
MTX 15 (67); AZA 13 (15)
MTX/SSZ/Pred 76 (72); SSZ 79 (32)
* ACR20 - American College of Rheumatology 20% improvement criteria [6]; MTX= methotrexate; Cyclo =cyclosporin;
AUR - auronofin; Gold = sodium aurothiomalate; AZA = azathioprine; SSZ = sulphasalazine; Pred = Prednisolone.
t In this trial, all patients were being treated with MTX before the trial began, so it was included as a placebo-controlled trial of cyclosporin.
cf/sease efurafton and responsiveness of outcome measures
Among the disease activity measures associated with response were the patient's assessment
of pain and the swollen joint count, as well as the patient's and the physician's global assessments.
Each of diese factors increased die likelihood of response, while the opposite trend occurred for
physical function as measured by die HAQ score. In the univariate analyses, die effect of die
HAQ score appeared substantial, at 0.77 per unit on the 0-3 scale used for the HAQ. The test of
significance had low power, however, widi /> = 0.15, because HAQ assessments were available in
only 3 of the trials. In the multivaiiate analysis of the "all variable" data set, the patient's global
assessment was the sole significant disease activity variable affecting the likelihood of response.
Table 8.2: Patient factors and disease activity measures across the 14 trials
No. of trials
Overall mean Range of means missing
Patient factors
Age, years
Female, %
Disease duration, years
Steinbocker class III, %
Prior use of DMARDs, %
Prednisone use, %
Disease activity measures
Pain assessment (0-100 scale)
Swollen joint count (of 66 joints)
Tender joint count (of 68 joints)
ESR, mm/hour
Grip strengdi, mm Hg
HAQ score (0-3)
Physician's global assessment (0-100 scale)
Patient's global assessment (0-100 scale)
DMARDs: disease-modifying anti-rheumatic drugs; ESR; erythrocyte sedimentation rate;
HAQ: Health Assessment Questionnaire.
In die final multivariate analysis, summarised in Table 8.3, among die variables in die "all
trial" data set, die results for die variables in common were similar to diose for die variables in die
"all variable" data set, except diat die effect of sex was less strong (OR,,,; 0.81 versus 0.72) and the
disease duration effect was stronger (OR^ 0.97 per year, which translates into 0.63 per 15 years,
versus an OR^j of 0.98 per year, corresponding to 0.74 per 15 years).
53
69
7.8
20
45
31
53
22.5
29.7
44
94
1.5
56
58
50-
55-
0.5-
12-
10-
3-
43-
14.8-
19.5-
34-
52-
1.4-
49-
47-
60
91
17.7
47
100
82
76
30.3
37.4
67
140
1.9
75
80
0
0
0
4
1
1
0
0
0
0
3
11
3
3
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Table 8.3: Association of patient and disease activity factois with the likelihood of patient improvement *
Multivariate models
Univariate analyses
"All variable" data set
of 10 trials
(n - 985)
"All trial" data set
of 14 trials
(n - 1,404)
Patient factors
Age (per year)
Sex(F)
Disease duration (per year)
Steinbrocker functional class (per 1)
Any prior DMARDs (yes)
Any prednisone during trial (yes)
Baseline disease activity measures
ESR (per mm/hour)
Pain assessment (0-10 scale) (per unit)
Tender joint count (0-68) (per unit)
Swollen joint count (0-66) (per unit)
Grip strength (per mm Hg)
HAQ (0-3 scale) (per unit)
Patient's global assessment (0-10 scale) (per unit)
Physician's global assessment (0-10 scale) (per unit)
.99
.79
.97
.66
.59
.98
1.00
1.05
1.00
1.01
1.00
0.77
1.10
1.08
.341
.053
.001
.007
.001
.871
.512
.085
.813
.064
.419
.145
.001
.030
.72
.98
.60
.62
1.02
1.01
1.11
1.09
.040
.028
.004
.008
.590
.356
.027
.148
.81
.97
1.00
1.10
1.10
.095
.001
.085
.172
.010
All analyses adjusted for treatment. OR^j: - adjusted odds ratio (see Table 8.2 for other definitions).
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The strong effect of disease duration on response to treatment for most of the different
treatments can be seen in Figure 8.1. Among the patients receiving active treatment, there was a
response rate of 53% for those with a disease duration under 1 year, 43% for a disease duration
between 1 year and 2 years, 44% for 2-5 years' disease duration, 38% for 5-10 years' disease
duration, and 35% for patients with a disease duration exceeding 10 years. The pattern of response
was similar for the different DMARD treatments, particularly for the treatments in the OOBRA
trial, in which all but 10% of participants had < 1 year of disease. Because there were only 9
subjects treated with Prosorba who had a disease duration under 5 years, the response rate
estimate of 22% (2 of 9 subjects) for that range was unstable, but the response was steady at 33%
and 35%, respectively, in the longer ranges of disease duration.
.8-
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5^ -6"
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Figure 8.1: Proportion of patients in 14 trials having a response satisfying the ACR-20%
improvement criteria [6], within each combination of treatment and disease duration category.
Treatments are placebo, sulphasalazine (SSZ), auranofin (AUR), sodium aurothiomalate (Gold), azathioprine
(AZA), combination of methotrexate and auranofin (MTX + AUR), methotrexate (MTX), cyclosporin (Cydo),
combination of methotrexate, sulphasalazine, and step-down prednisolone (MTX + Pred + SSZ), and an
lmmunoadsorption column, apheresis-based treatment containing Staphylococcal protein A (Prosorba).
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The difference between active treatment and placebo response rates was not affected by
disease duration or the other factors. Table 8.4 shows response rates for active treatment and
placebo-treated patients in all of the trials by categories of disease duration, Steinbrocker
functional class, sex, and patient global assessment. The differences in response were generally
~30% regardless of category, and did not vary significandy across die strata (P >0.05 in each
case). Too few placebo-treated subjects had not had prior DMARD use (« - 6) to evaluate die
response rates for diis factor.
Table 8.4: ACR response rates for active treatment and placebo-treated patients within the strata
of factors related to response
Overall
By sex
Male
Female
By baseline patient's
global assessment
<5
>5
By Steinbocker functional class
I or II
III
By disease duration
j<lyear
>1 , <2>cars
>2,j<5 years
>5, _< 10 years
> 10 years
Active treatment
No.
1178
371
807
222
943
710
194
312
148
245
213
260
ACR
response, %
43
46
41
39
44
43
38
52
43
44
39
35
Placebo treated
No.
262
72
190
42
212
166
96
10
9
36
72
135
ACR
response, %
10
13
8
5
11
13
4
20
22
14
7
9
Active-placebo
difference, %
33
31
33
34
33
30
34
32
21
30
32
26
We examined the response by disease duration for each of the core set components
separately. For each core set measure, we found lower proportions of patients who improved by at
least 20% widi longer disease duration. The response in tender joint count and swollen joint count
dropped off more steeply than did the response in other core set items (Figure 8.2), yet these 2
items, both of which must improve by at least 20% for the ACR improvement criteria to be
satisfied, remained more likely to improve than did any of die odier 5 items in each of the 5
intervals of disease duration. The drop-off in response widi disease duration was fairly uniform
across all components of die ACR core set.
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Figure 8.2: Proportion of patients in 14 trials improving by at least 20% in each of 7 ACR core-
set items, within each disease duration category.
ACR core-set items are tender joint count (TfC), swollen joint count (SJC), erythrocyte sedimentation rate
(ESR), patient's assessment of disease severity (PTSEV), physician's assessment of disease severity (PHYSEV),
grip strength (in 11 trials) or health assessment questionnaire score (in 3 trials) (GRIP/HAQ), and patient's
assessment of pain (PAIN).
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Discussion
The major findings of our analyses are that disease duration has a considerable impact on
response to treatment, as do the Steinbrocker functional class and previous DMARD use.
Understanding the magnitude of these effects and of the difference in response for male and
female patients can be useful to both patients and physicians in anticipating the likelihood of
response to treatment with any of these DMARDs. In these trials, we saw a net 5% greater
response probability for male versus female patients and between Steinbrocker functional class II
and functional class III patients, as well as a 10% greater response probability among patients who
had not previously been treated with DMARDs.
Some effect of disease activity is to be expected in patients entering a clinical trial. We found a
5% difference in response for patients with high versus low baseline disease activity levels as
measured using the patient global assessment. In part, this may represent regression to the mean,
since the usual requirement of a certain level of disease activity for patients entering a clinical trial
generally results in some improvement in disease activity during the trial, independent of any
effects of medication. However, the effect of disease activity seen in these data was substantial, as
large as the difference seen between male and female patients and between the 2 levels of disease
severity.
A limitation of this study was the absence, from the trial data available to us, of information
on rheumatoid factor, which may affect response to treatment [22,23]. In addition, only 3 trials
had HAQ data available as a measure of physical function, with the remainder of trials providing
grip strength data. It is possible that we could have found stronger results for the independent
effects of physical function on response to treatment if a more comprehensive measure had been
available in a greater number of trials.
A lesser limitation is that 3 of the trials whose data were included did not have 1 of the ACR
core set measures available, specifically, the physician's global assessment. This meant that it was
slightly more difficult for the patients in these trials to achieve the ACR response compared with
patients in other trials. To satisfy the response criteria, the patients in these trials were required to
improve by at least 20% in 3 of 4 items rather than 3 of the 5 available to a patient in whom all
core set items had been measured. The trials affected were both of the MTX versus injectable gold
trials and the larger of the 2 MTX versus AZA trials. The effects may be seen in Figure 8.1, where
the response to injectable gold was consistently less than the response to cyclosporine or to MTX
for each disease duration category. Similarly, the AZA response in these data was relatively low,
being only slightly higher than that of patients with similar disease duration who were treated with
AUR.
The disease duration effect was strongest in patients with a shorter disease duration. When
the GOBRA trial, with its very short disease duration, was not included in the multivariate analysis
(using the 10-trial "all variable" data set), the disease duration effect, though still statistically
significant, was attenuated (OR j^ 0.74 per 15 years versus OR^j 0.63 in the "all trial" data set).
Also, there was no disease duration trend for the small number of Prosorba-treated participants, of
whom more than 80% (39 of 48) had substantial disease duration of 5 5 years.
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The most widely used treatments for RA are represented in our data, but we did not have trial
data on major new agents for RA, especially those targeting tumor necrosis factor a. It is not clear
whether response rates also diminish with longer disease duration when these agents are used.
We found an —30% difference between active and placebo treatment response that varied
little across the strata of disease duration, Steinbrocker functional class, disease activity, and sex.
An implication of this finding is that the distribution of patients in a trial with respect to levels of
these factors should have little effect on the statistical power of the trial. Nevertheless, the
interpretability of trial results in general would be enhanced by die explicit use of disease duration
strata in particular. Many trials have already planned to include or exclude patients on the basis of
disease duration, prior DMARD use, Steinbrocker functional class, or sex. When trials include
patients in multiple strata, the presentation of trial results by these strata would facilitate
comparisons of results across trials.
A problem with the interpretation of our finding of a reduced likelihood of response to
treatment with greater duration of disease would arise if die disease duration effect were an artifact
of die way response is measured. It could be that some components of die core set are less
responsive than odiers for patients widi greater disease duration, and thus arguably unsuited for
use as part of a response criterion in longer-standing disease. In particular, it might be expected
diat die presence of fixed residual swelling of joints would reduce responsiveness of die swollen
joint count, and diat physical function might also be intrinsically less responsive in patients with
longer-standing and more advanced disease. Our examination of the relationship between disease
duration and response for each separate ACR core set item showed a fairly uniform drop-off in
response with increasing disease duration. This suggests that there is a real decline in disease
responsiveness widi greater duration of disease, and diat die decrease is not an artifact of
measurement.
Patients widi longer disease duration who enter clinical trials are likely to have prior DMARD
exposure, and these DMARDs may not have worked well for diem, odierwise it is unlikely diat
diey would be participating in a clinical trial. Our data show independent effects of disease
duration, disease severity, and prior DMARD exposure widi respect to ACR response, which
suggests diat die patients who are least likely to respond are diose who have long-standing,
refractory disease.
In summary, we have found, from an analysis of patient-level data in a set of 14 clinical trials
in RA, diat patients witii longer disease duration do not respond as well to treatment in RA as do
tiiose widi earlier disease, and diat female sex, prior DMARD use, and worse functional class also,
simultaneously, reduce die likelihood of patient response. There is no evidence diat die ACR
improvement criteria are less valid in longer-standing disease, nor should die power of trials be
adversely affected by any particular distribution of patients across die various strata of factors
related to response. The implications for trial interpretation and for clinical expectations of
patients, however, are diat die response can be expected to vary according to which group a
patient is in widi respect to each of die variables of disease duration, sex, prior DMARD use, and
disease severity. In particular, diere is a window of opportunity for effective treatment of RA
during die early stages of die disease.
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Responsiveness of the Core Set, Response Criteria and
Utility Measures in Early Rheumatoid Arthritis
Abstract
Oby'ecf/Ve: Validation of responsiveness and discriminative power of the World Health
Organisation/ International League of Associations for Rheumatology (WHO/ILAR) core set, the
American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
criteria for improvement/response, and other single and combined measures (indices) in a trial
with early rheumatoid arthritis (RA).
MefAtods: Ranking of measures by response (standardised response means and effect sizes) and
between-group discrimination (unpaired f test and x* values) at two time points in the COBRA
study. This study included 155 patients with early RA randomly allocated to two treatment groups
with distinct levels of expected response: combined treatment, high response; sulphasalazine
treatment, moderate response.
Resu/fs: At week 16, standardised response means of core set measures ranged between 0.8 and
3.5 for combined treatment and between 0.4 and 1.2 for sulphasalazine treatment (95% confidence
interval ± 0.25). Performance of patient oriented measures (for example, pain, global assessment)
was best when the questions were focused on the disease. The most responsive single measure was
the patient's assessment of change in disease activity, at 3.5. Patient utility, a generic health status
measure was moderately (rating scale) to poorly (standard gamble) responsive. Response means of
most indices (combined measures) exceeded 2.0, the simple count of core set measures improved
by 20% was most responsive at 4.1. Discrimination performance yielded similar but not identical
results: best discrimination between treatment groups was achieved by the EULAR response and
ACR improvement criteria (at 20% and other percentage levels), die pooled index, and the disease
activity score (DAS), but also by the Health Assessment Questionnaire (HAQ) and grip strength.
Conc/us/ons: Responsiveness and discrimination between levels of response are not identical
concepts, and need separate study. The WHO/ILAR core set comprises responsive measures diat
discriminate well between different levels of response in early RA. However, the performance of
patient oriented measures is highly dependent on dieir format. The excellent performance of
indices such as the ACR improvement and EULAR response criteria confirms they are the preferred
primary endpoint in RA clinical trials.
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Introduction
Many end point measures are available to assess treatment efficacy in rheumatoid arthritis
(RA). The OMERACr consensus on end point measures in RA facilitates comparison of results
from different trials in treatment evaluation [1]. The OMERACT initiative has called for further
validation of the measures included in the World Health Organisation/International League of
Associations for Rheumatology (WHO/ILAR) core set (also known as American College of
Rheumatology (Ao<) core set [2]) and combined measures (indices) such as improvement and
response criteria [3,4]. To determine the applicability of a measure in a certain setting, the
QMERACr filter has been proposed, containing three elements: truth, discrimination, and feasibility
[5]. The first two elements capture classic validity concepts. The topic of this study is
discrimination. To be discriminative in trials, a measure has to detect clinically relevant change;
moreover, it has to detect clinically relevant differences in change between treatment groups.
Highly responsive measures are preferred because they allow clinical trials to be done with fewer
patients, and also because they facilitate detection of small - but potentially important -
differences in treatment effect [6]. For the clinician, applying responsive measures in patient care
will allow better tailoring of individual treatment. However, individual patient care may require
another selection of measures than those used in trials: for example, assessment of morning
stiffness and disease activity in the feet joints remain useful in the clinic despite their exclusion
from the core set [7].
As every measure is bound to pick up some noise together with the intended signal, its
responsiveness is determined by the ratio of treatment effect to its variability (signal-to-noise
ratio). Two classes of responsiveness statistics can be distinguished: the first is based on
measurement of change in the course of a therapeutic intervention with known efficacy (external
criterion, gold standard); the second is directed at the correlation of change in the tested measure
with change in a "criterion measure". However, as this last class of responsiveness statistics is
based on the variability between subjects, regardless of whether group changes occur, they yield
little information about the ability of a measure to detect treatment effects [8].
The purpose of this study was to validate further the responsiveness of the core set, of the
ACR improvement [3] and European League Against Rheumatism (EULAR) response criteria [4],
and of other single measures and indices with data from a recent trial. The COBRA study [9]
(Dutch acronym: COmbinatietherapie Bij ReumatoYde Artritis) was a randomised controlled trial
in patients with early RA that showed excellent clinical response, low toxicity, and less progression
of radiographic joint damage with treatment of combined step-down prednisolone, methotrexate
and sulphasalazine, compared with treatment with sulphasalazine alone. The trial allowed us to
create one "gold" and one "silver" standard for relevant response against which to validate
performance of end point measures: we proposed the hypothesis a priori that patients in the
combination group would on average show large and, certainly, relevant improvements at week 16
owing to the corticosteroid pulse (gold standard). Also, we assumed on the basis of the well
known effects of sulphasalazine on disease activity that patients in the sulphasalazine-only group
would also show relevant improvements, but to a lesser degree (silver standard).
135
comö/nat/on f/ieraov //? r/ieumato/d arthrrt/s: chapter 9
We then ranked the end point measures and indices used in the COBRA study by their relative
responsiveness, and also by their ability to discriminate between the (changes in the) treatment
groups. Ultimately, this discriminatory ranking yields the most relevant results. However, one must
realise that this ranking is post-hoc: as the difference in response between the groups was the
primary study question of the trial, the presence and extent of such a difference was unknown
before the start of the trial.
Patients and methods
The COSR/* sfudy
The COBRA study [9] was a 56 week clinical trial that randomly assigned 155 patients with RA
(ACR criteria [10]), aged 23-70, to one of two treatments. All patients had early, active disease
(diagnosis < 2 years). No prior treatment with disease-modifying anti-rheumatic drugs, apart from
anti-malarials, was allowed. One group was treated with a combination of sulphasalazine,
methotrexate, and, initially, high dose oral prednisolone, the other group with sulphasalazine and
double placebo. The prednisolone dose was 60 mg daily in the first week, tapered in weekly steps
to the maintenance dose of 7.5 mg in week 7. Prednisolone and methotrexate (or the placebos)
were tapered and stopped after weeks 28 and 40, respectively, while sulphasalazine was continued.
Core sef measures
A broad variety of endpoints was assessed, including all disease activity measures of the
Who/lLAR core set [1]. This comprises tender and swollen joint count (68 and 48 joints,
respectively [11]), pain, assessor's and patient's global assessment (on 10 cm visual analogue scales
[VAS]), acute phase reactant (that is, erythrocyte sedimentation rate, Westergren method [ESR] or
C reactive protein [CRP]), and physical function (by Health Assessment Questionnaire; Dutch
HAQ [12,13]).
A/on-core sef measures
Non-core set measures included other joint counts and score such as the Ritchie index, grip
strength (by vigorimetry, Martin, Tottiingen, Germany, mean of medians of three measurements in
both hands [14]), Arthritis Impact Measurement Scale (AIMS) [15] - a modified and validated
Dutch version with scales for mobility, pain, and self-efficacy, and the McMaster Toronto Arthritis
patient preference questionnaire (MACTAR) [16]. The MACTAR is an instrument that follows
improvement in five impaired activities, elicited and ranked in priority by the patient at baseline,
together with changes in quality of life, psychological, social, and emotional wellbeing. Its scores
increase as functional ability improves and vary from 11 (maximum deterioration) to 47 (maximum
improvement). In its original format the baseline scores differ from the follow-up scores because
items inquiring about change are not included. To make these scores directly comparable mock
change items were added at baseline and scored as "unchanged". To compare the responsiveness
and discriminatory power of different formats of patient global assessment (see Appendix), two
items from the MACTAR interview (change in disease activity by seven point Likert scale, and
physical function by two questions with a six point scale), and a question on the actual state of
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disease activity ffrom a monitoring questionnaire; five point likeit scale} w?e evaluated together
•with the paaetH's global assessment of health indicated en a 10 cm VAS.
Whereas these disease-specific measures are sensitive to dinfcal change in RÄ, other - generic
- measures yield a broader picture of patients* health status and allow eomp»rss©Q across a range
of conditions [17]. LWity sensed as the central concept of generic measures in the Ö3BM
[18]- IHity is a single value or preference that patients assign to a particular heakh state.
is expressed on a scale ranging from 1 (perfect heakh} to 0 (death) ami lakes into account both the
positive treatment effects and negative side-effects. The rating scale and standard gamble methods
assessed utility, the rating scale method derives utilities directly by asking the patients to place
health states on a thermometer scale (dial is, vertical VAS),, the standard gamhk method derives
utilities from the patients* responses to decision situations under risk [19*20}. l&ilky scores -sere
assessed at baseline, and weeks 28 and 56.
Various indices (that is, composites from several measures) were assessed in the COBRA study
(Table 9.1), In fact, a pooled index of five measures (composite measure to reflect each patient's
standardized improvement) - was the assigned primary outcome. Pooling is a validated method to
increase responsiveness of separate measures [21]. To obtain a patient's pooled index score, the
standardised change score was calculated by dividing change in one measure by its pooled standard
deviation of change per treatment group at week 28. This procedure was repeated for five
measures; the pooled index is the mean of standardised scores. Finally, a constant •was added so
that all index values started with a zero value at baseline. To obtain pooled index values for other
time points than week 28, change scores at that point were divided by die same factor (the SD of
change of die measure at week 28). The trial was designed before die conception of the
WHO/ILAR core set [1]. Recommendations at that time were to select five measures for maximum
sensitivity to change [22]: tender joint count, global assessment by an independent assessor,, grip
strength, and MACTAR. The original Disease Activity Score (DAS) [23] was also calculated. This
index contains the Ritchie tender joint index, swollen joint count,, and patient's global assessment
on a 10 cm VAS (calculation: 0.54- A^Ritchie] + 0.065-[swollen joint count] + 0.33-ln[ESR] +
0.072-[patient's global].
Rem/ss/on, /mprovemer/f and response
Improvement in individual patients was also assessed in several ways: the ACR[24] and DAS
remission criteria [25], ACR improvement [3] and EULAR response [4] criteria, and count of
improved core set measures [26] (Table 9.1). Because fatigue was not measured in die trial
"probable remission" described instances in which a patient would be in remission when absence
of fatigue was assumed. Modified ACR improvement criteria and counts of improved core
measures were also calculated with improvement thresholds varying from 0 to 70% (Table 9.1). To
calculate percentage improvement, values were recoded where necessary to ensure that all scales
decreased on improvement.
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Fo//ow-up
Initially, grip strength, and patient's assessment of disease activity (five point Likert scale)
were registered weekly by research nurses, later at least every four weeks. All other reported
assessments - with exception of utilities - were made at baseline and at weeks 16, 28, (40, and 56)
by trained independent assessors who contacted the patients only at these times. This way, the
assessors were unaware of effects of high-dose prednisolone during the first six weeks of the
protocol. Utility scores were assessed biannually, thus for these measures only 28 week follow-up
measures are reported.
Sfaf/sf/ca/ ana/ys/s
All analyses were based on intention to treat: only five patients (3%, all in the sulphasakzine
group) were lost to follow-up before week 56 of the trial. The primary statistic of responsiveness
was the standardised response mean (SRM): mean observed change from baseline divided by the
standard deviation of this change [27]. The effect size (ES) [28]: the mean change from baseline
divided by the standard deviation (SD) of baseline scores was also calculated. Confidence intervals
of SRMs were calculated with the assumption that its distribution is approximately Gaussian with
mean zero and SD of one over the square root of the sample size [29]. From the confidence
intervals, statistical difference between SRMs could be evaluated. With no correction made for
multiple comparison these findings are solely informative. Most evaluated variables are on an
ordinal radier than interval or ratio scale level. However, as the underlying phenomenon (disease
activity) is on an interval scale, these measures can be analysed parametrically, if the sample size is
large enough, as in die COBRA study database (central limit dieorem).
Ceiling and floor effects may impair responsiveness when baseline values are found on die
upper and lower end of the scale. We arbitrarily defined these extremes at die upper and lower
one-sixdi of the scale (comparable to baseline HAQ scores < 0.5 or > 2.5) and analysed the
variables in die core set.
As stated in die introduction, statistics based on change from dierapeudc interventions need a
priori confidence diat die treatment is effective - diat is, diat die mean improvement in die treated
group is relevant. The a priori criterion was a large change from baseline in die combined-
treatment group at 16 weeks ("gold standard"); less change from baseline was expected in the
group treated with sulphasakzine ("silver standard"). This proved to be true, diough the change
reached at 28 weeks was slighdy larger, especially in die sulphasalazine-only group. Thus, die
combined-treatment group SRM at week 16 was the primary statistic of responsiveness to form a
league table for responsiveness. The SRMs in die sulphasakzine group can be used to assess die
ability of a measure to detect smaller - but still meaningful - changes, or changes occurring in a
smaller proportion of the treatment group.
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To indicate the discriminative powsr between groups the unpaired Student's ? test values aie
repotted. X" values reflect between-group contrast (that is, discriminative power) in the nominal
variabks: improvement and remission criteria. Because the primary study question of die GüBRA
trial concerned contrast between treatment groups, this contrast could not be an a priori criterion
such as improvement in the combined-treatment group as outlined above [30]. Consequently, the
ranking based on discrimination must be interpreted •with caution. Ttie 28 week data are included
to allow further exploration of trends in responsiveness and discriminatory power.
Table 9.1: Definition of indices.
Index [reference] Calculation
Pooled index (measures A, B, C . ) [21]
Disease Activity Score (DAS) [23]
ACR remission [24]
COBRA, "probable" ACR remission [9]
DAS remission [25]
ACR improvement (20%) [3]
Modified ACR improvement (# %)*
No of core measures improved (# %)* [26]
EULAR response [4]
mean of [change in measure A / S D ^ ^ g g A.;
change in measure B / SDcnangg B>
change in measure C / SL\hange C > ^ - 3
0.54 V [Ritchie index] + 0,065 [swollen joint count]
+ 0.33 ln[ESR] + 0.072 [patient global],
5 out of 6, for _>2 months:
morning stiffness _< 15 min, no joint pain,
no joint pain on exam, no joint swelling»
ESR <30 mm (men, <20 mm/h), and no fatigue
4 out of 5, absence of fatigue assumed (not assessed)
DAS < 1.6
improvement by at least 20% in tender joint count
rfraf swollen joint count p/«s in at least 3 out of
the remaining 5 core set measures: acute phase
reactant, physical function, physician's global
assessment, patient's global - , and pain
Improvement by at least 20% in tender joint count
d«i^ swollen joint count p/«s in at least 3 out of
the remaining 5 core set measures
count of core set measures improved by at least # %
)gooäf': improvement in DAS > 1.2
dwi final DAS < 2.4
VnaiCTtfte': not meeting criteria for "good",
fort improvement in DAS >0.6
*W final DAS <3.7
'wow': remaining
> # % - thresholds varying from 0 to 70%.
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Results
The combined-treatment group included 76 and the sulphasalazine group 79 patients. The
groups were balanced in important demographic and prognostic variables [9,18]. At week 16 the
mean improvement in terms of die pooled index was 1.4 for the combined-treatment group and
0.7 for the sulphasalazine group (/> < 0.0001). At week 28 these values were 1.5 u 0.8 (/> <
0.0001). In die combined-treatment group rates and rapidity of ACR 20, 50, and 70 improvement
were similar to diose reported in recent trials on anti-tumour necrosis factor (antiTNF) treatment
(see below).
At week 16, most measures indicated large improvement from baseline in bodi groups (SRM
0.4-4.1, ES: 0.3-3.2), and all measures except patient's global assessment of health (VAS)
significantly distinguished combined treatment from sulphasalazine (Table 9.2, Figure 9.1).
Statistics of responsiveness were larger in the combined-treatment group than in the
sulphasalazine group, confirming a priori assumptions of greater improvement in diis group. The
relative responsiveness ranking of measures was similar in both groups, suggesting the ranking is
stable over a broad range of relevant response. However, in t i e sulphasalazine-only group die
absolute differences in responsiveness between measures were less, in proportion to die overall
decreased response. All indices (diat is, pooled index, MACTAR, DAS and count of improved core
set measures) were - in bodi treatment groups - considerably more responsive dian single core set
measures such as tender joint count. The only exception to diis was die highly responsive single
item patient's assessment of change in disease activity on a seven point Likert scale. The
responsiveness of most single measures was satisfactory but not equal (for example, high
responsiveness for pain and ESR, lower for tender joint count and Qtf>). A confidence interval
smaller dian 0.5 around die SRM estimates indicates diat a difference between SRMs of 0.35 or
greater would be significant when tested at die two sided 0.05 level. The results at week 28 were
generally similar (Table 9.3, Figure 9.1).
The format of patient assessment of disease activity, physical impairment, and global
wellbeing strongly influenced responsiveness (for a description of die formats see Appendix). The
item in die MACTAR interview diat asked for change of disease activity (seven point Likert scale)
proved to be most responsive, patient's global assessment of health indicated on a VAS, least
responsive. MACTAR, HAQ, some AIMS subscales and single item patient global assessment of
physical function were not equally responsive. The utility rating scale showed responsiveness close
to die patient global assessment of disease activity, whereas utility measured by standard gamble
was die least responsive of all measures.
Analyses on floor and ceiling effects showed diat, of die core set variables, ESR and tender
and swollen joint count were vulnerable to a certain degree of floor effect, widi respectively 17,15,
and 15% of die patients in die lowest one sixdi segment of die scale. Global and pain assessments,
and also die HAQ had fewer patients diat scored at die extremes of die scale.
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Table 9.2: Indices of responsiveness at week 16 of follow-up, for each treatment group, ordered
by standardised response mean (SRM) of the combination group
Count core set measures
_>20% improved
Change in disease activity
by patient, 7 point Likert
Pooled index
composite measure
MACTAR
interview
Count core set measures
_> 50% improved
Disease Activity Score (DAS)
composite measure
AIMS
pain scale
Health Assessment
Questionnaire
Pain assessment
by patient, VAS
Disease activity
by patient, 5 point Likert
ESR
(mm/lh)
Swollen joint count
AT? A 4 R
AI\/\ TO
Grip strength
(kPaj
Count core set measures
_>70% improved
Global assessment
by observer, VAS
Physical function
by patient, 6-point Likert
Tender joint count
AT} A £ Q
ARA Do
Ritchie Arthritis Index
tender joints
CRP
(mg/L)
AIMS
mobility scale
Global assessment
by patient, VAS
AIMS
self-efficacy scale
combined
mean
change
5.9
2.6
1.4
12
4.6
-2.1
-8.4
-1.1
-3.3
-1.7
-41
-9
22
3.0
-30
1.8
-14
-10
-33
5.3
-2.2
5.1
( » -
SE,
0.2
0.1
0.1
0.6
0.2
0.1
0.5
0.1
0.3
0.1
3
1
2
0.3
3
0.2
1
1
4
0.7
0.3
0.8
treatment
75)
SRM
4.1
3.5
2.4
2.2
2.2
1.9
1.8
1.5
1.5
1.5
1.4
1.4
1.3
1.3
1.3
1.3
1.2
1.2
0.9
0.9
0.8
0.8
ES
-
-
3.2
_
1.9
2.3
1.5
1.6
1.6
1.2
1.0
1.5
_
1.3
1.7
1.0
1.0
0.8
1.0
1.1
0.9
sulphas alazine
mean
change
4.1
1.7
0.7
8.5
2.4
-1.2
-5.7
-0.4
-1.8
-1.1
-23
-5
8
1.4
-14
1.3
-6
-7
-18
2.1
-1.7
2.4
(« = 7
SE.
0.2
0.2
0.1
0.8
0.3
0.1
0.5
0.1
0.3
0.1
3
1
1
0.2
3
0.2
1
1
5
0.5
0.3
0.6
9)
SRM
2.2
1.2
1.1
1.3
1.0
1.0
1.2
0.8
0.7
0.9
0.9
0.7
0.6
0.7
0.6
0.9
0.5
0.8
0.5
0.5
0.6
0.4
ES
-
_
2.1
_
1.2
1.6
0.6
0.8
1.1
0.7
0.6
0.4
_
0.7
1.2
0.4
0.6
0.5
0.3
0.9
0.4
t
value
5.7
5.3
6.5
3.7
6.0
4.9
3.6
6.2
4.0
2.7
4.1
4.2
5.8
4.8
4.3
2.2
4.1
2.5
2.2
3.9
1.1
2.7
SEA = standard error of change; SRM = standardized response mean; ES - effect size; r value
unpaired (i.e., between group). SRM 95% confidence intervals have a width of <0.5 around die listed
value, between-SRMs differences _>0.35 are significant (two sided P <0.05, no correction for
multiple comparison)
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T a b l e 9.3: Indices of responsiveness at week 28 of follow-up, for each treatment group*
Count core set measures
_>20% improved
Change in Disease activity
by patient, 7-point Likert
Pooled Index
composite measure
MACTAR
interview
Count core set measures
_>50% improved
Disease activity score (DAS)
composite measure
AIMS
pain scale
Health Assessment
questionnaire
Pain assessment
by patient, VAS
Disease activity
by patient, 5-point Likert
ESR
(mm/lh)
Swollen joint count
AD A 4 Q
Al\A tfl
Grip Strength
Count core set measures_>70% improved
Global assessment
by observer, VAS
Physical function
by patient, 6-point Likert
Utility
rating scale technique
Tender joint count
AD A /1OAlxA OO
Ritchie Arthritis Index
tender joints
CRP
(mg/L)
AIMS
mobility scale
Global assessment
by patient, VAS
AIMS
self-efficacy scale
Utility*
standard gamble technique
combined treatment
mean
change
5.8
2.5
1.5
12
4.8
-2.3
-8.5
-1.1
-3.4
-1.8
-40
-10
25
3.6
-3.3
2.0
0.24
-16
-11
-32
5.3
-2.4
5.2
0.10
(«-75)
SE. !
0.2
0.1
0.1
0.6
0.3
0.1
0.5
0.1
0.3
0.2
3
1
2
0.3
0.3
0.2
0.02
2
1
5
0.6
0.3
0.7
0.02
SRM
3.6
2.8
2.4
2.3
2.2
1.8
1.8
1.4
1.4
1.4
1.4
1.3
1.5
1.5
1.3
1.3
1.3
1.1
1.2
0.9
1.0
1.0
0.8
0.7
ES
_
-
-
3.3
_
2.2
2.4
1.5
1.7
1.7
1.2
1.1
1.6
_
1.4
1.7
1.3
1.2
1.1
0.8
1.0
1.2
0.9
0.7
sulphasalazine
mean
change
4.5
1.6
0.8
8.6
3.0
-1.4
-5.8
-0.6
-2.0
-1.2
-27
-5
11
1.9
-1.7
1.4
0.15
-8
-7
-22
3.2
-1.9
2.9
0.06
(«-79)
SE.
0.3
0.2
0.1
0.8
0.3
0.1
0.6
0.1
0.3
0.1
3
1
2
0.2
0.3
0.2
0.02
2
1
4
0.6
0.3
0.7
0.02
SRM
1.9
1.1
1.1
1.2
1.2
1.0
1.2
0.9
0.7
1.0
1.0
0.7
0.7
0.9
0.7
0.7
0.8
0.5
0.8
0.7
0.6
0.7
0.4
0.3
ES
_
-
-
2.2
_
1.4
1.4
0.8
0.9
1.2
0.8
0.7
0.5
_
0.8
1.2
0.8
0.5
0.7
0.7
0.5
1.0
0.4
0.3
£
value
3.9
4.6
5.7
3.8
4.7
4.4
3.5
4.5
3.2
2.8
3.1
3.4
5.6
4.4
3.9
2.5
2.7
3.7
2.4
1.5
2.6
1.1
2.3
1.4
* Abbreviations, see Table 9.2. SRM 95% confidence intervals have a width of <0.5 around the listed
value, between-SRMs differences _>0.35 are significant (two sided P <0.05, no correction for multiple
comparison), t Utilities were only assessed at week 28.
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The ranking for between-group discrimination showed interesting trends. This is best seen in
Figure 9.1: highest rvalues (that is, most discriminative power) were found for pooled index, count
of core set set measures improved by 50%, DAS, HAQ but, also, grip strength. Between the two
assessments a catch-up effect is seen in the sulphasakzine group: whereas improvements in die
combination group were already maximum at week 16, the sulphasakzine group improved further
between week 16 and week 28, resulting in a smaller between-group difference (and thus a smaller
rvalue).
At 16 weeks, ACR 20% improvement and EULAR response criteria showed large x* values,
consistent with significant differences in response between treatment groups (Table 9.4). The
discriminatory performance of these criteria ranks high among all the measures tested (Figure 9.4):
based on P values a x^ value of 8 roughly corresponds with a t value of 3; similarly, a x* value of 12
corresponds with a f value of 4, and a x* value of 25 with a f value of 5. At week 28, the
differences between the groups were smaller. At week 16, modification of the percentage value in
the ACR improvement criterion between 0% (no improvement, no worsening) and 50% did not
change its discriminatory capacity, at week 28, this was also true for the 70% cut off point (Table
9.4). The ACR and DAS remission criteria did not show a significant between-group difference.
Table 9.4: Discriminative ability of the preliminary ACR improvement criteria at different
thresholds, EULAR response criterion, ACR and DAS remission criteria to distinguish between
two treatment groups at two moments of follow-up
Criterion
ACR improvement
0% threshold
10% threshold
20% threshold
30% threshold
40% threshold
50% threshold
60% threshold
70% threshold
EULAR response;
good + moderate
good
ACR remission
'probable'
DAS remission
(DAS <1.6)
*; combined-treatment
week
improved *
88 xs 63%
78 is 44%
72 is 32%
64 is 24%
58 xs 16%
43 is 14%
26 is 8%
16 is 6%
86 ts 56%
37 xs 15%
12 xs 6%
12 ts 9%
16
x'
12.9
18.0
25.7
25.7
28.6
16.6
9.7
3.6
20.2
1.4
0.4
.0003
<.0001
<.0001
<.0001
<.0001
<.0001
.002
.06
<.0001
.23
.54
week 28
improved *
82 is 62%
74 ts 49%
72 xs 49%
67 is 39%
55 xs 30%
49 xs 27%
37 ts 22%
29 xs 10%
86 ts 63%
47 xs 24%
21 is 11%
17 xs 10%
(w - 76) ts sulphasakzine treatment (n - 79) group.
x'
7.3
9.7
8.6
12.1
9.8
8.1
4.4
8.8
13.4
2.7
1.6
.007
.002
.003
.0005
.002
.004
.04
.003
.001
.10
.20
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Figure 9.1: Comparison of responsiveness and discrimination performance of end points.
The order of the measures evaluated corresponds with that of Table 9.3. Dark bars: standardised response means of the combined-treatment group
at weeks 16 (black) and 28 (dark grey). Light bars: SRMs of the sulphasalazine group at 16 (light grey) and 28 (white) weeks. Dots: unpaired f values
of the between-group comparison at 16 (black) and 28 weeks (white). pL = points Iikert scale; MACTAR = McMaster Toronto Arthritis patient
preference questionnaire; DAS = disease activity score; ATMS = arthritis impact measurement scale; HAQ = health assessment questionnaire;
VAS - visual analogue scale; ESR — erythrocyte sedimentation rate; CRP = C reactive proteine; RS — rating scale; SG - standard gamble.
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Discussion
Ulis study is the first independent confirmation of the responsiveness of the WHO/ILAR. core
set measures and response criteria in a trial of eaiiy RA patients. In addition, it lends strong
support to the use of other indices in such a trial. The conclusions are strong because they are
based on the findings in two groups of patients with a high and moderate level of expected
response. They extend the validity of both the core set and die ACR response criteria, became
diese had initially been selected, designed, and tested mainly in the setting of placebo controlled
studies.
The fact that indices are more responsive than most single measures is not surprising, as
combining measures (or items in a questionnaire) reduces scatter. Even a simple count of
improved core set outcome variables proved to be a very responsive index, especially at the 20%
threshold. Direcdy asking for change can also reduce scatter, even though the answer may be
biased towards the current condition. Evidenced for this is shown by die high responsiveness of
the patient change question and the MACTAR (diat incorporates many change items). The
responsiveness of functional scales may be partly explained by die fact diat they generally
comprise several items in a multi-item questionnaire. Nevertheless, a set of two physical function
questions on a six point Likert scale was also responsive.
The strong influence of format and content of the patient's global assessment questions on
responsiveness is worrying. Similarly, die responsiveness of pain as a measure depends on the
format. It is likely diat die focus of doctors (or odier assessors) is on die patients' disease, but diis
seems not always be die case for die patients diemselves. Aldiough not specified in great detail in
die original formulation of the WHO/lLAR core set, we advocate focusing the format of patient
oriented instruments on die disease, and paying close attention to the exact wording of the
question(s).
Utility scores are advocated as a generic measure of dierapy benefits. The two mediods to
derive utilities proved to have quite different levels of responsiveness. The rating scale (which is a
patient preference radier dian a true utility) performed adequately (comparable to observer's global
assessment on VAS). However, die standard gamble mediod (a true utility because choices are
made in a situation of uncertainty) showed low responsiveness. Economists prefer standard
gamble because it conforms better to dieoretical principles, but in practice its application was
hindered by limited comprehension of die mediod by our patients and dieir risk aversive attitude.
This phenomenon has been seen before in patient groups widi a non-fatal or chronic disease
[31,32].
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The data on between-group discrimination must be interpreted with caution. The extent of
differences between the groups was not known before the trial, and may have been large in
comparison with expected differences in current and future head-to-head trials. Nevertheless, the
results are unique and extremely interesting as they indicate that responsiveness, the ability to
detect change, may not parallel die capacity to discriminate between different levels of response.
Both the ACR improvement criteria (at various percentage levels) and the EULAR response
criterion showed excellent discriminatory capacity. This is at odds with the other trials in the
review of Felson ef a/ [32], who concluded that 20% remained the best cut off point for the ACK
criteria. A possible explanation is the relatively large contrast between treatment groups in the
COBRA study [34]. Odier indices were also better discriminators than most single measures, with
the exception of grip strength. In contrast, the discriminatory capacity of the MACTAR, though
good, was less than expected based on its excellent responsiveness. This difference in performance
between the HAQ and the MACTAR is hard to explain, and will need replication in other studies.
Grip strength was included in the design of the trial based on the work of Anderson et a/ [22].
Despite its good performance in trials up to 1989, it was eventually excluded in the core set for
reasons of redundancy. Nevertheless, in early RA the fact that it is a composite measure of hand
function with pain, swelling, stiffness, and muscle strength may contribute to its excellent
performance. Muscle strength, particularly, may be a physical function variable with potency in
early and established RA [35].
From published reports we know that different responsiveness statistics - also those that are
solely based on change from therapeutic intervention - may [36] or may not [37] yield different
rank orders. In general, rankings based on paired Student's f test values and SRM will only be
discrepant when different sample sizes are used for different measures. SRM is least influenced by
sample size as it avoids the use of standard error of the mean in the denominator. Sample size was
not an issue in this report as few values were missing. ES and SRM generally yield similar ranks,
though discrepancies occur when the within-group SD at baseline (the denominator in the ES
calculation) differs much from the SD of within-group change (the denominator in the SRM
calculation). Obviously, ES cannot be calculated for measures that directly evaluate change,
because their do not have a baseline variance. It may be a typical feature of these transitional
measures - and indices that include change questions, such as the MACTAR - to pair a large SRM
with a relatively small unpaired £ value.
Despite their strong evidence, the data represent only one study in one subgroup - that is,
early RA. The generalisability of our findings may be slightly limited, as the effects of treatment in
the combined-treatment arm were large compared with many other trials in RA, but similar to
those seen in recent anti-TNF trials. A meta-analysis of effectiveness of low-dose corticosteroids
in RA reported somewhat smaller ES in measurements of grip strength, swollen and joint tender
count, and (0.4-1.0) than we did; in particular, the ES values found in the corticosteroid treatment
arms were smaller [38]. However, the effect in the sulphasalazine group resembles that found in
trials of methotrexate and intramuscular gold [39-42]. Thus for studies of such moderately
effective drugs, the ranking of the sulphasalazine group might be more appropriate.
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Analyses on floor and ceiling effects showed that ESR and tender and swollen joint count
•were vulnerable to a certain degree of floor effect. The study's inclusion criteria towards disease
duration and disease activity, with evaluation based on ESR and joint counts, probably prevented a
serious floor effect in the study group. With global and pain assessments on a visual analogue
scale, people tend to put their mark somewhere at the middle of the scale.
Buchbinder et a/ [43] studied the ability of end points to discriminate between treatment
effects in a placebo controlled trial of cyclosporin in RA. As the difference between cyclosporin
and placebo was the primary study question of that trial, their approach is similar to the post hoc
discrimination tests between treatment groups in this report. Compared with the COBRA study,
differences between treatment groups were smaller for and swollen joint counts but similar in
other measures. They found physician's and patient's global measures (measured as a change
question), as well as the AIMS pain subscale to be most discriminatory, and and pain (five point
scale) to be least discriminatory, with all other core set measures, including another physician's
global question, the HAQ and a modification of the MACTAR (that is, PET), falling in between.
These results agree with our observation on the importance of the exact format of the questions.
The discrepancy found in the is expected: lack of responsiveness of is well known during
treatment with cyclosporin. More surprising is the relatively poor performance of the physical
function questionnaires. It may be that the cyclosporin trial included patients with longstanding
disease and more fixed disability that was less likely to respond to treatment. Patients in the
COBRA study had a median disease duration of only 4 months.
Differences in responsiveness, and especially discrimination, have important implications for
trial design. The use of responsive and discriminative measures allows reduced patient numbers or
detection of smaller - yet relevant - differences between groups. This is important especially in
trials of early RA. Simpler trial design through use of a limited number of measures saves costs and
effort, and facilitates interpretation of the results. In routine patient care, use of a limited number
of highly responsive measures facilitates the collection and interpretation of long-term follow-up
data. Obviously, additional measures should be applied according to the characteristics of the
individual patient.
In summary, this study convincingly shows that responsiveness and the ability to discriminate
between different levels of response are not identical concepts. The data provide strong evidence
for the responsiveness and discriminatory capacity of the WHO/lLAR core set as well as the ACR
and EULAR response criteria in the study of moderately and strongly effective drugs in early RA.
However, where information is elicited from the patient, researchers should select and focus their
instruments on the disease, as performance is strongly dependent on the exact format of
questions.
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Appendix
Formats of items with patient assessment:
Assessment of change in disease activity (7 point Likert scale)
Q. When you /b/n/c of your arthriZ/s during /he fwo wee/cs before /be f7rs/ /n/erWew,
how much better or worse overa// has your ar/hriZ/s become ? • 7 a greaZ dea/ better
• e modera/e/y better
• 5 s//gb//y better
Q 4 no change
• 3 s//ghZ/y worse
Q 2 moderaZe/y worse
• 1 a greaZ dea/ worse
Assessment of disease activity (5 point Likert scale)
Q. When you Zh/n/c of your arZbriZ/s,
bow wou/d you say your cond/Z/on bas been over Zbe pasZ wee/c ? Q 5 good
Q4 reasonab/y good
Q3 moderaZe
Q2 poor
• , very poor
Assessment of physical function (two questions, 6 point Likert scale)
Qa. How wou/d you say your overa// pbys/ca/ funcfon/ng bas been ?
Over fbe /as/ week you fb/n/c of /f as ...
Qb. /s your pbys/ca/ ft/ncfen no/ as good as # m/gbf be
because of your artbnY/s ? Q 0
• 5
• 4
• 3
Ü2
•1
yes
good
good Zo fa/r
fa/r
fa/r to poor
poor
no
Global assessment (10 cm visual analogue scale)
Q. How bas your genera/ nea/Zn been during /be pas/ wee/c ?
I-
worst
imaginable
Pain assessment (10 cm visual analogue scale)
Q. How mucb pa/n d/d you bave during /be pas/ wee/c ?
I
best
imaginable
no pain
at all
worst pain
imaginable
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American College of Rheumatology Criteria For Improvement In
Rheumatoid Arthritis Should Only Be Calculated From Scores
That Decrease On Improvement
Abstract
Ob/ecf/Ve: Change in a patient's condition is expressed as a percentage of the baseline value for a
core set of measures in the American College of Rheumatology (ACR) improvement criteria for
rheumatoid arthritis (RA), and this is used as the basis to decide whether a patient has improved.
The result is dependent on whether the underlying measure has a score that increases or decreases
on improvement. We examined the importance of this effect in the application of the ACR
improvement criteria.
MeMocte: Data were obtained from the COBRA trial, in which 155 patients with early active RA
had been randomised to receive either combination treatment with step-down prednisolone,
methotrexate, and sulphasalazine or sulphasalazine alone. Patient and physician global assessments
were recoded to reflect decreasing scores on improvement. The effects of this difference in
scoring systems were compared among 3 response criteria levels (20%, 50%, and 70%) that are
currently being used to assess improvement in RA clinical trials.
Resu/fS: Analyses showed that the effects of a decreasing, versus increasing, score on the
designation of improvement cannot be ignored, especially at higher percentages of improvement
(eg., 50%, 70%).
Conc/us/on: We recommend that percentage improvement in RA be calculated only on scores
that decrease on improvement. When necessary, raw data should be recoded before the ACR
improvement criteria are applied.
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introduction ^ ^ „^
Selection and assessraetK of outcomes in rheumatology remain of parrieakr interest to
clinicians. T k OMERACT ("Outcome Measures in Rheumatology*} initiative pswisteä 4 fof«ia
for mtemaüGuai consensus on a core set of end points to be used in rheumatoid arthritis fRA)
clinical triab [1], Subsequently; improvement criteria wet* iermukted by the American College for
Rheumatology (ACK) and the European League Against RheuöEÄÄtn (EULAR) [23]. *HK current
ACR improvement criteria for RA are designed to reflect a level of 20% improvement from
baseline in the core set measures, and this is used as the basis to decide whether ä pätfeis has
improved. We present a hitherto unrecognized set of problems in the interpretation of the criteria,,
a problem we feel becomes more pertinent now that the original percentage (30%) is frequently
replaced by higher percentages of impaivement, such as 50 and 70.
Two distinct problems can arise in the application and interpretation of the ACJR criteria,
which comprise, in effect, an index composed of ratio measures. 1} When die denominator (the
baseline score) in one or more of the component measures is small, the percentage change
exaggerates die absolute change. The impact of die exaggeration is dependent on wheiher the
score decreases or increases on improvement. 2) Widi measures diat increase on improvement, the
end of the scale limits die possibilities to improve by a certain percentage.
Furthermore, the combination of several ratios into one index compounds lbs pföbfctis for
example, in one patient, some scores may be (much) lower initially than others, leading to
differential weighting of die components. Also, the index can combine measures that decrease on
improvement with diose that increase on improvement.
In most core set measures (joint counts, pain assessments, and acute-phase reactant levels),
scores decrease when die patient improves. However, in diree of die core set measures (patient
and physician global assessment and functional index), die direction of improvement depends on
choices made by die investigator. For example, in a global assessment, die direction of die score is
determined by die anchors used on die scale. Several interesting measures diat are currendy not
include in die core set (e.g., the Medical Outcomes Study 36-item short form heakh survey, and
utility measures) have scores diat increase on improvement. Furthermore, a non-core measure
such as grip strengdi not only increases on improvement, but also has no set maximum.
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Methods
We analysed the importance of these considerations in the dataset of the COBRA trial [4]. In
diis trial, 155 patients with early active RA had been randomised to receive either combination
treatment with step-down prednisolone, methotrexate, and sulphasalazine (COBRA) or
siJpha.sala7.ine alone. Both the patient and physician global assessments were initially scored on a
0-10 point scale that increased on improvement. In the final (published) analysis, these
assessments were recoded to decrease in score on improvement. We compared the effects of using
an increasing versus a decreasing score for improvement in core set measures, according to the
levels of improvement currently being used in RA cliniacal trials: 20%, 50%, and 70%.
Results
The relationship between the initial score and end score (Figures 10.1A and 10.1B) and
between the initial score and die change in the initial score (Figures 10.1C and 10. ID) for a
measure diat increases on improvement (Figures 10.1A and 10.1C) and a measure diat decreases
on improvement (Figures 10.1B and 10.1D) was compared among die three different
improvement criteria levels. In die case of a score that increases on improvement, patients deemed
severe (starting widi low scores) could easily improve by more than 100%, but patients considered
to be mild or moderately severe on initial scores were limited in dieir percentage improvement by
die end of die scale. Thus, a patient reaching die optimum score (in diis case, 10) may not be
classified as improved.
In contrast, in measures diat decrease on improvement (Figures 10.1 B and D), die relation
between the initial score and end score (or die change) remains interpretable at every percentage.
The disadvantage of exaggeration at low initial scores (in this case, in patients with mild disease) is
still a factor, however, a patient can never improve by more dian 100%. At 100% improvement,
the score is always at its optimum (zero). Thus, a patient widi an initial score of 1 can reach 20%
improvement dirough a decrease of 0.2 points, a change diat is probably not clinically relevant;
100% improvement is reached when die final score is zero.
Table 10.1 shows die total number of occurrences of improvement according to die
physician's global assessment (summed over die four assessment times; dius, each patient could
contribute a maximum of four occurrences of improvement), according to treatment group and
percentage improvement among die patients in the COBRA trial. We included in our analysis die
occurences of improvement diat were eidier added or removed, as welll as die net change, after
recoding die global assessements to reflect decreasing scores widi increasing improvement, which
gave us die final count for comparison. A substantial number of occurrences of improvement was
affected by die recoding. Because some of die effects cancelled out, our results show diat recoding
has a moderate-to-small positive net effect on die number of occurrences of impovement on die
basis of die 20% and 50% improvement criteria, and a more prominent negative effect on die
number of occurences meeting an improvement level of 70%. Moreover, the effects were not
completely equal across treatment groups. Recoding the patient global assessments had similar
effects (data not shown).
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scores /ncrease on /mprove/nenf scores decrease on /mprove/nenf
3 4 5 6 7
initial score
8 9 10 0 1 2 3 4 5 6 7
initial score
8 9 10
worsf score -> besf score toesf score <- worsf score
Figure 10.1: The relationship between the initial score and end score (A and B) and the change in
the initial score (C and D) for a measure that increases on improvement (A and Q and a measure
that decreases on improvement (B and D). For example, a patient with an initial score of 5 who
improves by 70% will increase the score by 3.5 (Q to end with a score of 8.5 (A) (see dotted lines;
examples for 50% improvement at an initial score of 4, and 20% at an initial score of 3 are also
indicated). In the case of an increas in score on improvement, patients cannot improve beyond the
maximum score; therefore, lines in C are truncated at diat point. Thus, patients with intermediate
or high initial scores (corresponding to intermediate-to-low disease activity) can go into remission
(maximum score) without satisfying the improvement criterion.
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Table 10.1: Total occurences of improvement in physician global assessment during the COBRA
trial, by ACR criterion level and treatment group*
ACR
improvement
criteria
20%
50%
70%
Combined treatment
Original
217
170
134
+
25
41
34
( « -
-
4
31
53
76)
Net
21
10
-19
(%)
(10)
(6)
(14)
Final
238
180
115
Original
178
117
91
Sulphasalazine
(
+
23
32
23
« = 79)
—
13
26
39
Net
10
6
-16
(%)
(6)
(5)
(18)
Final
188
123
75
* Each patient can contribute up to four occurrences of improvement for each percentage level of
American College of Rheumatology (ACR) improvement. The original count is on scores that increase on
improvement. On recoding scores to reflect a decrease in score on improvement, new occurrences of
improvement were added (+) and "no longer occurrences of improvement" were subtracted (-) to obtain
the final count. Net change is shown as an absolute count and as a percentage of die original count.
Table 10.2 shows the effect of recoding both die physician and die patient global assessments
on the total number of patients classified as improved in each treatment group, for two cardinal
time points: 28 weeks (the last assessment before prednisolone was tapered and stopped) and 56
weeks (die end of die trial). As previously reported, at 28 weeks the difference between treatment
groups was maximal; whereas at 56 weeks it was gone [4]. Again, die net effect of recoding is
radier modest, mosdy because patients who were not classified as improved on recoding were
replaced by odiers who newly classify as improved. However, at die 70% improvement criteria
level, die effects are more pronounced.
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Table 10.2: Total occurences of improvement in physician global assessment during the OOBRA
trial, by ACR criterion level and treatment group*
Time point
ACR
improvement
criteria
28 weeks
20%
50%
70%
56 weeks
20%
50%
70%
Combined treatment
Original
68
47
29
46
21
11
i
+
4
2
4
3
5
1
(«-76)
-
0
0
4
0
1
1
Net
4
2
0
3
4
0
Final
72
49
29
49
25
11
Original
48
23
8
46
25
11
Sulphas alazine
(n-79)
+
1
4
5
2
4
3
-
0
0
3
0
0
3
Net
1
4
2
2
4
0
Final
49
27
10
48
29
11
* Each patient was assessed at 28 and 56 weeks for improvement. The original ACR criterion is based on
scores of physician and patient global assessment that increased on improvement. On recoding to reflect
a decrease in score on improvement, new patients who met the criterion of improvement were added (+)
and patients who no longer met the criterion were subtracted (-), to obtain the final percentage.
Discussion
On the basis of methodological considerations and the above results, but also to facilitate
comparisons between trials, we recommend that percentage improvement be calculated only on
scores that decrease on improvement. When necessary, raw data should be recoded before the
ACR criteria are applied. In practice, the effect of disregarding this advice seems modest for the
ACR 20% improvement criteria, but results may be biased when higher percentages of
improvement are used.
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Validity of MACTAR Questionnaire as Functional Index
in a Rheumatoid Arthritis Clinical Trial
Abstract
Ob/ecf/Ves. The McMaster Toronto Arthritis patient preference questionnaire (MACTAR) is a
functional index that measures change in unpaired activities selected by each patient in a baseline
interview, and change in rheumatoid arthritis (RA) disease activity. In addition, it contains
questions on the state of physical, social, and emotional function, overall health, and their relation
to RA. We evaluated MACTAR's feasibility and validity (content validity, construct validity, and
responsiveness).
Mefhods. A randomised trial of combined treatment in 155 patients with early RA; patients' mean
age at baseline was 50 years and median disease duration since diagnosis was 4 months.
Resu/fs. /"fasi&t/ify: MACTAR requires trained interviewers. In the trial, interviews took about 15
minutes. In longer-term follow-up, activities selected at baseline may become less relevant as the
pattern of disability changes. Follow-up from 153 patients (99%) was available. At least 5 impaired
activities were identified and ranked by 147 patients (95%), interviewers could follow 99% of
these. The scoring system proved complex and required amendments. GWÄWÄ ts/K&ty: Although
its main focus is physical function, the MACTAR also contains generic questions; 75% of the
patients named at least one impaired activity from the category "mobility". Only 48% were
covered by Health Assessment Questionnaire (HAQ) items. Cbnsrrwct w/wirty MACTAR scores
correlate highly with other functional indices and with measures of disease activity. /?0/W8«enes:
At 16 weeks the standardised response mean for the total MACTAR score in the combined-
treatment group was excellent, at 2.2. Items that directly address change were even more
responsive.
Conc/us/on. The MACTAR interview is a valid and highly responsive instrument to assess change
in functional ability of patients with early RA with active disease. It provides insight into problems
- mainly of physical function - that really matter to patients. For standard clinical trials and clinical
care, feasibility of the MACTAR is limited and the simpler HAQ remains the instrument of choice.
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Introduction
Physical function, an important outcome in rheumatoid arthritis (RA) is included in the World
Health Organization/ International League of Associations for Rheumatology (WHO/ILAR) core
set for assessment of this ubiquitous disease [1]. Examples of widely used questionnaires to
measure physical function are the Stanford Health Assessment Questionnaire (HAQ) [2] and
Arthritis Impact Measurement Scale (AIMS) [3]. However, these measures do not include patient
priorities. Including such priorities may lead to better face validity and responsiveness [4]. An
example of a functional scale that takes account of patient priorities is the McMaster Toronto
Arthritis patient preference disability questionnaire (MACTAR) [5]. Its developers noted good
responsiveness in RA patients in a controlled trial that demonstrated clinically important change.
In the MACTAR, an interviewer elicits which 5 impaired activities are most important to the
individual patient, and follows their changes over rime. The MACTAR also includes questions on
social and emotional functioning and probes whether any problems are due to arthritis (see
•dpperafix). Because of this format, the MACTAR concept of function may be more comprehensive
than that of traditional fixed-item questionnaires such as the HAQ, and reveal issues that really
matter to the patient.
The recent COBRA study compared combined treatment of step-down prednisolone,
methotrexate, and sulphasalazine with single sulphasalazine treatment in early RA patients with
active disease [6]. In the setting of this multicentre randomised trial, we studied feasibility, content
validity (comprehensiveness), construct validity (correlation with other measures) and
responsiveness (discriminatory validity) of the MACTAR interview.
Patients and Methods
In the COBRA multicenter randomised controlled trial enrollment of RA patients (ACR
criteria) with early, active disease, took place in 10 clinical centers in The Netherlands and Belgium
between May 1993 and May 1995. Patients were randomised to combination therapy of disease-
modifying anti-rheumatic drugs with step-down prednisolone, methotrexate and sulphasalazine (n
= 76) or single therapy with sulphasalazine (w - 79). Methotrexate and sulphasalazine doses were
fixed at 7.5 mg per week and 2000 mg per day, respectively, but daily prednisolone doses were 60
mg in week 1, 40 mg in week 2, 25 mg in week 3, 20 mg in week 4, 15 mg in week 5, 10 mg in
week 6, and 7.5 mg from week 7 onwards. At baseline patients' mean age was 50 years and median
disease duration (since ACR diagnosis [7]) 4 months. Apart from the MACTAR questionnaire several
other measures of function and disease activity were assessed at baseline, and in weeks 16, 28, 40
and 56. This included validated Dutch versions of the HAQ [8] and AIMS [9-10], and grip strength
assessed by a vigorimeter [11].
A priori, the largest improvement was expected at the first major assessment (after 16 weeks)
in the combined-treatment group, and a smaller - but also clinically relevant improvement - in the
sulphasalazine group.
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The term 'semi-structured interview' rather than questionnaire, best describes the MACTAR
because interviewers fill out the answers on standard forms. The MACTAR comprises two parts
(see Appendix for a 'back translation' of the Dutch version we used). The first part - which we
refer to as 'the transitional questions' - starts with a question about patient perceived change in
arthritis activity (7 point Liken scale; ^«esrto« /df). It is complemented widi questions aimed at the
change in ability to perform 5 impaired activities, elicited and priority ranked by the patient during
a baseline interview (^«ejftow 2). Patients are asked to consider daily routine problems they face as
a result of their disease. Once they finish identifying problems spontaneously, the interviewer
reads a series of 'probes' to assist the patient. These probes are open-ended questions covering
broad areas of function: domestic care, self-care, professional activities, leisure activities, sexuality,
social interaction and roles. Patients are allowed to identify up to 10 problems. Subsequently, they
are asked to identify and rank the 5 most important problems, i.e. the activities they most eagerly
wish to perform without pain or discomfort. The second part of the interview - which we refer to
as 'the status questions' - elicits the patient's health status by one question each on general health
(^«ejtjcw /<*), satisfaction widi life (3 point Likert scales; ^«eshow JA), psychological, social and
emotional well being (5 point Likert scales; ^«ejtiows 4d, 5a <*«^  &* resp«Tiij»/;y). When the
questions reveal a less than optimal status, a second question probes whether this is due to arthritis
(^«esfiow J&, 4&, 5&, <jwti 6&). Presumably, the appreciation of any adverse event due to treatment
of the disease is implicitly reflected in these status questions.
Higher scores on the MACTAR reflect improvement. Scores vary from 11 to 47. In its original
format, the baseline interview has no scores for the transitional question part. To allow easier
interpretation of change between baseline and follow-up we added mock (or dummy) scores (14
points) consistent with a 'no change situation', to baseline total scores. With this adjustment,
baseline scores vary from 19 to 39. Thus, theoretically a change score can vary from -28
(maximum deterioration, with a baseline score of 39 subtracted from a follow-up score of 11) to
+28 (maximum improvement, with a baseline score of 19 subtracted from a follow-up score of
47). Also in instances with no available follow-up score, a mock score indicating 'no change' was
assigned.
The MACTAR offers the possibility of weighting the impaired activities (iw ^wefton 2) by an
assigned priority rank. The developers suggest weighting the change score in the activity with the
highest priority 5 times, the second highest 4 times, et cetera. To evaluate visual analogue scales
compared to Likert scales, an extension to the original format of the interview was made by having
patients mark perceived change on a 10-centimeter visual analogue scale after they answered the
3-point Likert scale item (^«eshcw 7a; improved/ no change/ worsened).
The MACTAR interview was translated into Dutch by one of the authors (AV). Next, a
rheumatologist (MB) and 2 health scientists compared the translation with the original to verify
cross-cultural equivalence. The first version was pre-tested in a selection of volunteers with
arthritis.
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Blinding of the patient and interviewer to treatment allocation is an important validity issue in
randomised controlled trials, especially when subjective impressions of patients and assessors are
reflected in outcomes. Obviously, the MACTAR scoring reflects such subjective impressions.
Optimum blinding was guaranteed by the study design in which assessors did not contact patients
between measurements at baseline, and follow-up at week 16, 28, 40, and 56. This was especially
pertinent during the first 6 weeks of the protocol, when potential (side) effects of high-dosed
prednisolone would be most apparent. Also, the assessors were asked not to discuss disease
activity or the blinded treatment effects with the patients
Listing the requirements and time needed for the interviewing assessed ^wst&t/ify. Also the
response rate and loss to follow-up was noted. A second 'baseline interview* was taken at week 56
to repeat the elicitation of impaired activities; the purpose was to evaluate the feasibility of the
MACTAR interview in extended follow-up of patients with treated and dierefore less active disease.
Besides feasibility, aspects of validity that have been studied are content validity
(comprehensiveness), construct validity, and responsiveness.
The cowtewf xa/a&fy (comprehensiveness) of the MACTAR was appraised by listing the impaired
activities elicited by the patients and matching diese with items from the HAQ. TWO assessors did
this because of the qualitative nature of it. Cohen's K (Kappa) reflects inter-rater reliability.
Cbrasfn«* W&&)' was assessed by correlating MACTAR scores widi other functional indices: we
used Pearson's moment correlation with HAQ, AIMS, and grip strength at week 16 of follow-up.
As all these indices have the construct 'functional ability" in common, correlations are expected to
be high, and specifically higher than correlations between MACTAR and measures of other
dimensions of die burden of disease. Tender and swollen joint count (68 and 48 joints [12],
respectively), erythrocyte sedimentation rate (ESR), patient's and assessor's global assessments (5
point likert scale and 10 cm visual analogue scale, respectively), and patient's pain assessment (10
cm visual analogue scale), served as measures of such dimensions.
Within-group n2spons«xewes5 of separate items and parts of the MACTAR was evaluated by
standardresponse means (SRMs) [13]. This is die mean observed change widiin one treatment
group divided by die standard deviation of this change. In each treatment group, SRMs at week 16
of MACTAR and odier functional, as well as non-functional outcome measures were compared.
Confidence intervals of SRMs were calculated under die assumption that its distribution is
approximately Gaussian widi mean zero and SD of one over die square root of die sample size
[14]. To get an impression of between-group discriminative power we also report f values for
between-treatment group comparisons at week 16 of follow-up. However, diese unpaired £ values
should be interpreted widi caution, as between-group comparison constituted die primary study
question. They are less suited for a direct evaluation of outcomes' comparative discriminatory
capacity [15].
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Results
The main findings of the COBRA trial have been published [6]. Briefly, combined treatment
caused almost immediate and strong improvement in disease activity, resulting in similarly strong
and significant functional improvement assessed at week 16. Single treatment with sulphasalazine
caused lesser but also significant improvement at week 16. Both treatment groups improved
further up to week 28. Most of the clinical difference between the groups disappeared when
prednisolone was subsequently withdrawn, with no further change after withdrawal of
methotrexate. At week 28, the combination therapy group had significantly less progression of
radiographic joint damage compared to the sulphasalazine group (/* < 0.0001), this difference
persisted up at least to week 80, i.e., 1 year after withdrawal of prednisolone.
During the trial, baseline and follow-up MACTAR interviews were taken from 153 patients
(99% follow-up). The duration of the interviews at baseline and follow-up was about 15 minutes.
No interviews were broken off. The mean number of impaired activities identified by a single
patient at baseline was 6.6 (SD: 2.2); 147 patients (95%) were at that time able to identify and rank
at least 5 impaired activities (one patient identified 2, and 7 patients identified 4 activities). Of the
total of 765 activities, the interviewers were able to follow 754 (99%) in the follow-up interview at
week 16; at week 28, 40 and 56, these numbers were 743 (97%), 706 (92%) and 715 (93%),
respectively. In the repeated baseline interview at week 56, data from 83 patients were available. At
that moment, with reduced disease activity compared to baseline in the majority of patients, only
55 patients (66%) were able to name 5 or more impaired activities. The number of elicited
activities per patient at week 56 was not influenced by the (previous) treatment allocation
(unpaired £ test: /> - 0.97). Of the total number of 392 activities named at week 56, 339 had a
priority rank of 1 to 5; 124 (37%) were equal or very similar to 'top-five' priority activities named
by the same patient at baseline.
The majority of impaired activities ranked as one of 5 most important were in the category
'mobility with paraphrases referring to bicycling (peddle, brake, get on and off the bicycle), driving
(steer, use gear, park, go in and out the car, open doors), walking, climbing stairs, getting up, ability
to be in the same position for long, to kneel down, bend over, reach down or get out of bed; these
activities were named 171 of 763 times (22%). Hundred-and-seventeen patients (75%) mentioned
at least one 'top-five' activity that was assigned to the category "mobility". Other categories are
listed in Table 11.1. The comprehensiveness of the MACTAR is also illustrated by the incomplete
coverage of patient elicited items by the HAQ. Both assessors rated that 48% of the phrases in
patient elicited activities were also covered by items from the HAQ (inter-rater agreement was
good: Cohen's K - 0.81).
High correlations were found between total MACTAR score, its partitions and other functional
indices, in descending order HAQ, AIMS mobility, and grip strength (all P < 0.0001, Table 11.2).
The correlation between scores on the item with which the patients were asked to rate change in
disease activity (^«estio« /d) and change scores in five high-priority activities (lywesrsons 2a-^ -
together forming the transitional part of the MACTAR - was 0.72 at week 16. At week 16,
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correlation between total MACTAR and 'non-functional' outcomes (Le., ESR, various pain scales,
joint counts, and global assessments) was also high, ranging from 0.38 to 0.77 (aD /* <0.0001).
Table 11.1: Activities elicited by the MACTAR interview, that the patients wanted to improve
most eagerly (max. 5 activities per patient, 2 treatment groups with 155 patients, total of 765
activities elicited).
category phrases patients
phrasing « (%) w (%)
mobility 171 (22%) 117 (75%)
bicycling, driving, walking, climbing stairs, getting up,
inability to be in one position for long, to kneel down,
bend over, reach down, and get out of bed.
housekeeping activities 150 (20%) 103 (66%)
vacuum-cleaning, cooking with heavy pans, mopping,
washing windows or dishes, shopping, peeling potatoes,
doing small repairs, tying up garbage bags, and lifting buckets,
self care activities 123 (16%) 94 (61%)
washing body and hair, dressing (especially socks,
zippers, bra and sweater), combing, shaving, drying hair,
wiping, get off the toilet, or get out the bathtub,
leisure activities I l l (15%) 87 (56%)
dancing, sports including jogging, tennis, aerobics, billiards
and swimming, gardening, knitting, making music, woodcarving,
bird raising, painting, going out to theater or cinema.
profession 37 (5%) 33 (21%)
eating and drinking 34 (4%) 30 (19%)
cutting meat or bread, open milk pack or bottle, pour from bottle.
family role (in relation to spouse, partner or parents) 32 (4%) 30 (19%)
child care 30 (4%) 22 (14%)
miscellaneous, upper extremities 23 (3%) 22 (14%)
shaking hands, turning keys, writing, leaning on wrists,
lifting unspecified items, using pair of scissors, reaching up.
social roles 22 (3%) 22 (14%)
sexuality 18 (2%) 18 (12%)
symptoms and complaints 8 (1%) 7 (5%)
not activities but complaints Eke stiffness and fatigue,
sleeping and resting 6 (1%) 6 (4%)
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Compared to other outcome measures, the total MACTAR interview showed
responsiveness as reflected by SRMs (Table 11.3). The MACTAR with weighted scores had slightly
better responsiveness. Questions that ask directly for change (so-called transitional questions)
showed best responsiveness. The responsiveness of 5 summarised 10 cm visual analogue scales
elucidating changes in impaired activities, was not better than the corresponding summarised
scores from the original questions with 3 response categories (data not shown). In this trial with
large between-group differences at week 16, all function measures were capable to discriminate
significandy between the treatment groups. HAQ, grip strength, and MACTAR (especially the part
widi transitional questions) served best for diis matter.
Table 1L2: Correlations between outcomes at week 16 follow-up (« - 153).
parts of the MACTAR
status questions
transitional questions
transitional questions, «eg!«»/
functional outcomes
HAQ
AIMS mobility scale
grip strength
odier outcomes
global assessment assessor VAS
global assessment patient 5-point likert
AIMS pain scale
pain VAS
tender joint count
AIMS self efficacy scale
erydirocyte sedimentation rate
swollen joint count
total
MACTAR
score
.92
.84
.82
-.73
.61
.46
-.77
-.74
-.71
-.68
-.62
.55
-.39
-.38
status
questions
part *
-
.56
.54
-.62
.55
.38
-.67
-.71
-.64
-.60
-.57
.47
-.29
-.33
transitional
questions
partf
-
.97
-.67
.43
-.67
-.59
-.61
-.60
-.51
52
-.42
-.33
transitional
questions
part •K«g6tai
-
-.66
52
.43
-.65
-.57
-.59
-.59
-.51
51
-.37
-.32
Pearson's correlations (without correction for multiple comparisons); r _>0.29 have P <0.0003.
*; Status questions have numbers la, 3a, 3b, 4a, 4b, 5a, 5b, 6a, and 6b, in baseline ami follow-up interviews
(see Appendix),
t; Transitional questions have numbers Id and 2a-e, and are not included in the baseline interview.
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Table 11.3: Responsiveness and between-group discrimination of MACTAR and a selection of
other outcome measures at week 16. Upper part: comparison MACTAR interview items and total
scores. Lower part: other functional and non-functional core set measures.
MACTAR status questions
general health status
satisfaction with life
physical well-being
social well-being
emotional well-being
question
number*
1 a
3 ab
4 ab
5 ab
6 ab
MACTAR transitional questions
change in disease activity
change in function
- xa^uagtog
MACTAR total score
other functional outcomes
HAQ
grip strength (kPa)
AIMS mobility scale
core-set outcomes
pain VAS
global assessment patient
ESR (mm/h)
swollen joint count
1 d
2 a-e
2 *e
global assessment assessor VAS
tender joint count
range
of scale
5 - 2 5
1- 3
1- 4
1- 6
1- 6
1- 6
6 -22
1- 7
5 -15
75-45
11-47
27-77
0- 3
0-120
7 - 2 8
0- 10
0 - 4
0-150
0 - 4 8
0- 10
0-68
combined
treatment
('
mean
i-75)
change SD^
5.5
0.8
0.8
1.8
0.8
1.2
6.6
2.6
4.0
72.0
12.2
20.3
-1.1
22
5.3
-3.3
-1.7
- 4 1
-9.1
-3.0
- 14
2.7
0.7
1.1
1.4
1.5
1.3
1.9
0.7
1.4
4.2
5.4
7.4
0.7
17
5.8
2.2
1.1
29
6.7
2.3
12
SRM
1.2
1.1
0.7
1.3
0.6
0.9
3.5
3.9
2.8
2.9
2.2
2.«
1.5
1.3
0.9
1.5
1.5
1.4
1.4
1.3
1.2
sulphas alazine
treatment
(
mean
;»-78)
change SDA
4.2
.6
.6
1.3
.8
.9
4.3
1.7
2.6
7.S
8.5
73.»
-0.4
8
2.1
-1.8
-1.1
- 2 3
-4.0
-1.4
- 6
4.7
0.7
1.0
1.5
1.7
1.7
3.5
1.4
2.3
7.0
6.9
77.0
0.6
13
4.5
2.6
1.3
25
6.7
2.3
13
i
SRM
0.9
0.8
0.6
0.9
0.5
0.5
1.2
1.2
1.1
7.7
1.2
7.3
0.8
0.6
0.5
0.7
0.9
0.9
0.7
0.6
0.5
r
value
1.8
2.2
1.0
22
0.2
1.4
5.4
5.3
4.5
5.0
3.7
4.3
6.2
5.8
3.9
4.0
2.7
4.1
4.2
4.3
4.1
SD^: standard deviation of changes. SRM: Standardised Response Mean: average change divided bySDa-
MACTAR: McMaster Toronto Arthritis questionnaire, VAS: visual analogue scale,
HAQ: health assessment questionnaire, ATMS: arthritis impact measurement scale,
ESR: erythrocyte sedimentation rate. *; see Appendix.
167
coroo/nat/on therapy /n rfieumato/d art/i/rt/s: chapter
Discussion
This study confirms that the MACTAR interview is a useful extension to the arsenal of
functional indices. Over a one-year period, it was valid and highly responsive in patients with early
and active RA that started disease-modifying antirheumatic treatment. Changes in disease status
and patients' adaptation to their limitations will shift patient priorities and probably make long-
term follow-up by MACTAR less useful. This is illustrated by the results of the second baseline
interview after one year. 2 thirds of prioritised impaired activities were new, and many patients
were unable to name at least 5 impaired activities.
The MACTAR'S unconventional method of calculating change and a lack of knowledge on
reliability and stability of patient preferences during a stable functional period have been noted as
limitations [16]. Interviewing implies extra requirements: interviewers need to be well trained to
secure standard implementation. In addition, adequate and accessible administration of baseline
records is mandatory. Therefore, is it important that the same interviewer asks questions at
baseline as well as follow-up. Specific attention has to be paid to sufficiently circumscribed
definition of the elicited and followed impaired activities. Especially with longer follow-up periods,
the activities should not be associated with a season. The MACTAR scoring method is somewhat
awkward, due to the combination of status and transitional questions. The many different
answering formats may cause confusion; also, summarising improvement in scores that increase as
patients improve can be bothersome [17]. We recommend the use of baseline mock scores for
transitional questions to facilitate comparison between baseline and follow-up scores.
The results of this analysis suggest that the MACTAR's comprehensiveness is indeed better
than that of the HAQ, another widely accepted measure; It includes questions on non-physical
aspects of function that are not included in the HAQ - but are covered by the AIMS. More
importantly, the HAQ only covered half of the items named by patients. The follow-up of impaired
functions that are most relevant to the patient is an important part of the interview. Not only do
these questions provide insight into patients' priorities that otherwise stay hidden, but - together
with the patients' assessment of change in disease activity- they comprise the part of the MACTAR
that is exceptionally responsive (SRM - 3.5).
With respect to construct validity, the performances of different parts of the interview were
approximately the same. The moderate or high correlation between the total MACTAR score and
any of the other functional indices are reassuring (Table 11.2). All these variables seem to reflect
one common construct. Presumably this construct is 'functional ability*. The correlation with grip
strength is relatively small, but obviously this measure only monitors one aspect of hand function,
whereas the MACTAR interview reflects a much broader concept of function. The highest
correlations with 'non-function' outcomes are found for global assessments and various pain-
scales. Probably, these are more closely linked to function than process parameters of
inflammation such as ESR and swollen joint count. All correlations are significant. This suggests
that all reported outcome measures have a construct in common: most likely, this is 'disease
activit/. In other words: at least in early RA, functional ability is to a large extent a disease activity
measure, rather than a measure of irreversible damage.
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Functional scales are among the most responsive, although other traditional measures also
perform adequately. Responsiveness of the MACTAR is large (Table 11.3). The part with
transitional questions shows excellent responsiveness in a situation where other measures also
indicated significant improvement from baseline in both treatment groups, together with
significant differences in improvement between the combined-treatment and sulphasalazine group.
The rank order of SRMs is similar in both treatment groups with their different levels of response:
high response exemplified by the combined-treatment group, traditional response (similar to that
of methotrexate) exemplified by die sulphasalazine group. Both response levels are currendy very
relevant, as trials widi active treatment control are becoming the standard. Consistent ranking of
responsiveness at diese 2 levels suggests MACTAR will also be responsive at other levels, but we
can offer no direct proof of diis.
Recording of change with die help of visual analogue scales did not improve responsiveness a
great deal, nor did weighting changes in function by assigned priority ranks. Excellent
responsiveness of weighted scores for die patient-specific impaired function items was reported by
U^hg^t rfrai ybwfitg (SRM = 4.9) in patients undergoing elective hip arthroplasty [18]. The COBRA
trial also showed a large SRM - 2.9 for diese items (Table 11.3). The slighdy better responsiveness
of die weighted MACTAR can be explained by die larger contribution to die total score of die more
responsive 'transitional questions'. Not surprisingly, die questions diat ask direcdy for change
showed die best responsiveness. This type of questioning rules out some of die scatter associated
widi scoring twice (and calculating change afterwards) [19]. Admittedly, transitional questions may
be more prone to socially desirable answering and recall bias but diis is not necessarily a problem
in randomised trials widi adequate blinding of treatment allocation. The range of between-group £
values confirms die discriminatory capacity of die MXCTAR. However, validation of between group
discriminatory capacity requires comparisons widi response levels known <J /mm.
Application of a highly responsive and discriminative functional index is especially useful
when it is difficult to include enough patients in a clinical trial during a short period, and when
radier small between-group contrasts are to be expected. A priori, die COBRA trial widi RA
patients widi early and active disease, no previous second-line treatment, and active treatment in
die control group, was a clear example of such a situation, although die response in die combined-
treatment group clearly exceeded our expectations. In our opinion, when considering die MACTAR
mere is a strong case to use just die best performing transitional questions part in future trials
where high responsiveness of a functional index is a prerequisite to guarantee sufficient statistical
power widi comparatively small sample size. However, for large trials, for long-term follow-up of
existing cohorts, as well as in clinical practice, simpler mediods diat demand less time and effort,
such as die HAQ seem more suited. Indeed, a trade-off has to be made between more concise and
more informative but also more laborious measurements to assess function.
In conclusion, die MACTAR is a valid and highly responsive instrument to assess changes in
physical function diat are relevant to RA patients. Increased relevance comes at a price of reduced
feasibility compared to instruments such as die HAQ.
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Appendix
MACTAR
Note: Questions 1d and 2 in the follow-up interview are "transitional" questions that measure change.
The other questions measure a state; in the article they are referred to as "status" questions.
Baseline interview
Interviewers note: Read the questions and response categories provided. Tick the response given.
1a. Hoiv wou/d you say your overa// Aieaft/i has been during fhe /asf 2 woeks?
You (h/nk or /f as. O 3 very good
0 2 pretty gooof
• 1 not too good
2. ArtAirft/s may cause restrictions /n severa/ areas of your dai/y Wfe. For d;fferenf peop/e <he impact of artnrif/s is
a/so d/fferenf. We w/// ask you to name acf/Wf/es ;n w/7/cn you experience difficu/ties because of your arthritis.
Whar matters here, /s what your persona/ experience rias been.
P/ease, fh/nfc of vvnar became a prob/em, now that you have arthritis.
Interviewers note:
In order to elicit a comprehensive list of activities: First, give the patient opportunity to react spontaneously.
Then read the probes. Record the exact phrases of the patient on the lines hereunder.
To support you /n naming any prob/ems caused by arthritis, / w/7/ read you a number of areas
of your dai/y Wfe fhaf might be affected.
Does your arthritis /im/f. . .
• any (other} ac&wt/es around (he house such as cooking, housework e(c. ?
• any acfiV/ry re/afed to dressing such as buttoning, puffing a sweater over your head eto. ?
• any (orber) acb'wf/'es af your work foufs/tfe 'he Aiomej, drive a car or other /ransportaf/on?
• any (ofberj /e/sure ac(/w(/es. E/fher sport such as bow//ng, sw/mm/ng, go/f, eto.
or non-sports such as need/ework, woodwork eto. ?
• any fofherj soc/a/ acf/wf/es. Such as v/'s/tfng, p/ay/ng cards, go;ng to church eto. ?
• sexuafffy?
/4re (here changes /n (he re/a(/onsh/p wi(h your fam//y?
/f you //Ve (oge(her wrfb a husband/ wife/partner, are (here changes /n (he re/afton w/(h h/m/her?
/f you have cn//dren A'wng a( home, are (here changes /n your re/a(/onsh/p wrth (hem?
The line above is printed 10 times
Interviewers note: To rank the activities in order of importance to the patient, ask the following questions:
Wn/c/j of these ac(/V/(/es wou/d you most W*e (0 be ab/e to do without pain or discomfort of your arthritis?
Show and read the list to the patient. Write "V next to the activity the patient chose.
-After (read activity 1)
which activity wou/d you next most /ike to be ab/e to do without pain or discomfort of your arthriüs?
Show and read the list to the patient, with exception of the activity with priority 1.
Write '2' next to the activity the patient chose.
•After (read activity 1 and 2)
which activity wou/d you next most /ike to be ab/e to do without pain or discomfort of your arthrit/s?
Show and read the list to the patient, with exception of the activity with priority 1 and 2.
Write '3' next to the activity the patient chose.
Continue like this, until all activities are ranked.
The 5 with the highest priority will return in the follow-up interview.
3a. m genera/, how satisfying do you find the way you spend your //fe ?
Over the /asf week you think of it as... O3 comp/efe/y sat/sfying -» go to Q4a
• 2 pretty satisfying
01 not very satisfying
3b. /s your /ife not comp/efe/y satisfying
because of your arthritis ? do yes d i no
4a. How wou/d you say your overaff physica/ functioning has been ?
Over the/ast week you think of if as ... O5 good -»go toQ5a
• 4 fair to good
• 3 fair
G2 fair to poor
O1 poor
4b. /s your physica/ function not as good as it might be
because of your arthritis ? Do yes O1 no
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5a. How wou/d you say your overa// soc/a/ funcfioning has been ?
Over /he /as/ week you fh/nk of rt as... Os good
•4 fe/r (o good
• 3 fair
O2 fair to poor
O, poor
5b. /s your soc/a/ func//on/ng no( as we// as /f m/gnf be
because of your ar/bri//s ? öo yes •1 no
6a. How wou/d you say your overa// emofrbna/ funcZ/oning has been ?
Overthe/astweekyouZhinkofi/as... Cfe good
•4 fe/r to good
03 fe/r
• 2 fe/r to poor
O1 poor
6b. /s your emof/ona/ functioning not as we// as ft m/gb/ be
because of your ar/briZ/s ? Go yes O1 no
•• go to Q6a
-• stop here
Follow-up interview
1a. How wou/d you say your overa// bea/Zb nas been during /be /as( 2 weeks ?
Vou /Ai/nk of rt as..: Ü3 very good
•2 pretty good
O2 nor (00 good
1 b. Have you nof/ced any change /n your arthrifis s/nce we te/ked during fhe firs/ /'nterv/ew?
a yes O no -• 'no change'at Q1d, go toQ2a
1 c. P/ease describe how your arthrif/s has changed ?
1 d. When you fh/n/< of your arthrif/s during /he (wo weeks before /he frs( /nterwew.
How much berter or worse overa// has your arthriZ/s become ?
• 7 a grea/ dea/ better
O6 modera/e/y better
05 s//ghf/y better
•4 no change
O3 s//gh(/y worse
• 2 modera/e/y worse
O, a grea/ dea/ worse
You may remember /he firs/ //me we spoke. You to/d me wn/ch act/v/ft'es were a/ /ha/ //me prob/ems due to your
ar/hriZ/s. / w/7/ ask you again abou/ /he five mosZ /mportanZ.
2a. S/nce Zbe /JrsZ /nZerv/ew, have you noZ/ced any change /n your ab///Zy Zo (activity 1 )?
// /s ... O3 /ess of a prob/em
O2 /he same
01 more of a prob/em
2b. S/nce /he /7rs/ /n/ervfew, have you notfced any change /n your ab/7/(y to (activity 2 ) ?
/ / /s . . . O3 /ess of a prob/em
02 /he same
Of more of a prob/em
2c. S/nce /he firs/ interview, have you notfcec/ any change /n yourab///Zy Zo (activity 3 )?
/Z /s ... 03 /ess of a prob/em
O2 Zbe same
01 more of a prob/em
2d. S/nce /he firs/ /n/erv/ew, have you no/iced any change in your ab///Zy Zo (activity 4 )?
// /s ... O3 /ess of a prob/em
02 /he same
O1 more of a prob/em
2e. S/nce /he firs/ interview have you noticed any change in your abi/i'fy Zo (activity 5 ) ?
ft /s... O3 /ess of a prob/em
• 2 'ne same
• 1 more of a prob/em
Questions 3a to 6b are equal to the equally numbered questions in the baseline interview.
172
CHAPTER 12
SUMMARY AND
GENERAL DISCUSSION
Arco Verhoeven
comb/'naf/on tfieraov ;n rheumato/d art/wrt/s: chaofer 72
Summary and general discussion
"Hie systematic review in chapter 2 summarizes the many developments in the combined
drug treatment of rheumatoid arthritis (RA). We concluded that in early RA patients, step-down
bridge therapy with oral corticosteroids leads to enhanced efficacy at acceptable or low toxicity
(see Chapter 3). In patients with established disease, cyclosporin improves suboptimal clinical
response to methotrexate (MTX) [1], and the triple combination of MTX, sulphasalazine (SSZ),
and hydroxychloroquine appears to be clinically better dian these single components [2]. Other
combinations are either untested, tested at low sample size, or show negative interaction. In view
of the low volume of evidence, it was stated that most studies needed confirmation by replication.
Since then, confirmation for the usefulness of corticosteroids in early and active disease has been
provided by the FINRAGO study [3,4]. An important issue is the alleged progression of joint
damage after corticosteroid therapy has been withdrawn [5]. Hickling et a/ found progression
resumed once the low-dose prednisone added to standard disease-modifying and-rheumatic drug
(DMARD) therapy was stopped [5,6]. Other researchers even speak of an rebound effect which
might implicate that patients are in the end worse off due to the use of steroids before [7]. Data
from the COBRA trial did not confirm such an effect, on the contrary, the protective effects of
combined-therapy - presumably the prednisolone component in it - persisted up to 3 years after
their withdrawal according to trial protocol [8].
The randomised clinical COBRA trial in chapter 3 shows the value of intensive combination
therapy by comparing the clinical outcomes of combined step-down prednisolone, MTX and SSZ
with SSZ alone in patients with early and active RA Combined therapy immediately suppressed
damage progression, whereas SSZ did less effectively and with a lag of 6 to 12 months. Notably,
there were fewer withdrawals in the combined-therapy than die SSZ group, and these occurred
later. The combined-therapy regimen dius offers additional disease control [9] over and above diat
of SSZ alone and persists for at least a year after corticosteroids are stopped.
The design of the COBRA trial does not allow separate evaluation of MTX and prednisolone
effects, as both drugs were part of a triple therapy compared to single SSZ. However, the timely
pattern of reduced disease activity - with convergent effects direcdy after die withdrawal of
prednisolone and no change after withdrawal of MTX - suggests that MTX does not have a large
protective - nor harmful - effect on bone in addition to die effect that had already been achieved
by 7.5 mg/day prednisolone and 2000 mg/day SSZ. This view is supported by findings of
Haagsma et al's trial with no significant difference in clinical or radiological outcomes between
treatment groups with SSZ, MTX or dieir combination [10].
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Presently, other studies and long-term follow-up are available to prove the soundness of
aggressive treatment of early and active rheumatoid arthritis as well as the persistence of beneficial
effects over many years [5,6,8]. Notably, the follow-up of patients in the OOBRA trial shows an
persisting beneficial effect on progression of joint damage as visible on radiographs; 3 and more
years after medication dictated by the study protocol has been stopped there are still significant
differences in progression of RA related joint damage (erosions in small joints of hands and feet).
Analysis on follow-up data on erosion scores show regression lines per treatment group that
diverge, instead of converge as might be expected with shrinking between-group differences in
medication after withdrawal of short-term trial medication by protocol [8].
Recently, a new class of biological anti-tumor necrosis factor alfa (anti-TNFa) has come
available with drugs named: etanercept and infliximab. These are a recombinant human TNF
receptor and a chimeric human- murine monoclonal TNF antibody that bind to and thereby
inhibits the biological activity of TNFot. Corticosteroids are presumably 'less precise in their
action' as they inflict a series of systemic effects - including adverse like osteoporosis. The first
trials with etanercept and infliximab used in combination are published [11,12]. The results are
very promising but high costs and concerns about toxicity profiles presently limit their use. Post-
marketing surveillance is important as various serious adverse effects of etanercept and infliximab
have been reported [13-15]. With others we urge the scientific community to compare the effects
and (long-term) toxicity of parental anti-TNFa factors with those of oral corticosteroids in initially
high doses [16]. The COBRA medication protocol might serve as a model for diis 'aggressive'
corticosteroid approach [17].
Chapter 4 demonstrates the cost-effectiveness and cost-utility of early intervention in RA
patients, with combined step-down prednisolone, MTX and SSZ, compared to SSZ alone. This
conclusion is based on enhanced efficacy at lower or equal direct costs: Clinical, radiographic and
functional outcomes significantly favored combined treatment at week 28 (radiography also at
week 56 and 80) and utility scores measured by rating scale were significantly better at week 28.
Based on, among other factors, fewer days spent in the hospital, direct costs of combined therapy
were lower, although the level of significance was not reached. Notably, this is a regular
phenomena in - so-called 'piggy-back' - economic evaluations linked to clinical trials; a priori
power calculations based on clinical outcomes, and a skewed distribution of costs (caused by a
small number of patients widi extreme high costs) often have make it hard to reveal more than a
'trend' in lower cost with one of the treatment options under evaluation [18]. Moreover, the
narrow timeframe of just over one year made it also difficult to find a between-treatment group
differences in costs and QALYs. Nevertheless, our report was the first state-of-the-art cost-
effectivity analysis of therapy for rheumatoid arthritis based on prospective data (previous studies
were based on models or rates instead of 'real-time' measurements and costprices) [19]. We were
nor the first nor the only research group to conclude that in patients with a chronic condition
(such as arthritis) utility scores measured with the rating scale technique are more responsive than
with standard gamble [20]. Indirect costs were not included in this first publication but the trial
design comprised patient dairies and questionnaires to evaluate indirect costs (manuscript
submitted; Korthals-de Bos IBCef a/).
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After initially positive experiences with corticosteroids for RA during the fifties, the
recognition of important side effects of high doses and lower doses in established disease caused a
communis opinio that this should not be done. However, these observations may be biased by the
fact that corticosteroids are usually prescribed in patients with established and therapy-resistant
disease. These patients are especially vulnerable to all kind of adverse effects that are associated
with corticosteroids. Corticosteroids can play an important role in the reduction of disease activity
in RA patients with early and active disease as illustrated by the COBRA trial as well as other
studies. Therefore they should not be considered as a class of drugs that merely reduce symptoms
but as DCARDs; disease-controlling antirheumatic drugs [9]. The systematic review in chapter 5
showed that bone loss due to corticosteroids in the spine and hips of RA patients is in general
more limited than in patients with other diseases. This conclusion was based on data from cohorts
in papers published between 1966 and 1995 but is confirmed and accepted by recent publications
[21,22]. Non-RA patients on high doses of corticosteroids regularly lose clinically relevant amounts
of bone (arbitrarily set at 5% within 1 year), but this is rare in patients with RA. Most bone is lost
in early or uncontrolled disease. Disease control with corticosteroids neutralises - at least partially
- the corticosteroid induced bone loss. Patients in the combination therapy group of the COBRA
trial - to whom 2345 mg prednisolone was subscribed during 28 weeks - 8 of 64 patients lost
more than 5% of spinal bone (versus 6 of 62 in the SSZ group). Mean bone loss in the lumbar
spine was indeed larger in the combination group (P - 0.06) but this stabilized after the
withdrawal of prednisolone.
In RA the pathological destruction of collagen in bone and cartilage, causes the crosslink
bridges in mature collagen to be resorbed more rapidly than normal. These collagen crosslinks are
excreted in urine. Apart from the crosslink resorption at the site of inflamed joints, there might be
increased resorption due to general bone loss associated with RA disease activity. Important
collagen crosslinks and markers of destruction of bone and cartilage are pyridinoline (PYD) and
deoxypyridinoline (DPD). Because of circadian rhythm in bone remodelling excretion in 24-hours
collection is the standard. The findings described in chapter 6 support that in longitudinal studies
also urinary spot samples collected during a fixed day time (with concentrations corrected for
creatinine) reflect 24-hour excretion levels well. In chapter 7 we conclude from the available data
in the COBRA trial, that prednisolone and DMARD therapy in these patients with early and active
RA were both independently associated with decreased levels of urinary excretion of the bone
collagen resorption markers PYD and DPD. In early RA the markers of bone formation an^
resorption closely followed changes in disease activity measure such as ESR in &o£& treatment
groups [23]. Reduced bone resorption together with reduced bone formation - reduction of
formation initially at a somewhat faster pace - resulted in less bone turnover and may explain the
observed small and partially reversible extra bone loss in the lumbar spine associated with
prednisolone.
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Chapter 8 confirms that patients with longer disease duration do not respond as well to
treatment in RA, and female gender, prior DMARD use, ARA class and disease activity also have
effects on the likelihood of patient response to treatment. This has implications for trial
interpretation and for clinical expectations of patients. It also supports the view that there is a
'window of opportunity' in the treatment of RA. Aggressive suppression of disease activity in the
early phase of active disease (with apparent inflammation of small joints of hands and feet) is
mandatory to prevent joint damage. Association of cumulative disease activity with joint erosions
and function loss at later stages stresses the importance of disease duration. The opportunity to
intervene early with second-line antirheumatic drugs relies heavily on the early diagnosis and rapid
referral of patients; health care systems should be specifically organized to facilitate this process
[24].
The analysis described in chapter 9 focussed on the validation of responsiveness and
discriminative power of the World Health Organization/ International League of Associations for
Rheumatology (WHO/ILAR) core set, together with the American College of Rheumatology (A<3?)
and European League Against Rheumatism (EULAR) criteria for improvement/response, and other
single and combined measures (indices) in a trial in patients widi early RA It shows that at the
moment of maximum between-group difference standardized response means (as sign for
responsiveness) for various core set measures differs largely. Performance of patient oriented
measures (for example, pain, global assessment) is best when die questions were focused on the
disease. The most responsive single measure is the patient's assessment of change in disease
activity. Patient utility, a generic health status measure was moderately (rating scale) to poorly
responsive (standard gamble). Combined measures (indices) no matter how simple did better than
most single measures; the simple count of core set measures improved by 20% was die most
responsive. Discrimination performance yielded similar but not identical results: best
discrimination between treatment groups was achieved by the EULAR response and ACR
improvement criteria (at 20% and odier percentage levels), the pooled index, and the disease
activity score (DAS), but also by the Healdi Assessment Questionnaire (HAQ) and grip strength.
We concluded diat responsiveness and discrimination between levels of response are not identical
concepts. As a matter of fact diey need separate study. The WHO/ILAR core set comprises
responsive measures that discriminate well between different levels of response in early RA
However, die performance of patient oriented measures is highly dependent on their format. The
excellent performance of indices such as the ACR improvement and EULAR response criteria
confirms diey are the preferred primary endpoint in RA clinical trials.
When ACR improvement criteria are applied, measured scores should decrease on
improvement. This, not only on the basis of methodological considerations (illustrated by data
examples from the COBRA trial in chapter 10 of this diesis) but also to facilitate comparisons
between trials. Where necessary, raw data should be recoded before die ACR criteria are applied.
This advice seems to gain importance with diresholds for improvement larger dien die classical
20%.
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The MACTAR interview evaluated in chapter 11 (indeed an interview rather than a
questionnaire) is a valid and highly responsive instrument to assess change in functional ability of
early RA patients with active disease. The items that directly address change were among the most
responsive of all. The MACTAR interview provides insight into problems - mainly of physical
function - that really matter to patients. The feasibility of the MACTAR in standard clinical trials
as well as clinical care, is considered to be limited compared with widely used instruments for
physical disability such as the Health Assessment Questionnaire [25].
Patients that are willing to participate in clinical studies are rare and in almost every instance
more rare than was expected. Our patients were prepared to be interviewed, touched, squeezed,
and punctured. For this they deserve compassion and deepest respect; their participation is an act
of philanthropy aimed at the benefit of future fellow-patients. In diis context, valid and sensitive
measurement, sound methodology, and careful and 'economic' use of eligible patients should be a
matter of course. The quest for - the most - valid and responsive measures should never stop.
Both disease-specific and generic measures of function and health-related quality of life are
capable to detect improvements in RA patients. Using both types of measures for evaluating
therapies will identify discernible changes that are important to patients, and will facilitate
comparisons across different disease states [26].
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Samenvatting
Reumatoide artritis (RA) is een veel voorkomende aandoening met onbekende oorzaak die
gekenmerkt wordt door een chronische ontsteking van de kleine gewrichten van handen en
voeten. De patient of patiente - de meeste patienten zijn vrouw - heeft pijnlijke en gezwollen
gewrichten, er is ochtendstijfheid en vermoeidheid. Ook op andere manieren kan de ziekte zieh
manifesteren, bijvoorbeeld met reumaknobbeltjes of bloedvatontsteking. Soms is het beloop van
de ziekte vrij mild en gaat het als vanzelf beter met de patient maar meestal wisselen goede en
siechte perioden elkaar af. Vaak zijn na verloop van tijd - soms al kort nadat de ziekte is
vastgesteld - afwijkingen te zien op röntgenfoto's; gaatjes in het bot bij de kleine gewrichten. Pijn,
zwelling en stijfheid zijn uitingen die wel beschreven worden als de ziekteacriviteit; naarmate deze
heviger is en langer bestaat, is het waarschijnlijker dat meer schade aan de gewrichten optreedt. Op
den duur ontstaan de kenmerkende en invaliderende standsafwijkingen. De ziekte bedreigt de
kwaliteit van leven van patienten en vermindert zelfs hun levensverwachting.
De behandeling van RA bestaat van oudsher uit leefregels, fysiotherapie en ontstekings-
remmende middelen uit de groep van zogenaamde niet-steroide anti-inflammatoire middelen
(NSAIDs). Deze medicijnen worden beschouwd als relatief onschuldig maar zij kunnen het
reumatoide ontstekingproces niet werkelijk remmen. Wel hebben zij een effect op pijn en stijfheid.
Bij patienten die onvoldoende baat vinden bij de ingestelde therapie wordt behandeling gestart
met een tweedelijns antireumatica (geneesmiddelen zoals goud, sulfasalazine en methotrexaat).
Deze middelen hebben soms ernstige bijwerkingen maar zij kunnen wel de schade afremmen die
de reumatoide ziekteacriviteit aanricht. De werking van deze middelen laat vaak enige üjd op zieh
wachten. In het geval van bijwerkingen of - na verloop van tijd - bij vaststelling van onvoldoende
effect, wordt een ander middel geprobeerd. Patienten met de meer hardnekkige vormen van RA
werden aldus over jaren behandeld met steeds andere, maar ook steeds zwaardere middelen; men
spreekt van de therapeutische piramide (zie figuur).
biologicals
cytotoxische middelen
MTX, SSZ
hydroxychloroquine of goud
leefregels, fysiotherapie, NSAIDs
Figuur De klassieke therapeutische piramide voor de behandeling van reumatoide artritis
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Corticosteroiden vormen een apaite groep van middelen die veel gebruikt wordt in de
reumatologie. Kort na de intioductie in de vijftiger jaren was het enthousiasme groot. Met het
bredere gebruik werden ook de bijwerkingen duideiijker. Onder het publiek is vrij algemeen
bekend dat bijvoorbeeld het middel prednison is verbonden met gewichtstoename en
botontkalking. Hoewel corticosteroiden veel worden gebruikt bij met name langer bestaande RA,
menen veel reumatologen dat zij alleen ingezet mögen worden als een laatste redmiddel.
Eind jaren negentig groeide het ongenoegen onder reumatologen over de traditionele
behandeling van RA. Het werd duidelijk dat de hevigheid van de reumatoide ontstekingen
samenhangt met de schade die de ziekte aanricht aan de gewrichten. Tevens bleek dat de meeste
beschadigingen in de eerste ziektejaren optreden - vooral bij patienten met een hevige
ziekteactiviteit. Met de voorzichtige stap voor stap Strategie gaat veel tijd verloren om een therapie
te vinden die min of meer adequaat de ziekteactiviteit kan onderdrukken. Omdat behandelaars het
idee hadden in veel gevallen achter de feiten (lees gewrichtsschade) aan te lopen ontstond de roep
om sneller te behandelen met zwaardere middelen en met combinaties.
Door medicijnen te combineren hoopte men effecten te bereiken die even groot, of zelfs
groter zouden zijn dan de opgetelde effecten van de middelen afzonderiijk. Ook hoopte men op
minder bijwerkingen lagere doses te gebruiken. Hoewel diverse combinatie-therapieen reeds
frequent werden toegepast ontbrak het wetenschappelijk bewijs ter rechtvaardiging van deze
praktijk nog. Het beperkte onderzoek dat wel was gedaan gaf weinig reden tot optimisme en met
name over de rol van corticosteroiden in combinatie met antireumatica bestond onduidelijkheid.
De basis voor dit proefschrift werd gelegd binnen Ontwikkelingsgeneeskunde. Dit initiatief
van de Ziekenfondsraad was gericht op het beoordelen van de waarde van nieuwe technieken of
benaderingen op het gebied van diagnostiek of therapie te evalueren. Evaluatie van kosten-
effectiviteit maakte een integraal onderdeel uit van alle projecten. In ons project werd de
werkzaamheid onderzocht van combinatietherapie (met tweedelijns antireumatica) b_'j vroege
reumatoide artritis (het COBRA-onderzoek). Het geven van hoge doses prednisolon bij patienten
met kort bestaande RA, was op het moment van starten van het onderzoek uiterst controversieel.
Dit proefschrift bevat 10 hoofdstukken die eerder als artikelen in internationale medische
vaktijdschriften gepubliceerd zijn. Na de algemene inleiding (hoofdstuk 1) volgen drie delen:
• Het eerste deel omvat een systematisch overzicht van onderzoeken naar combinatietherapie
met tweedelijns antireumatica bij RA. Daarna handelen twee hoofdstukken over de klinische
uitkomsten en kosten-effectiviteit van de combinatie-therapie zoals die toegepast is binnen het
COBRA-onderzoek (hoofdstukken 2, 3 en 4).
• Het tweede deel handelt over de invloeden van corticosteroiden op de botstofwisseling bij
RA-patjenten (hoofdstukken 5,6 en 7).
• Het derde deel gaat onder andere over onderzoekstechnische aspecten van het vaststellen van
uitkomsten bij RA-parienten (hoofdstukken 8, 9,10 en 11).
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Het beperkte aantal beschikbare anrireumatica biedt gelegenheid tot een enorme diversiteh
van combinaties. Hoofdstuk 2 geeft een systematisch overzicht van hoge-kwaliteit onderzoeken
naar combinatietherapie bij RA. In patientengroepen met kort bestaande RA bleek de
combinatietherapie uit het OOBRA-onderzoek (zie hoofdstuk 3) de klinische uitkomsten
belangrijk te verbeteren zonder onacceptabele bijwerkingen. Bij patienten met langer bestaande
RA bleek het middel cyclosporine gegeven naast methotrexaat de klinische uitkomsten te
verbeteren. Ook de combinatie van methotrexaat, sulfasalazine en hydroxychloroquine liet betere
klinische uitkomsten zien dan elk van deze 3 middelen afzonderlijk. Veel combinaties zijn niet
onderzocht, andere bleken te zijn getoest in te kleine groepen, of de combinaties toonden een
effect dat geringer was dan verwacht werd van elk van de middelen afzonderlijk.
In het OOBRA-onderzoek beschreven in hoofdstuk 3 zijn twee groepen van patienten
vergeleken. Een groep kreeg de combinatie van drie middelen: sulfasalazine, methotrexaat en
prednisolon. De andere groep kreeg alleen sulfasalazine. Prednisolon werd na 28 weken gestopt,
methotrexaat na 40 weken. De ziekteactiviteit (ontstoken gewrichten, bloedbezinking, etc.)
verminderde in de groep met combinatietherapie vrijwel onmiddellijk; de verbetering was bijna
tweemaal zo groot als die door alleen sulfasalazine. Na het stoppen van prednisolon nam het
verschil tussen de groepen af (en was niet langer significant). Het stoppen van methotrexaat (het
tweede middel uit de combinatie) deed vervolgens niets toe of af aan het verschil. Uit het
onderzoek van röntgenfoto's van handen en voeten bleek dat in de groep met combinatietherapie
veel minder nieuwe gewrichtschade was ontstaan. Dit significante verschil bestond na een half jaar
combinatietherapie maar bleek te blijven bestaan tot tenminste een jaar na het stoppen van de
prednisolon. Er werden geen ernstige bijwerkingen gezien in de patientengroep met
combinatietherapie; het aantal uitvallers was gering en significant minder dan in de sulfasalazine-
groep. Ook de verwachte botontkalking door prednisolon bleek gering.
Verrassend genoeg bleek bij het volgen van de patienten en hun röntgenfoto's (tot meer dan 4
jaren na aanvang van het onderzoek) dat de verschillen in gewrichtsschade tussen de
oorspronkelijke twee behandelgroepen bleven bestaan. Dit duidt op de noodzakelijkheid van het
vroegtijdig onderdrukken van de ziekteactiviteit; zonder deze harde aanpak gaat de kans op
voorkomen van gewrichtsschade voorbij! Sinds kort is voor de behandeling van RA een nieuwe
klasse medicijnen beschikbaar anti-TNFa-middelen (in het Engels ook wel aangeduid als
'biologicals'). De extreem hoge kosten en onzekerheid over bijwerkingen op korte en lange termijn
maken ruime toepassing van deze middelen vooralsnog problematisch. Een directe vergelijking
van de effecten van deze middelen met die van corticosteroiden ligt voor de hand.
De financiele gevolgen van RA zijn groot door o.a. medische kosten en arbeids-
ongeschiktheid. Bij analyse van de behandelkosten beschreven in hoofdstuk 4 bleek de
combinatietherapie uit het OOBRA-onderzoek iets goedkoper. De extra medicatie en
verrichtingen voor controle van o.a. botdichtheid resulteerden in een bescheiden toename van de
kosten, maar daar tegenover stonden besparingen in o.a. doktersbezoek en ziekenhuisopnames.
De vergelijkbare kosten en superieure effectiviteit samen maken dat combinatietherapie meer
kosten-effectief is dan alleen sulfasalazine - bij patientengroepen zoals in dit onderzoek.
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Het tweede deel van dit proefschrift met de hoofdstukken 5, 6 en 7 draait om de invloeden
van corticosteroiden op botstofwisseling bij RA-patienten.
In hoofdstuk 5 is gepoogd de invloed van corricosteroiden op botdichtheid uit te drukken in
maat en getal. Uit de gecombineerde gegevens van prospectieve onderzoeken bleek de door
corricosteroiden veroorzaakte botontkalking in de wervelkolom en heupen van RA-patienten
doorgaans beperkter dan bij andere ziekten. Bij RA treedt het meeste botverlies op vroeg in het
beloop van de ziekte en bij hoge ziekteactiviteit. Corricosteroi'dengebruik leidt enerzijds tot een
verminderde botdichtheid, deze wordt echter anderzijds tenminste gedeeltelijk gecompenseerd
door een betere beheersing van de ziekteactiviteit.
Bij RA is er ontsteking van de gewrichtskapsels met de kenmerkende botontkalking rond de
gewrichten. Ook in de rest van het skelet is de botstofwisseling veranderd door RA Diverse
stofwisselingproducten in het bloed en de urine kunnen een inzicht geven in het niveau van
botaanmaak en botafbraak onder invloed van ziekte en medicarie. In hoofdstuk 6 wordt
aangetoond dat urinemonsters die zijn verzameld op een vast rijdsrip een 24-uurs urineverzameling
kunnen vervangen bij de bepaling van merkstoffen van botafbraak. In hoofdstuk 7 is wederom
gebruik gemaakt van de gegevens uit het GOBRA-onderzoek. Hieruit volgt de conclusie dat
gebruik van prednisolon en sulfasalazine beide zijn verbonden met afgenomen uitscheiding van de
merkstoffen voor botafbraak. De stofwisseling onder invloed van medicarie lieten een afname zien
van zowel botafbraak als botaanmaak vergelijkbaar met de patronen die werden waargenomen bij
maten voor ziekteacriviteit. Het voorbijgaande extra botverlies in de wervelkolom in de groep met
combinatietherapie (o.a. prednisolon) is te verklaren uit de waameming dat in deze groep de
botaanmaak aanvankelijk meer werd geremd dan de botafbraak.
Het derde en laatste deel van dit proefschrift met de hoofdstukken 8, 9, 10 en 11 gaat onder meer
over de onderzoektechnische (methodologische) aspecten van vaststellen van uitkomsten. Omdat
er erg veel uitkomstmaten een rol spelen bij RA is dit een ingewikkeld - maar ook interessant -
onderzoeksveld.
Hoofdstuk 8 gaat over de rol van ziekteduur bij de behandeling van RA. Gegevens van 14
onderzoeken (waaronder het COBRA-onderzoek) zijn gebruikt in een analyse. Naast geslacht,
ziekteactiviteit, voorafgaand medicijngebruik en functiebeperking, blijkt ziekteduur bepalend voor
de mogelijk bereiken klinische verbeteringen. Ten einde gewrichtschade op termijn te voorkomen
is het van eminent belang dat de ziekteactiviteit (die tot uitdrukking komt in onder ander pijnlijke
en gezwollen gewrichten) snel wordt onderdrukt met medicijnen. Vroege herkenning en verwijzing
van patienten naar de reumatoloog is noodzakelijk.
Patienten werven voor een klinisch onderzoek blijkt telkens weer moeilijker dan verwacht,
bovendien komen belangrijke onderzoeksresultaten nooit te vroeg. Daarom is het van groot
belang - ook in dit opzicht - zuinig om te gaan met patienten en te kiezen voor
onderzoeksmethoden en uitkomstmaten die in zo kort mogelijke tijd en met medewerking van zo
weinig mogelijk patienten leiden tot eenduidige uitslagen. Hoofdstuk 9 bevat een analyse van de
eigenschappen van de uitkomstmaten die gebruikt worden in het onderzoek naar RA Aan de hand
van deze analyse kunnen bruikbare en minder bruikbare uitkomstmaten worden onderscheiden.
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Met gegevens uit het CDBRA-onderzoek is het vermögen van uitkomstmaten om verbeteringen
binnen patienten en tussen patientgroepen op te sporen onderzocht. Samengestelde
uitkomstmaten (indices) bleken bijna ahdjd beter te presteren dan enkeh/oudige maten. De meest
gebruikte indices voor verbetering bleken goed te voldoen. Bij het bevragen van de patient is het
beter te informeren naar veranderingen in het ziektebeeld dan naar algemene gezondheid of
•welbevinden.
Bij het rapporteren van veranderingen uitgedrukt in percentages, stuitten wij op de haken en
ogen die hieraan vastzitten. Dit vormde de aanleiding voor hoofdstuk 10 met de aanbeveling om
voorafgaand aan de berekening van relatieve veranderingen, de data zo te bewerken dat scores
afnemen wanneer de patient vooruit gaat.
Hoofdstuk 11 behandelt de bruikbaarheid en waarde van een vragenlijst die ook ingezet werd
bij het OOBRA-onderzoek - als een van de 5 belangrijkste uitkomstmaten. Deze door de
onderzoekers afgenomen MACTAR-lijst meet veranderingen in functionele beperkingen, die door
de patienten werden benoemd als belangrijk. Uit het onderzoek kwam de MACTAR-lijst naar
voren als erg geschikt voor het opsporen van verschillen tussen patientgroepen. Daarnaast
verschaft hij inzicht in - meest lichamelijke - beperkingen die belangrijk zijn vanuit het
gezichtspunt van de patient. Voor de alledaagse patientenzorg blijft het gebruik van meer gangbare
lijsten (bijvoorbeeld de HAQ) aan te bevelen omdat deze eenvoudiger zijn af te nemen en te
interpreteren.
Hoofdstuk 12 is de engelstalige samenvatting. Hierin worden conclusies getrokken en
aanbevelingen gedaan die - in hopelijk begrijpelijkere termen - ook dit nederlandstalige hoofdstuk
zijn te lezen.
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Diny Somhorst in het Medisch Spectrum Twente te £ rcscÄecfe en het Twenteborg Ziekenhuis te
/4 //we/o; Marie-Louise Westedt en Jende van Zeben in het Bronovo Ziekenhuis te 5
188
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